https://lymphomahub.com daily 1 2026-10-28T17:50:43.905Z https://lymphomahub.com/subtypes weekly 0.8 2025-03-24T11:07:00.000Z https://lymphomahub.com/subtypes/mcls weekly 0.7 2025-04-15T10:45:00.000Z https://lymphomahub.com/subtypes/hl weekly 0.7 2025-04-15T10:45:00.000Z https://lymphomahub.com/subtypes/aggressive-nhl weekly 0.7 2025-04-24T14:07:00.000Z https://lymphomahub.com/subtypes/indolent-nhl weekly 0.7 2025-04-24T14:07:00.000Z https://lymphomahub.com/subtypes/clls weekly 0.7 2025-03-24T11:07:00.000Z https://lymphomahub.com/subtypes/tnk-np weekly 0.7 2025-03-24T11:07:00.000Z https://lymphomahub.com/subtypes/rr-dlbcl weekly 0.7 2025-03-13T14:32:00.000Z https://lymphomahub.com/subtypes/rrfl weekly 0.7 2025-03-24T11:07:00.000Z https://lymphomahub.com/subtypes/covid-19 weekly 0.7 2025-03-24T11:07:00.000Z https://lymphomahub.com/subtypes/rare-nhl weekly 0.7 2025-03-24T11:07:00.000Z https://lymphomahub.com/therapeutics weekly 0.8 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/kinase-inhibitors weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/bcl-2-inhibitors weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/cellular-therapy weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/conjugates-antibodies weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/car-t-cell-therapy weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/checkpoint-inhibitors weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/chemotherapy weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/nuclear-receptor-agonists weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/antibody-therapy weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/immune-modulators weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/celmods weekly 0.7 2025-06-16T08:54:00.000Z https://lymphomahub.com/therapeutics/histone-modifiers weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/proteasome-inhibitors weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/hypomethylating-agents weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/protein-degraders weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/malt1-inhibitors weekly 0.7 2025-06-30T16:58:00.000Z https://lymphomahub.com/therapeutics/radiotherapy weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/nuclear-export-inhibitors weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/t-cell-engagers weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/mitochondrial-metabolism-inhibitors weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/multi-cytokine-inhibitors weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/pro-apoptotic-molecules weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/phospholipid-drug-conjugates weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/micro-rnas weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/chemokine-receptor-antagonists weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/therapeutics/mtor-inhibitors weekly 0.7 2025-04-24T08:10:00.000Z https://lymphomahub.com/congresses weekly 0.8 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/ash weekly 0.7 2026-01-12T16:22:00.000Z https://lymphomahub.com/congresses/eha weekly 0.7 2025-07-03T09:50:00.000Z https://lymphomahub.com/congresses/asco weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/iach weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/icml weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/eef-2025 weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/ebmt-2024 weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/car-t-meetings weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/iwwm-13 weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/soho weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/aacr weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/tct-meetings weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/esmo-2022 weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/other-events weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/llmc-1 weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/costem-2022 weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/european-school-of-haematology weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/iwcll weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/aspho weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/eli-workshop weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/congresses/ash-lymphoma-biology weekly 0.7 2025-04-29T14:12:00.000Z https://lymphomahub.com/trials weekly 0.8 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/sympatico weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/halo weekly 0.7 2026-10-12T17:09:00.000Z https://lymphomahub.com/trials/daly-2-eu weekly 0.7 2025-12-03T15:24:00.000Z https://lymphomahub.com/trials/hd21 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/euronet-phl-lp1 weekly 0.7 2026-10-02T10:24:00.000Z https://lymphomahub.com/trials/atalanta-1 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/bruin-cll-313 weekly 0.7 2025-12-03T15:27:00.000Z https://lymphomahub.com/trials/study-evaluating-the-safety-and-pharmacokinetics-of-jcar017-in-b-cell-non-hodgkin-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/bruin-cll-314 weekly 0.7 2025-12-05T09:36:00.000Z https://lymphomahub.com/trials/epcore-nhl-2 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/epcore-fl-1 weekly 0.7 2025-11-19T18:02:00.000Z https://lymphomahub.com/trials/starglo weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/perspective weekly 0.7 2025-06-10T11:36:00.000Z https://lymphomahub.com/trials/ibrutinib-in-previously-untreated-binet-stage-a-chronic-lymphocytic-leukemia-with-risk-of-disease-progression weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/renoir weekly 0.7 2026-09-04T08:31:00.000Z https://lymphomahub.com/trials/daly-ii-usa weekly 0.7 2026-02-23T15:13:00.000Z https://lymphomahub.com/trials/pinacle-h2h weekly 0.7 2026-08-27T12:12:00.000Z https://lymphomahub.com/trials/palisades-1 weekly 0.7 2026-09-03T09:42:00.000Z https://lymphomahub.com/trials/polargo weekly 0.7 2025-06-09T15:53:00.000Z https://lymphomahub.com/trials/triangle weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-evaluating-safety-and-efficacy-of-jcar017-in-subjects-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-or-small-lymphocytic-lymphoma-sll weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/matrixielsg43 weekly 0.7 2026-08-13T10:19:00.000Z https://lymphomahub.com/trials/epcore-dlbcl-3 weekly 0.7 2025-06-10T11:43:00.000Z https://lymphomahub.com/trials/a-phase-3-study-of-ibrutinib-pci-32765-versus-ofatumumab-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-obinutuzumab-chlorambucil-acalabrutinib-acp-196-obinutuzumab-and-acalabrutinib-in-subjects-with-previously-untreated-cll weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-of-acalabrutinib-vs-investigator-s-choice-of-idelalisib-plus-rituximab-or-bendamustine-plus-rituximab-in-rr-cll weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/resonate-2 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/sequoia weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/elevate-rr weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/alpine weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/flair weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/amplify weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/bruin-cll-321 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/gaiacll13 weekly 0.7 2025-07-30T08:09:00.000Z https://lymphomahub.com/trials/bruin-cll-322 weekly 0.7 2026-06-23T11:52:00.000Z https://lymphomahub.com/trials/echo weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cadance-101 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/alpha3 weekly 0.7 2026-07-30T15:42:00.000Z https://lymphomahub.com/trials/polar-bear weekly 0.7 2026-07-30T09:15:00.000Z https://lymphomahub.com/trials/cll14 weekly 0.7 2026-07-27T15:13:00.000Z https://lymphomahub.com/trials/epcore-dlbcl-1 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/soundtrack-f1 weekly 0.7 2026-07-20T14:05:00.000Z https://lymphomahub.com/trials/bgb-11417-101 weekly 0.7 2025-07-24T08:29:00.000Z https://lymphomahub.com/trials/vt-ebv-201 weekly 0.7 2026-07-10T08:29:00.000Z https://lymphomahub.com/trials/front-mind weekly 0.7 2025-06-10T08:44:00.000Z https://lymphomahub.com/trials/epcore-nhl-1 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/sunmo weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/antler weekly 0.7 2026-06-17T12:15:00.000Z https://lymphomahub.com/trials/boven weekly 0.7 2025-08-07T15:14:00.000Z https://lymphomahub.com/trials/inmind weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/primavera weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/nx-5948-301 weekly 0.7 2025-08-07T11:15:00.000Z https://lymphomahub.com/trials/eortc-1537-cobra weekly 0.7 2025-06-09T15:54:00.000Z https://lymphomahub.com/trials/bruin weekly 0.7 2025-07-01T13:09:00.000Z https://lymphomahub.com/trials/a-study-to-compare-the-efficacy-and-safety-of-jcar017-to-standard-of-care-in-adult-subjects-with-high-risk-transplant-eligible-relapsed-or-refractory-aggressive-b-cell-non-hodgkin-lymphomas weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/swog-1826 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ibrutinib-plus-venetoclax-in-subjects-with-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/glow weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/morningsun weekly 0.7 2025-06-09T15:54:00.000Z https://lymphomahub.com/trials/olympia-3 weekly 0.7 2025-12-03T15:22:00.000Z https://lymphomahub.com/trials/zuma-2 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/epcore-nhl-6 weekly 0.7 2025-12-05T09:41:00.000Z https://lymphomahub.com/trials/elm-2 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/rituximab-plus-lenalidomide-for-patients-with-relapsed-refractory-indolent-non-hodgkin-s-lymphoma-follicular-lymphoma-and-marginal-zone-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/celestial-rrmcl weekly 0.7 2025-07-24T08:29:00.000Z https://lymphomahub.com/trials/bgb-11417-201 weekly 0.7 2025-10-14T14:17:00.000Z https://lymphomahub.com/trials/a-study-of-duvelisib-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/combined-rituximab-and-lenalidomide-treatment-for-untreated-patients-with-follicular-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/chess weekly 0.7 2026-04-21T16:26:00.000Z https://lymphomahub.com/trials/go29781 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/jackpot26 weekly 0.7 2025-06-10T11:45:00.000Z https://lymphomahub.com/trials/cristallo weekly 0.7 2025-12-03T15:25:00.000Z https://lymphomahub.com/trials/swog-s0016 weekly 0.7 2026-03-26T14:34:00.000Z https://lymphomahub.com/trials/checkmate-744 weekly 0.7 2026-03-23T17:20:00.000Z https://lymphomahub.com/trials/transcend-fl weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/elechon-3 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/resmain weekly 0.7 2026-03-17T09:41:00.000Z https://lymphomahub.com/trials/symphony-1 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/direct weekly 0.7 2026-02-25T14:16:00.000Z https://lymphomahub.com/trials/zuma-14 weekly 0.7 2026-02-12T11:57:00.000Z https://lymphomahub.com/trials/sgn35-027 weekly 0.7 2026-02-10T10:45:00.000Z https://lymphomahub.com/trials/study-of-efficacy-and-safety-of-ctl019-in-adult-dlbcl-patients weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/hovon-158next-step weekly 0.7 2026-01-27T14:27:00.000Z https://lymphomahub.com/trials/cll-17 weekly 0.7 2026-01-20T12:39:00.000Z https://lymphomahub.com/trials/mithic-fl2 weekly 0.7 2025-12-03T15:23:00.000Z https://lymphomahub.com/trials/pilot weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/viper-101 weekly 0.7 2025-12-18T12:27:00.000Z https://lymphomahub.com/trials/descar-t weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/epcore-cll-1 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/fil-ri-chop weekly 0.7 2025-12-03T15:21:00.000Z https://lymphomahub.com/trials/loc-r01 weekly 0.7 2025-12-03T15:22:00.000Z https://lymphomahub.com/trials/deb weekly 0.7 2025-12-03T15:23:00.000Z https://lymphomahub.com/trials/smart-stop weekly 0.7 2025-12-03T15:23:00.000Z https://lymphomahub.com/trials/allg-pacific-nhl35 weekly 0.7 2025-12-05T09:39:00.000Z https://lymphomahub.com/trials/bellwave-003 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/stair weekly 0.7 2025-12-03T15:27:00.000Z https://lymphomahub.com/trials/study-to-evaluate-the-efficacy-of-response-adapted-strategy-in-follicular-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/elara weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/rosewood weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ecwm-1 weekly 0.7 2025-12-03T15:22:00.000Z https://lymphomahub.com/trials/window-3 weekly 0.7 2025-12-03T15:26:00.000Z https://lymphomahub.com/trials/traverse weekly 0.7 2025-12-03T15:27:00.000Z https://lymphomahub.com/trials/rock-1 weekly 0.7 2025-12-05T09:38:00.000Z https://lymphomahub.com/trials/study-of-a-treatment-driven-by-early-pet-response-to-a-treatment-not-monitored-by-early-pet-in-patients-with-aa-stage-3-4-or-2b-hl weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/rathl weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/hd0607 weekly 0.7 2025-06-09T15:53:00.000Z https://lymphomahub.com/trials/zuma-25 weekly 0.7 2025-12-03T15:24:00.000Z https://lymphomahub.com/trials/earlymind weekly 0.7 2025-11-19T14:52:00.000Z https://lymphomahub.com/trials/aspen weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/bgb-3111-lte1 weekly 0.7 2025-11-14T14:02:00.000Z https://lymphomahub.com/trials/polarix weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/skyglo weekly 0.7 2025-11-07T14:02:00.000Z https://lymphomahub.com/trials/reliance weekly 0.7 2025-11-04T21:04:00.000Z https://lymphomahub.com/trials/a-study-to-evaluate-the-safety-and-efficacy-of-lenalidomide-with-mor00208-in-patients-with-r-r-dlbcl weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/firmmind weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/fil-v-rbac weekly 0.7 2025-10-31T11:23:00.000Z https://lymphomahub.com/trials/enrich weekly 0.7 2025-10-30T12:30:00.000Z https://lymphomahub.com/trials/coalition weekly 0.7 2025-10-06T11:51:00.000Z https://lymphomahub.com/trials/golseek-4 weekly 0.7 2025-09-12T15:40:00.000Z https://lymphomahub.com/trials/lotis-7 weekly 0.7 2025-06-10T10:59:00.000Z https://lymphomahub.com/trials/study-of-the-combination-of-rituximab-cyclophosphamide-doxorubicin-velcade-and-prednisone-or-rituximab-cyclophosphamide-doxorubicin-vincristine-and-prednisone-in-patients-with-newly-diagnosed-mantle-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-ibrutinib-a-bruton-s-tyrosine-kinase-inhibitor-versus-temsirolimus-in-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-who-have-received-at-least-one-prior-therapy weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/shine weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/oasis-ii weekly 0.7 2025-05-30T10:39:00.000Z https://lymphomahub.com/trials/goldilox weekly 0.7 2025-08-07T11:13:00.000Z https://lymphomahub.com/trials/gate1 weekly 0.7 2025-08-07T11:13:00.000Z https://lymphomahub.com/trials/bruin-mcl-321 weekly 0.7 2025-08-07T11:14:00.000Z https://lymphomahub.com/trials/waveline-006 weekly 0.7 2025-08-07T11:14:00.000Z https://lymphomahub.com/trials/nx-2127-001 weekly 0.7 2025-08-07T11:14:00.000Z https://lymphomahub.com/trials/tai-shan5 weekly 0.7 2025-08-07T13:25:00.000Z https://lymphomahub.com/trials/tai-shan8 weekly 0.7 2025-08-07T13:26:00.000Z https://lymphomahub.com/trials/epi-rchop weekly 0.7 2025-07-17T08:19:00.000Z https://lymphomahub.com/trials/apg2575cc201 weekly 0.7 2025-07-15T08:23:00.000Z https://lymphomahub.com/trials/improve weekly 0.7 2025-07-03T17:59:00.000Z https://lymphomahub.com/trials/marietta weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/waveline-003 weekly 0.7 2025-05-30T10:37:00.000Z https://lymphomahub.com/trials/prospect weekly 0.7 2025-05-30T10:39:00.000Z https://lymphomahub.com/trials/sakk-3819 weekly 0.7 2025-06-10T11:31:00.000Z https://lymphomahub.com/trials/golseek-1 weekly 0.7 2025-06-10T11:33:00.000Z https://lymphomahub.com/trials/guidance-02 weekly 0.7 2025-06-10T11:34:00.000Z https://lymphomahub.com/trials/imatrix-glo weekly 0.7 2025-06-10T11:37:00.000Z https://lymphomahub.com/trials/brawm weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/pacifico weekly 0.7 2025-06-10T11:32:00.000Z https://lymphomahub.com/trials/valym weekly 0.7 2025-06-10T11:35:00.000Z https://lymphomahub.com/trials/polaris weekly 0.7 2025-06-10T11:42:00.000Z https://lymphomahub.com/trials/cll-16 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/tellomak weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ahod2131 weekly 0.7 2025-06-10T11:34:00.000Z https://lymphomahub.com/trials/niveau weekly 0.7 2025-06-10T11:42:00.000Z https://lymphomahub.com/trials/efficacy-and-safety-study-of-lenalidomide-plus-r-chop-chemotherapy-versus-placebo-plus-r-chop-chemotherapy-in-untreated-abc-type-diffuse-large-b-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/lotis-2 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ecog-acrin-ea4151 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/lotis-5 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/swog-2308 weekly 0.7 2025-06-23T18:56:00.000Z https://lymphomahub.com/trials/luminice-203 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/epcore-dlbcl-2 weekly 0.7 2025-06-18T19:23:00.000Z https://lymphomahub.com/trials/maptivate-6 weekly 0.7 2025-06-09T17:29:00.000Z https://lymphomahub.com/trials/epcore-nhl-5 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/scent-02 weekly 0.7 2025-05-30T10:38:00.000Z https://lymphomahub.com/trials/orient-21 weekly 0.7 2025-05-30T10:38:00.000Z https://lymphomahub.com/trials/clover-wam weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cll6-residuum weekly 0.7 2025-05-28T12:46:00.000Z https://lymphomahub.com/trials/a-prospective-multicenter-phase-ii-trial-of-ibrutinib-plus-venetoclax-in-patients-with-creatinine-clearance-greater-30-mlmin-who-have-relapsed-or-refractory-chronic-lymphocytic-leukemia-rr-cll-with-or-without-tp53-aberrations weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/re-mind weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/re-mind2 weekly 0.7 2025-05-19T14:45:00.000Z https://lymphomahub.com/trials/realmind weekly 0.7 2025-05-19T14:46:00.000Z https://lymphomahub.com/trials/1st-flor weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/np30179 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-to-evaluate-the-benefit-of-venetoclax-plus-rituximab-compared-with-bendamustine-plus-rituximab-in-participants-with-relapsed-or-refractory-chronic-lymphocytic-leukemia weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/zuma-12 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/zuma-5 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/epcore-nhl-3 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/mithic-fl-1 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/juliet weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/safety-and-efficacy-of-kte-c19-in-adults-with-refractory-aggressive-non-hodgkin-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-of-polatuzumab-vedotin-dcds4501a-in-combination-with-rituximab-or-obinutuzumab-plus-bendamustine-in-participants-with-relapsed-or-refractory-follicular-or-diffuse-large-b-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-phase-2b-open-label-study-of-selinexor-kpt-330-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/elm-1 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/pola-r-ice weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/allg weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/keynote-667 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ecwm-2 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/mithil-fl weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/eradic weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/valentine-ptcl01 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/nivahl weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/indie weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/keynote-c11 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ratify weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/chl001 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/keyform-008 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-phase-3-study-of-brentuximab-vedotin-sgn-35-in-patients-at-high-risk-of-residual-hodgkin-lymphoma-following-stem-cell-transplant weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-pembrolizumab-mk-3475-in-participants-with-relapsed-or-refractory-classical-hodgkin-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-nivolumab-in-patients-with-classical-hodgkin-s-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-frontline-therapy-trial-in-participants-with-advanced-classical-hodgkin-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/keynote-204 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/istopmm weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/assessment-of-venetoclax-in-combination-with-ibrutinib-in-patients-with-chronic-lymphocytic-leukaemia weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/e7438-g000-101 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/tidal weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/efficacy-of-axicabtagene-ciloleucel-compared-to-standard-of-care-therapy-in-subjects-with-relapsedrefractory-diffuse-large-b-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-multi-center-study-of-ibrutinib-in-combination-with-obinutuzumab-versus-chlorambucil-in-combination-with-obinutuzumab-in-patients-with-treatment-naive-cll-or-sll weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-of-ibrutinib-in-combination-with-bendamustine-and-rituximab-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/alliance-a041202 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/genuine weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/evidence weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/reality weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/pembrowm weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/checkmate-436 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/outcomes-in-refractory-diffuse-large-b-cell-lymphoma-results-from-the-international-scholar-1-study weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/aall1231 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/venice-1 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/go29834 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/m13-982 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/zuma-18 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/jackpot8 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/magnolia weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/alycante weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-of-obinutuzumab-ro5072759-plus-chemotherapy-in-comparison-with-rituximab-plus-chemotherapy-followed-by-obinutuzumab-or-rituximab-maintenance-in-patients-with-untreated-advanced-indolent-non-hodgkin-s-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/transcend-world weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/tisagenlecleucel-in-adult-patients-with-aggressive-b-cell-non-hodgkin-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/rituximab-and-bendamustine-hydrochloride-rituximab-and-ibrutinib-or-ibrutinib-alone-in-treating-older-patients-with-previously-untreated-chronic-lymphocytic-leukemia weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/determine-efficacy-and-safety-of-ctl019-in-pediatric-patients-with-relapsed-and-refractory-b-cell-all-and-high-risk-b-cell-all-at-first-relapse-determine-feasibility-and-safety-of-ctl019-therapy-in-pediatric-patients-with-high-risk-b-cell-all-that-relaps weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cll8 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cll10 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ibrutinib-with-rituximab-in-adults-with-waldenstrom-s-macroglobulinemia weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/epicovideha weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-randomised-evaluation-of-molecular-guided-therapy-for-diffuse-large-b-cell-lymphoma-with-bortezomib weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cll2-give weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cll2-bio weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cll2-big weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cll2-bag weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cll2-bcg weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/smart-start-a-phase-ii-study-of-rituximab-lenalidomide-and-ibrutinib weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ibrutinib-and-rituximab-compared-with-fludarabine-phosphate-cyclophosphamide-and-rituximab-in-treating-patients-with-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ublituximab-tgr-1202-compared-to-obinutuzumab-chlorambucil-in-patients-with-untreated-and-previously-treated-chronic-lymphocytic-leukemia weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/aern-trial weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-trial-of-obinutuzumabgdc-0199-plus-ibrutinib-in-relapsedrefractory-mantle-cell-lymphoma-patients weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/imcl-2015 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/transcend-outreach-007 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/nct04712864 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/citadel-205 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/citadel-204 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/citadel-203 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/alpha2 weekly 0.7 2026-07-30T15:56:00.000Z https://lymphomahub.com/trials/a-phase-12-open-label-dose-escalation-safety-and-tolerability-study-of-incb050465-and-itacitinib-in-subjects-with-previously-treated-b-cell-malignancies weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/alpha weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/rapid weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-kw-0761-versus-vorinostat-in-relapsedrefractory-ctcl weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/first-mind weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/abt-199-and-ibrutinib-in-mantle-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-obinutuzumab-combined-to-lenalidomide-for-the-treatment-of-relapsedrefractory-follicular-and-aggressive-b-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/chemoradiotherapy-and-peripheral-stem-cell-transplantation-compared-with-combination-chemotherapy-in-treating-patients-with-non-hodgkin-s-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-to-investigate-the-efficacy-and-safety-of-bendamustine-compared-with-bendamustine-obinutuzumab-ga101-in-participants-with-rituximab-refractory-indolent-non-hodgkin-s-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/chronos-3 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/senior weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/s1918 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-phase-2-study-of-duvelisib-in-subjects-with-refractory-indolent-non-hodgkin-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-phase-3-study-of-duvelisib-versus-ofatumumab-in-patients-with-relapsed-or-refractory-cllsll weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/e1412 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-of-obinutuzumab-in-combination-with-chop-chemotherapy-versus-rituximab-with-chop-in-participants-with-cd20-positive-diffuse-large-b-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-safety-and-pharmacokinetics-pk-study-of-venetoclax-in-participants-with-non-hodgkin-s-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/significance-of-duration-of-maintenance-therapy-with-rituximab-in-non-hodgkin-lymphomas weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-to-assess-the-efficacy-and-safety-of-ublituximab-tgr-1202-with-or-without-bendamustine-and-tgr-1202-alone-in-patients-with-previously-treated-non-hodgkins-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/advl0912 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/efficacy-of-upfront-and-maintenance-obinutuzumab-in-mantle-cell-lymphoma-treated-by-dhap-and-mrd-driven-maintenance weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/alexander-maurer-1 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/sabrina weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cc-122-nhl-001 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-clr-131-in-relapsed-or-refractory-select-b-cell-malignancies weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-comparing-maintenance-subcutaneous-rituximab-with-observation-only-in-participants-with-relapsed-or-refractory-indolent-non-hodgkin-s-lymphoma-who-had-responded-to-rituximab-based-immunochemotherapy-induction-and-2-year-maintenance-with-subcutane weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/pivotal weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/lymrit-37-01 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-comparison-of-brentuximab-vedotin-and-chp-with-standard-of-care-chop-in-the-treatment-of-patients-with-cd30-positive-mature-t-cell-lymphomas weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/dshnhl-2006-1bact-2 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-trial-of-ibrutinib-lenalidomide-and-rituximab-for-patients-with-relapsedrefractory-mantle-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/belief weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/lenalidomide-plus-rituximab-followed-by-lenalidomide-versus-rituximab-maintenance-for-relapsedrefractory-follicular-marginal-zone-or-mantle-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/phase-iii-feasibility-study-combining-brentuximab-vedotin-with-second-line-salvage-chemotherapy-dhap-in-hodgkin-lymphoma-patients weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/durability weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/embolden weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/auto-versus-allotransplantation-in-t-nhl-autologous-or-allogeneic-transplantation-following-conventional-chemotherapy-in-younger-patients-18-60-yrs-with-mature-peripheral-t-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/alisertib-mln8237-or-investigator-s-choice-in-patients-with-relapsedrefractory-peripheral-t-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/chop-vs-gem-p-in-1st-line-treatment-of-t-cell-lymphoma-multicentre-phase-ii-study weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/flash weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/calgb-50403 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ho75 weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/t-cell-project-prospective-collection-of-data-in-patients-with-peripheral-t-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/rituximab-and-combination-chemotherapy-in-treating-patients-with-non-hodgkin-s-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/confirmatory-phase-ii-study-of-blinatumomab-mt103-in-patients-with-minimal-residual-disease-of-b-precursor-acute-lymphoblastic-leukemia weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-trial-of-pembrolizumab-mk-3475-in-participants-with-blood-cancers weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cd30-car-t-cells-relapsed-cd30-expressing-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/dose-escalation-study-of-ucart19-in-adult-patients-with-relapsed-refractory-b-cell-acute-lymphoblastic-leukaemia weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-ucart19-in-pediatric-patients-with-relapsedrefractory-b-acute-lymphoblastic-leukemia weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-abexinostat-in-patients-with-relapsed-or-refractory-follicular-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/primary-rituximab-and-maintenance weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-phase-3-evaluation-of-how-pet-scans-can-help-guide-further-therapy-or-no-therapy-for-patients-with-previously-untreated-high-tumour-burden-follicular-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/rituximab-and-cvp-plus-interferon-for-follicular-non-hodgkins-lymphoma-nhl weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-lenalidomide-maintenance-versus-placebo-in-responding-elderly-patients-with-dlbcl-and-treated-with-r-chop weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-of-pf-05280586-rituximab-pfizer-or-mabthera-r-rituximab-eu-for-the-first-line-treatment-of-patients-with-cd20-positive-low-tumor-burden-follicular-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/trial-for-patients-with-newly-diagnosed-primary-central-nervous-system-cns-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/cranial-radiotherapy-or-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-for-primary-central-nervous-system-lymphoma-in-young-patients weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/rituximab-and-combination-chemotherapy-in-treating-patients-with-diffuse-large-b-cell-non-hodgkin-s-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-of-pinatuzumab-vedotin-dcdt2980s-combined-with-rituximab-or-polatuzumab-vedotin-dcds4501a-combined-with-rituximab-or-obinutuzumab-in-participants-with-relapsed-or-refractory-b-cell-non-hodgkin-s-lymphoma-nhl weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/r-ice-versus-r-dhap-in-patients-aged-18-65-with-relapse-diffuse-large-b-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/rituximab-after-lymphoma-directed-conditioning-and-allogeneic-stem-cell-transplantation-for-relapsed-and-refractory-aggressive-non-hodgkin-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/autologous-bone-marrow-transplantation-as-compared-with-salvage-chemotherapy-in-relapses-of-chemotherapy-sensitive-non-hodgkin-s-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ofatumumab-in-treating-patients-with-previously-untreated-stage-ii-stage-iii-or-stage-iv-follicular-non-hodgkin-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/efficacy-and-safety-evaluation-of-ibi308-in-treatment-of-patients-with-relapsedrefractory-classical-hodgkin-s-lymphoma-a-multicenter-single-arm-phase-ii-study weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/rituximab-in-primary-central-nervous-system-lymphoma-a-randomized-hovon-allg-intergroup-study weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/ofatumumab-bendamustine-combination-compared-with-bendamustine-monotherapy-in-indolent-b-cell-nhl-unresponsive-to-rituxtherapy weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-pembrolizumab-mk-3475-in-participants-with-relapsed-or-refractory-primary-mediastinal-large-b-cell-lymphoma-or-relapsed-or-refractory-richter-syndrome weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-phase-ii-study-evaluating-the-effect-of-the-addition-of-lenalidomide-to-r-chop-for-patients-with-newly-diagnosed-myc-positive-dlbcl-and-bcl-u weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/bendamustine-and-rituximab-for-the-treatment-of-splenic-marginal-zone-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/rituximab-standard-chop-vs-rituximab-bi-weekly-chop-for-untreated-stage-iiiiv-low-grade-b-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/hd12-for-advanced-stages weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-of-obinutuzumab-ro5072759-ga101-in-combination-with-chop-chemotherapy-in-patients-with-previously-untreated-advanced-diffuse-large-b-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-phase-3-trial-of-brentuximab-vedotin-sgn-35-versus-physician-s-choice-methotrexate-or-bexarotene-in-participants-with-cd30-positive-cutaneous-t-cell-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/a-study-of-pci-32765-ibrutinib-in-patients-with-refractory-follicular-lymphoma weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/trials/study-of-bendamustine-hydrochloride-and-rituximab-br-compared-with-r-cvp-or-r-chop-in-the-first-line-treatment-of-patients-with-advanced-indolent-non-hodgkin-s-lymphoma-nhl-or-mantle-cell-lymphoma-mcl weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/expert-opinions weekly 0.8 2025-04-30T09:45:00.000Z https://lymphomahub.com/drug-updates weekly 0.8 2025-04-30T09:45:00.000Z https://lymphomahub.com/educational-resources weekly 0.8 2026-02-13T15:55:00.000Z https://lymphomahub.com/educational-resources/visual-abstracts weekly 0.7 2025-10-21T08:42:00.000Z https://lymphomahub.com/educational-resources/drugs-approvals-in-lymphoma-and-cll weekly 0.7 2025-10-21T08:42:00.000Z https://lymphomahub.com/educational-resources/lym-hub-symposiums weekly 0.7 2025-10-21T08:42:00.000Z https://lymphomahub.com/educational-resources/steering-committee-meetings weekly 0.7 2025-10-21T08:42:00.000Z https://lymphomahub.com/educational-resources/spotlights weekly 0.7 2025-10-21T08:42:00.000Z https://lymphomahub.com/educational-resources/masterclass weekly 0.7 2026-02-12T15:44:00.000Z https://lymphomahub.com/educational-resources/editorial-themes-and-reviews weekly 0.7 2025-12-23T10:41:00.000Z https://lymphomahub.com/educational-resources/treatment-of-older-patients-with-lymphoma-and-cll weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/educational-resources/special-populations weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/educational-resources/management-of-treatment-related-toxicities weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/educational-resources/guidelines weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/educational-resources/supportive-care weekly 0.7 2025-04-29T14:15:00.000Z https://lymphomahub.com/medical-information/phase-iii-sympatico-trial-ibrutinib-venetoclax-in-nonblastoid-mcl monthly 0.9 2026-10-27T09:00:00.000Z https://lymphomahub.com/medical-information/outcomes-with-allo-hsct-and-auto-hsct-in-hepatosplenic-t-cell-lymphoma monthly 0.9 2026-10-23T09:00:00.000Z https://lymphomahub.com/medical-information/phase-iii-halo-trial-first-line-brentuximab-vedotin-bendamustine-in-elderly-patients-with-chl monthly 0.9 2026-10-19T14:00:00.000Z https://lymphomahub.com/medical-information/fda-clears-ind-for-lb2501-in-patients-with-rr-b-cell-malignancies monthly 0.9 2026-10-16T12:47:00.000Z https://lymphomahub.com/medical-information/iach-2026-live-congress-coverage-from-the-lymphoma-hub monthly 0.9 2026-10-21T14:42:00.000Z https://lymphomahub.com/medical-information/how-do-you-see-tandem-car-t-cell-therapies-fitting-into-the-future-treatment-landscape-for-lbcl monthly 0.9 2026-10-22T12:40:00.000Z https://lymphomahub.com/medical-information/visual-abstract-boven-in-patients-with-tn-cllsll-long-term-follow-up-results monthly 0.9 2026-10-13T10:00:00.000Z https://lymphomahub.com/medical-information/how-might-key-findings-from-the-hd21-trial-influence-1l-treatment-of-advanced-stage-chl monthly 0.9 2026-10-12T16:22:00.000Z https://lymphomahub.com/medical-information/phase-iii-euronet-phl-lp1-trial-complete-surgical-resection-or-cvp-in-pediatric-patients-with-nlphl monthly 0.9 2026-10-09T09:32:00.000Z https://lymphomahub.com/medical-information/phase-iii-atalanta-1-study-dose-escalation-of-glpg5101-for-rr-b-cell-nhl monthly 0.9 2026-10-06T09:00:00.000Z https://lymphomahub.com/medical-information/fda-approves-pirtobrutinib-for-previously-untreated-cllsll monthly 0.9 2026-10-05T16:01:00.000Z https://lymphomahub.com/medical-information/visual-abstract-daly-2-eu-primary-analysis-zamto-cel-in-2l-transplant-ineligible-patients-with-rr-lbcl monthly 0.9 2026-10-08T09:28:00.000Z https://lymphomahub.com/medical-information/liso-cel-for-rr-lbcl-5-year-follow-up-of-the-pivotal-transcend-nhl-001-study monthly 0.9 2026-10-02T09:04:00.000Z https://lymphomahub.com/medical-information/chinas-nmpa-approves-pirtobrutinib-monotherapy-for-adults-with-cllsll monthly 0.9 2026-09-29T14:02:00.000Z https://lymphomahub.com/medical-information/phase-ibii-epcore-nhl-2-trial-first-line-epcoritamab-r2-in-fl monthly 0.9 2026-09-29T09:00:00.000Z https://lymphomahub.com/medical-information/health-canada-approves-epcoritamab-in-combination-with-lenalidomide-rituximab-for-rr-fl monthly 0.9 2026-09-28T13:52:00.000Z https://lymphomahub.com/medical-information/mosunetuzumab-with-response-adapted-polatuzumab-vedotin-obinutuzumab-in-previously-untreated-fl-or-mzl monthly 0.9 2026-09-25T09:00:00.000Z https://lymphomahub.com/medical-information/what-do-the-3-year-follow-up-results-from-the-starglo-trial-tell-us-about-glofit-gemox-in-rr-dlbcl monthly 0.9 2026-10-08T17:50:00.000Z https://lymphomahub.com/medical-information/phase-iii-perspective-trial-ibrutinib-rituximab-in-previously-untreated-fl monthly 0.9 2026-09-22T09:00:00.000Z https://lymphomahub.com/medical-information/autologous-or-allogeneic-hematopoietic-stem-cell-transplantation-for-rr-chl monthly 0.9 2026-09-18T09:00:00.000Z https://lymphomahub.com/medical-information/the-cll12-trial-genetic-risk-factors-and-outcomes-with-ibrutinib-in-early-stage-cll monthly 0.9 2026-09-15T09:00:00.000Z https://lymphomahub.com/medical-information/life-years-saved-through-therapeutic-advances-in-blood-cancers-a-retrospective-analysis monthly 0.9 2026-09-11T09:26:00.000Z https://lymphomahub.com/medical-information/phase-iii-renoir-trial-rituximab-lenalidomide-maintenance-vs-rituximab-alone-in-rr monthly 0.9 2026-10-06T16:15:00.000Z https://lymphomahub.com/medical-information/the-pricelus-study-csf-biomarkers-for-pcnsl-diagnosis monthly 0.9 2026-09-04T10:00:00.000Z https://lymphomahub.com/medical-information/what-is-the-current-clinical-evidence-for-tandem-car-t-cell-therapies-in-rr-dlbcl monthly 0.9 2026-09-22T23:29:00.000Z https://lymphomahub.com/medical-information/phase-iii-polargo-trial-pola-r-gemox-vs-r-gemox-in-rr-dlbcl monthly 0.9 2026-09-01T09:00:00.000Z https://lymphomahub.com/medical-information/phase-iii-triangle-trial-ibrutinib-containing-therapy-rituximab-maintenance-in-mcl monthly 0.9 2026-08-28T09:00:00.000Z https://lymphomahub.com/medical-information/what-is-the-rationale-for-the-development-of-tandem-car-t-cell-therapies monthly 0.9 2026-09-15T10:45:00.000Z https://lymphomahub.com/medical-information/patient-reported-symptomatic-aes-following-car-t-cell-therapy-in-aggressive-b-cell-lymphomas monthly 0.9 2026-08-25T09:00:00.000Z https://lymphomahub.com/medical-information/abexinostat-monotherapy-in-rr-fl-phase-ii-study-results monthly 0.9 2026-08-20T11:16:00.000Z https://lymphomahub.com/medical-information/phase-iii-transcend-cll-004-trial-liso-cel-ibrutinib-in-rr-cllsll monthly 0.9 2026-08-18T11:26:00.000Z https://lymphomahub.com/medical-information/phase-iii-matrixielsg43-trial-hct-asct-vs-non-myeloablative-r-devic-consolidation-in-pcnsl monthly 0.9 2026-08-13T10:18:00.000Z https://lymphomahub.com/medical-information/phase-ii-epcore-dlbcl-3-trial-epcoritamab-lenalidomide-in-older-patients-with-dlbcl monthly 0.9 2026-08-11T09:00:00.000Z https://lymphomahub.com/medical-information/symposium-series-optimizing-treatment-for-chronic-lymphocytic-leukemia-with-btk-inhibitors monthly 0.9 2026-08-18T08:27:00.000Z https://lymphomahub.com/medical-information/nice-recommends-acalabrutinib-combinations-for-mcl-and-cll monthly 0.9 2026-08-07T13:46:00.000Z https://lymphomahub.com/medical-information/symposium-optimizing-chronic-lymphocytic-leukemia-management-in-a-changing-landscape monthly 0.9 2026-08-20T09:12:00.000Z https://lymphomahub.com/medical-information/phase-i-cadance-101-trial-update-tacabrutideg-for-rr-cllsll monthly 0.9 2026-08-18T08:33:00.000Z https://lymphomahub.com/medical-information/bridging-to-car-t-cell-therapy-in-lbcl-with-cd20-cd3-bsabs-vs-conventional-treatment monthly 0.9 2026-08-03T09:13:00.000Z https://lymphomahub.com/medical-information/symposium-btk-inhibitors-in-practice-treatment-selection-and-emerging-clinical-evidence monthly 0.9 2026-08-18T08:39:00.000Z https://lymphomahub.com/medical-information/fda-grants-rmat-and-fast-track-designation-to-cema-cel-for-first-line-consolidation-in-mrd-positive-lbcl monthly 0.9 2026-07-30T16:05:00.000Z https://lymphomahub.com/medical-information/phase-iii-polar-bear-trial-pola-r-mini-chp-vs-r-mini-chop-in-elderly-or-frail-patients-with-dlbcl monthly 0.9 2026-07-30T10:24:00.000Z https://lymphomahub.com/medical-information/symposium-btk-inhibitors-in-cll-mechanisms-clinical-considerations-and-unmet-needs monthly 0.9 2026-08-18T08:37:00.000Z https://lymphomahub.com/medical-information/cll14-venetoclax-obinutuzumab-in-previously-untreated-cll monthly 0.9 2026-07-27T15:00:00.000Z https://lymphomahub.com/medical-information/phase-iii-epcore-dlbcl-1-trial-epcoritamab-vs-cit-in-rr-lbcl monthly 0.9 2026-07-23T08:00:00.000Z https://lymphomahub.com/medical-information/phase-iii-soundtrack-f1-trial-surovatamig-rituximab-in-previously-untreated-fl monthly 0.9 2026-07-21T09:00:00.000Z https://lymphomahub.com/medical-information/phase-iib-bgb-11417-101-trial-sonrotoclax-zanubrutinib-in-tn-cllsll monthly 0.9 2026-08-04T13:18:00.000Z https://lymphomahub.com/medical-information/eha2026-what-are-the-key-findings-from-the-subgroup-analysis-of-the-epcore-fl-1-trial-in-rr-fl monthly 0.9 2026-07-16T12:13:00.000Z https://lymphomahub.com/medical-information/phase-ii-vt-ebv-201-trial-vt-ebv-n-for-ebv-positive-enktl monthly 0.9 2026-07-13T09:00:00.000Z https://lymphomahub.com/medical-information/phase-i-trial-of-lb2501-novel-in-vivo-cd19cd20-car-t-cell-therapy-for-rr-b-nhl monthly 0.9 2026-07-09T08:30:00.000Z https://lymphomahub.com/medical-information/ec-approves-epcoritamab-in-combination-with-lenalidomide-rituximab-for-rr-fl monthly 0.9 2026-07-07T12:53:00.000Z https://lymphomahub.com/medical-information/bruin-cll-322-phase-iii-pvr-vs-vr-for-rr-cll monthly 0.9 2026-07-07T08:43:00.000Z https://lymphomahub.com/medical-information/frontmind-phase-iii-tafasitamab-lenalidomide-r-chop-in-dlbcl-and-hgbl monthly 0.9 2026-07-03T08:00:00.000Z https://lymphomahub.com/medical-information/eha-2026-what-are-the-key-findings-from-the-daly-2-eu-trial-of-zamto-cel-in-rr-lbcl monthly 0.9 2026-07-30T12:45:00.000Z https://lymphomahub.com/medical-information/triangle-phase-iii-ibrutinib-containing-first-line-treatment-with-or-without-auto-hsct-for-mcl monthly 0.9 2026-06-30T13:47:00.000Z https://lymphomahub.com/medical-information/ema-chmp-issues-a-positive-opinion-for-the-approval-of-pirtobrutinib-in-cll-across-all-lines-of-therapy monthly 0.9 2026-06-29T16:37:00.000Z https://lymphomahub.com/medical-information/the-role-of-ngs-in-detecting-resistance-to-targeted-therapies-in-cll monthly 0.9 2026-08-18T08:32:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-for-patients-with-previously-untreated-cllsll-insights-from-the-sequoia-trial monthly 0.9 2026-09-18T14:01:00.000Z https://lymphomahub.com/medical-information/eha2026-live-congress-coverage-from-the-lymphoma-hub monthly 0.9 2026-06-23T15:00:00.000Z https://lymphomahub.com/medical-information/eha2026-congress-coverage-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma monthly 0.9 2026-06-23T15:00:00.000Z https://lymphomahub.com/medical-information/eha2026-congress-coverage-indolent-and-mantle-cell-nhl monthly 0.9 2026-06-23T14:59:00.000Z https://lymphomahub.com/medical-information/eha2026-congress-coverage-hodgkin-lymphoma-and-t-cell-lymphoma monthly 0.9 2026-06-23T15:00:00.000Z https://lymphomahub.com/medical-information/eha-2026-what-are-the-key-findings-from-the-phase-i-antler-trial-in-rr-b-cell-nhl monthly 0.9 2026-07-10T09:26:00.000Z https://lymphomahub.com/medical-information/eha-2026-what-are-the-most-recent-findings-from-the-phase-i-nx-5948-301-trial-evaluating-bexobrutideg-in-cll monthly 0.9 2026-09-22T14:43:00.000Z https://lymphomahub.com/medical-information/annual-oncology-meeting-key-highlights-in-lymphoma monthly 0.9 2026-06-22T11:16:00.000Z https://lymphomahub.com/medical-information/eortc-1537-cobra-phase-ii-very-early-pet-guided-therapy-in-advanced-stage-chl monthly 0.9 2026-08-18T08:40:00.000Z https://lymphomahub.com/medical-information/fda-approves-romidepsin-injection-solution-for-cutaneous-t-cell-lymphoma monthly 0.9 2026-06-05T12:30:00.000Z https://lymphomahub.com/medical-information/bruin-phase-iii-5-year-follow-up-pirtobrutinib-in-rr-wm monthly 0.9 2026-06-05T08:43:00.000Z https://lymphomahub.com/medical-information/eha2026-top-abstracts-whats-hot-in-lymphoma-and-cll monthly 0.9 2026-06-05T09:30:00.000Z https://lymphomahub.com/medical-information/curative-potential-of-car-t-cell-therapy-in-large-b-cell-lymphoma monthly 0.9 2026-08-18T09:54:00.000Z https://lymphomahub.com/medical-information/ec-approves-nivolumab-avd-for-chl monthly 0.9 2026-06-02T14:05:00.000Z https://lymphomahub.com/medical-information/ec-authorizes-label-expansion-for-venetoclax-combinations-in-cll monthly 0.9 2026-06-02T09:52:00.000Z https://lymphomahub.com/medical-information/congresses-asco26 monthly 0.9 2026-06-03T16:00:00.000Z https://lymphomahub.com/medical-information/zuma-2-phase-ii-5-year-follow-up-brexu-cel-in-rr-mcl monthly 0.9 2026-05-29T08:00:00.000Z https://lymphomahub.com/medical-information/australias-tga-approves-orelabrutinib-for-rr-mcl monthly 0.9 2026-05-28T13:15:00.000Z https://lymphomahub.com/medical-information/epcore-nhl-6-phase-ii-interim-analysis-outpatient-epcoritamab-for-2l-dlbcl monthly 0.9 2026-08-18T08:44:00.000Z https://lymphomahub.com/medical-information/tak-007-car-nk-cell-therapy-for-rr-b-cell-nhl-a-phase-ii-study monthly 0.9 2026-05-22T08:00:00.000Z https://lymphomahub.com/medical-information/phase-ii-elm-2-exploratory-analysis-cr-dynamics-with-odronextamab-in-rr-fl monthly 0.9 2026-05-20T08:04:00.000Z https://lymphomahub.com/medical-information/augment-phase-iii-5-year-follow-up-lenalidomide-rituximab-in-rr-inhl monthly 0.9 2026-05-15T10:48:00.000Z https://lymphomahub.com/medical-information/fda-grants-accelerated-approval-to-sonrotoclax-for-rr-mcl monthly 0.9 2026-05-14T15:58:00.000Z https://lymphomahub.com/medical-information/mosun-pola-in-rr-mcl-after-btki-therapy-a-phase-ibii-study monthly 0.9 2026-08-18T09:58:00.000Z https://lymphomahub.com/medical-information/primo-phase-ii-dose-expansion-final-analysis-duvelisib-monotherapy-in-rr-ptcl monthly 0.9 2026-05-08T08:00:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-in-tn-and-rr-wm-5-year-phase-ii-study-results monthly 0.9 2026-05-06T09:03:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-in-tn-and-rr-cllsll-long-term-phase-ii-study-results monthly 0.9 2026-05-01T08:00:00.000Z https://lymphomahub.com/medical-information/south-koreas-mfds-approves-anbalcabtagene-autoleucel-for-adults-with-rr-dlbcl-and-pmbcl monthly 0.9 2026-04-30T16:42:00.000Z https://lymphomahub.com/medical-information/relevance-phase-iii-10year-results-r2-vs-immunochemotherapy-in-previously-untreated-advanced-fl monthly 0.9 2026-04-28T11:00:00.000Z https://lymphomahub.com/medical-information/visual-abstract-hd21-final-analysis-pet-guided-brecadd-vs-ebeacopp-in-as-chl monthly 0.9 2026-07-14T11:42:00.000Z https://lymphomahub.com/medical-information/chess-phase-ii-zanubrutinib-rituximab-followed-by-shortened-chemoimmunotherapy-in-1l-mcl monthly 0.9 2026-04-24T09:01:00.000Z https://lymphomahub.com/medical-information/tafasitamab-rituximab-lenalidomide-approved-by-australias-tga-for-rr-fl monthly 0.9 2026-04-23T16:28:00.000Z https://lymphomahub.com/medical-information/nice-recommends-pirtobrutinib-for-adults-with-rr-cll monthly 0.9 2026-04-21T13:44:00.000Z https://lymphomahub.com/medical-information/gaiacll13-phase-iii-5year-follow-up-venetoclax-combinations-in-cll monthly 0.9 2026-04-21T08:00:00.000Z https://lymphomahub.com/medical-information/go29781-phase-iii-dose-expansion-sc-mosunetuzumab-in-rr-fl monthly 0.9 2026-04-17T09:00:00.000Z https://lymphomahub.com/medical-information/jackpot26-phase-ii-golidocitinib-maintenance-after-first-line-systemic-therapy-in-ptcl monthly 0.9 2026-04-14T09:12:00.000Z https://lymphomahub.com/medical-information/leap-regimen-a-phase-ii-study-of-sintilimab-pegaspargase-anlotinib-for-advanced-stage-nktcl monthly 0.9 2026-04-10T15:49:00.000Z https://lymphomahub.com/medical-information/mosunetuzumab-in-rr-richters-transformation-phase-iii-study-results monthly 0.9 2026-04-08T08:00:00.000Z https://lymphomahub.com/medical-information/fda-grants-full-approval-to-brexucabtagene-autoleucel-for-rr-mcl monthly 0.9 2026-04-07T16:05:00.000Z https://lymphomahub.com/medical-information/cristallo-phase-iii-primary-analysis-veno-vs-fcrbr-in-previously-untreated-cll monthly 0.9 2026-04-03T09:00:00.000Z https://lymphomahub.com/medical-information/epcore-nhl2-epcoritamab-r-dhaxc-for-transplant-eligible-rr-dlbcl monthly 0.9 2026-04-01T09:22:00.000Z https://lymphomahub.com/medical-information/swog-s0016-15year-follow-up-first-line-chop-based-therapy-in-advanced-stage-fl monthly 0.9 2026-03-27T10:12:00.000Z https://lymphomahub.com/medical-information/brazils-anvisa-approves-tafasitamab-r2-for-rr-fl monthly 0.9 2026-03-24T16:00:00.000Z https://lymphomahub.com/medical-information/phase-iii-bruin-pros-pirtobrutinib-in-cllsll-and-mcl monthly 0.9 2026-03-24T10:00:00.000Z https://lymphomahub.com/medical-information/fda-and-ec-approve-nivolumab-combination-therapies-for-chl monthly 0.9 2026-03-23T17:37:00.000Z https://lymphomahub.com/medical-information/transcend-fl-phase-ii-lisocabtagene-maraleucel-in-rr-mzl monthly 0.9 2026-03-20T09:00:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-in-rr-lbcl monthly 0.9 2026-03-18T09:00:00.000Z https://lymphomahub.com/medical-information/resmain-resminostat-maintenance-in-advanced-stage-mycosis-fungoides-or-sezary-syndrome monthly 0.9 2026-03-17T10:39:00.000Z https://lymphomahub.com/medical-information/transform-long-term-follow-up-liso-cel-for-2l-rr-lbcl monthly 0.9 2026-03-13T10:05:00.000Z https://lymphomahub.com/medical-information/phase-ii-study-of-mrd-driven-alr-or-alo-in-previously-untreated-mcl monthly 0.9 2026-03-10T09:00:00.000Z https://lymphomahub.com/medical-information/tazemetostat-voluntarily-withdrawn-for-fl monthly 0.9 2026-03-09T16:04:00.000Z https://lymphomahub.com/medical-information/pen-rma-for-pcnsl-phase-ii-study-results monthly 0.9 2026-03-06T09:00:00.000Z https://lymphomahub.com/medical-information/epcore-nhl-1-3-year-update-epcoritamab-for-rr-lbcl monthly 0.9 2026-03-03T11:00:00.000Z https://lymphomahub.com/medical-information/pirtobrutinib-approved-by-chinas-nmpa-for-rr-cll-or-sll monthly 0.9 2026-03-02T17:00:00.000Z https://lymphomahub.com/medical-information/visual-abstract-phase-iii-bgb-11417-201-trial-primary-analysis-sonrotoclax-monotherapy-in-rr-mcl monthly 0.9 2026-09-16T08:51:00.000Z https://lymphomahub.com/medical-information/direct-prognostic-value-of-pv-supported-ctdna-mrd-in-lbcl monthly 0.9 2026-02-26T14:33:00.000Z https://lymphomahub.com/medical-information/nice-recommends-epcoritamab-for-rr-fl monthly 0.9 2026-02-24T17:00:00.000Z https://lymphomahub.com/medical-information/daly-ii-usa-interim-results monthly 0.9 2026-02-24T10:00:00.000Z https://lymphomahub.com/medical-information/go29781-phase-iii-subgroup-analysis-mosunetuzumab-in-older-patients-with-rr-b-nhl monthly 0.9 2026-06-05T12:54:00.000Z https://lymphomahub.com/medical-information/venetoclax-acalabrutinib-approved-by-the-fda-for-previously-untreated-cll monthly 0.9 2026-02-20T15:00:00.000Z https://lymphomahub.com/medical-information/bruin-phase-iii-results-pirtobrutinib-in-rr-mzl monthly 0.9 2026-02-19T11:01:00.000Z https://lymphomahub.com/medical-information/swog-s1826-3-year-follow-up-n-avd-vs-bv-avd-in-adolescents-with-as-chl monthly 0.9 2026-02-17T10:50:00.000Z https://lymphomahub.com/medical-information/sequoia-arms-a-and-b-6-year-follow-up-results-from-ash-2025 monthly 0.9 2026-02-16T14:42:00.000Z https://lymphomahub.com/medical-information/masterclass-optimizing-btki-bcl-2i-combination-therapy-for-patients-with-cll monthly 0.9 2026-03-20T11:25:00.000Z https://lymphomahub.com/medical-information/zuma-14-phase-ii-results-axi-cel-rituximab-for-refractory-lbcl monthly 0.9 2026-02-13T13:32:00.000Z https://lymphomahub.com/medical-information/phase-ii-sgn35-027-trial-an-ad-for-early-stage-chl monthly 0.9 2026-02-10T11:03:00.000Z https://lymphomahub.com/medical-information/fda-approves-label-update-for-axi-cel-for-the-treatment-of-rr-pcnsl monthly 0.9 2026-02-09T17:00:00.000Z https://lymphomahub.com/medical-information/bruin-cll-314-pirtobrutinib-vs-ibrutinib-for-cllsll monthly 0.9 2026-02-06T09:00:00.000Z https://lymphomahub.com/medical-information/mrd-guided-treatment-with-ibrutinib-venetoclax-updates-from-the-flair-trial monthly 0.9 2026-02-04T14:00:00.000Z https://lymphomahub.com/medical-information/5-year-follow-up-mosunetuzumab-in-patients-with-heavily-pretreated-rr-fl monthly 0.9 2026-02-03T17:28:00.000Z https://lymphomahub.com/medical-information/juliet-5-year-follow-up-results-tisagenlecleucel-for-rr-lbcl monthly 0.9 2026-02-03T09:00:00.000Z https://lymphomahub.com/medical-information/hovon-158next-step-mrd-guided-ibrutinib-obinutuzumab-intensification-in-cll monthly 0.9 2026-01-30T10:00:00.000Z https://lymphomahub.com/medical-information/pirtobrutinib-approved-by-health-canada-for-the-treatment-of-rr-mcl-and-cllsll monthly 0.9 2026-01-28T18:00:00.000Z https://lymphomahub.com/medical-information/inmind-tafasitamab-lenalidomide-rituximab-for-rr-fl monthly 0.9 2026-01-27T09:00:00.000Z https://lymphomahub.com/medical-information/surovatamig-for-patients-with-rr-fl-3-year-follow-up-results monthly 0.9 2026-01-23T12:00:00.000Z https://lymphomahub.com/medical-information/cll-17-interim-analysis-fixed-duration-vs-continuous-treatment-for-cll monthly 0.9 2026-01-20T14:00:00.000Z https://lymphomahub.com/medical-information/mithic-fl2-phase-ii-mosunetuzumab-zanubrutinib-in-nd-fl monthly 0.9 2026-01-15T09:00:00.000Z https://lymphomahub.com/medical-information/boven-as-frontline-therapy-in-older-patients-with-mcl-phase-ii-preliminary-results monthly 0.9 2026-01-12T11:00:00.000Z https://lymphomahub.com/medical-information/visual-abstract-optimizing-post-treatment-monitoring-following-car-t-cell-therapy-policy-changes-and-adverse-event-data monthly 0.9 2026-07-14T11:44:00.000Z https://lymphomahub.com/medical-information/soquelitinib-for-rr-t-cell-lymphomas-phase-i-results monthly 0.9 2026-01-08T10:49:00.000Z https://lymphomahub.com/medical-information/echo-trial-50-month-follow-up-results-abr-vs-pbr-in-tn-mcl monthly 0.9 2026-01-05T09:36:00.000Z https://lymphomahub.com/medical-information/bruin-cll-313-pirtobrutinib-vs-br-for-treatment-naive-cllsll monthly 0.9 2025-12-29T13:00:00.000Z https://lymphomahub.com/medical-information/subcutaneous-mosunetuzumab-approved-by-the-fda-for-rr-fl monthly 0.9 2025-12-22T16:28:00.000Z https://lymphomahub.com/medical-information/tafasitamab-lenalidomide-rituximab-approved-by-japans-mhlw-for-rr-fl monthly 0.9 2025-12-22T15:48:00.000Z https://lymphomahub.com/medical-information/btki-for-patients-with-ccl-class-effects-guidelines-and-real-world-evidence monthly 0.9 2025-12-23T13:46:00.000Z https://lymphomahub.com/medical-information/ash-2025-key-highlights-in-lymphoma-and-cll monthly 0.9 2025-12-22T15:13:00.000Z https://lymphomahub.com/medical-information/tafasitamab-lenalidomide-rituximab-approved-by-the-ec-for-rr-fl monthly 0.9 2025-12-18T15:36:00.000Z https://lymphomahub.com/medical-information/ash-2025-latest-updates-from-the-phase-i-nx-5948-301-trial-of-bexobrutideg-in-patients-with-rr-cll monthly 0.9 2025-12-18T17:03:00.000Z https://lymphomahub.com/medical-information/nivolumab-avd-granted-priority-review-by-the-fda-for-chl monthly 0.9 2025-12-15T16:42:00.000Z https://lymphomahub.com/medical-information/ash-2025-epcore-fl-1-phase-iii-primary-results-epcoritamab-with-rituximab-lenalidomide-r2-vs-r2-alone-for-rr-fl monthly 0.9 2026-01-30T16:57:00.000Z https://lymphomahub.com/medical-information/ash-2025-3-year-follow-up-results-from-the-starglo-trial-of-glofit-gemox-vs-r-gemox-in-rr-dlbcl monthly 0.9 2025-12-11T11:00:00.000Z https://lymphomahub.com/medical-information/ash-2025-outpatient-administration-of-epcoritamab-monotherapy-for-rr-dlbcl-results-from-epcore-nhl-6-by-race-and-ethnicity monthly 0.9 2025-12-10T15:15:00.000Z https://lymphomahub.com/medical-information/ash-2025-live-congress-coverage-from-the-lymphoma-hub monthly 0.9 2025-12-18T14:07:00.000Z https://lymphomahub.com/medical-information/ash-2025-congress-coverage-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma monthly 0.9 2025-12-18T14:17:00.000Z https://lymphomahub.com/medical-information/ash-2025-congress-coverage-indolent-and-mantle-cell-nhl monthly 0.9 2026-01-06T11:07:00.000Z https://lymphomahub.com/medical-information/ash-2025-congress-coverage-hodgkin-lymphoma-and-t-cell-lymphoma monthly 0.9 2025-12-18T14:19:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-granted-approval-by-the-fda-for-patients-with-rr-mzl monthly 0.9 2025-12-07T18:34:00.000Z https://lymphomahub.com/medical-information/pirtobrutinib-granted-approval-by-the-fda-for-the-treatment-of-rr-cllsll monthly 0.9 2025-12-04T15:43:00.000Z https://lymphomahub.com/medical-information/ash-2025-top-abstracts-whats-hot-in-lymphoma-and-cll monthly 0.9 2025-12-03T17:31:00.000Z https://lymphomahub.com/medical-information/what-do-the-clinical-data-tell-us-about-fixed-duration-ibrutinib-venetoclax-for-patients-with-cll monthly 0.9 2025-12-17T09:35:00.000Z https://lymphomahub.com/medical-information/late-failure-outcomes-post-car-t-cell-therapy-in-lbcl-a-real-world-study monthly 0.9 2025-12-01T17:13:00.000Z https://lymphomahub.com/medical-information/triangle-noninvasive-genotyping-and-mrd-responses-with-ibrutinib-combination-therapy-in-mcl monthly 0.9 2025-11-28T09:00:00.000Z https://lymphomahub.com/medical-information/sonrotoclax-granted-priority-review-by-the-fda-for-rr-mcl monthly 0.9 2025-11-27T14:22:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-granted-approval-by-the-ec-for-patients-with-rr-mcl monthly 0.9 2025-11-26T16:50:00.000Z https://lymphomahub.com/medical-information/earlymind-real-world-efficacy-data-tafasitamab-lenalidomide-in-rr-dlbcl monthly 0.9 2025-11-24T11:00:00.000Z https://lymphomahub.com/medical-information/glofit-gemox-vs-r-gemox-in-patients-with-rr-dlbcl-results-from-the-starglo-trial monthly 0.9 2025-12-05T17:28:00.000Z https://lymphomahub.com/medical-information/epcoritamab-in-combination-with-rituximab-lenalidomide-approved-by-the-fda-for-patients-with-rr-fl monthly 0.9 2025-11-19T18:10:00.000Z https://lymphomahub.com/medical-information/subcutaneous-mosunetuzumab-granted-approval-by-the-ec-for-patients-with-rr-fl monthly 0.9 2025-11-19T17:50:00.000Z https://lymphomahub.com/medical-information/tafasitamab-receives-positive-chmp-opinion-for-rr-fl monthly 0.9 2025-11-17T17:08:00.000Z https://lymphomahub.com/medical-information/bi1808-received-a-positive-ema-comp-opinion-for-the-orphan-drug-designation-for-cutaneous-t-cell-lymphoma monthly 0.9 2025-11-17T15:31:00.000Z https://lymphomahub.com/medical-information/outcomes-following-ibrutinib-to-zanubrutinib-transition-in-waldenstrom-macroglobulinemia monthly 0.9 2025-11-17T09:00:00.000Z https://lymphomahub.com/medical-information/polarix-trial-pros-vs-clinician-reported-aes monthly 0.9 2025-11-14T09:00:00.000Z https://lymphomahub.com/medical-information/mb-105-granted-fda-rmat-designation-for-rr-cd5-t-cell-lymphoma monthly 0.9 2025-11-12T17:00:00.000Z https://lymphomahub.com/medical-information/glofit-pola-in-rr-lbcl-phase-ibii-results monthly 0.9 2025-11-10T14:56:00.000Z https://lymphomahub.com/medical-information/reliance-2-year-follow-up-relma-cel-in-rr-fl monthly 0.9 2025-11-07T11:00:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-spotlight-tafasitamab-in-rr-dlbcl-real-world-outcomes-and-maintenance-of-cd19-expression monthly 0.9 2025-12-04T16:09:00.000Z https://lymphomahub.com/medical-information/fil-v-rbac-trial-rbac-venetoclax-in-older-patients-with-high-risk-mcl monthly 0.9 2025-11-03T09:53:00.000Z https://lymphomahub.com/medical-information/enrich-trial-ibrutinib-rituximab-vs-immunochemotherapy-in-mcl monthly 0.9 2025-10-31T09:00:00.000Z https://lymphomahub.com/medical-information/what-factors-influence-btki-bcl-2i-treatment-selection-for-patients-with-cll monthly 0.9 2025-12-01T16:58:00.000Z https://lymphomahub.com/medical-information/sunmo-trial-mosun-pola-vs-r-gemox-in-rr-lbcl monthly 0.9 2025-10-28T09:00:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-rituximab-lenalidomide-in-de-novo-dlbcl-results-from-a-phase-ii-trial monthly 0.9 2025-10-24T09:00:00.000Z https://lymphomahub.com/medical-information/circulating-tumor-dna-mrd-assessment-in-lbcl monthly 0.9 2025-10-21T11:00:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-obinutuzumab-in-tn-patients-with-cll-6-year-follow-up-results-from-the-elevate-tn-trial monthly 0.9 2025-10-20T13:03:00.000Z https://lymphomahub.com/medical-information/eo2463-granted-fda-fast-track-designation-for-the-treatment-of-fl monthly 0.9 2025-10-16T15:18:00.000Z https://lymphomahub.com/medical-information/sonrotoclax-granted-breakthrough-therapy-designation-by-the-fda-for-rr-mcl monthly 0.9 2025-10-14T14:22:00.000Z https://lymphomahub.com/medical-information/pirtobrutinib-in-rr-follicular-lymphoma-bruin-trial monthly 0.9 2025-10-09T11:55:00.000Z https://lymphomahub.com/medical-information/iach-2025-live-congress-coverage-from-the-lymphoma-hub monthly 0.9 2025-10-09T17:48:00.000Z https://lymphomahub.com/medical-information/results-from-a-global-phase-ib-study-of-jnj-90014496-in-patients-with-relapsedrefractory-large-b-cell-lymphoma monthly 0.9 2025-10-22T14:13:00.000Z https://lymphomahub.com/medical-information/coalition-study-glofitamab-with-r-chop-or-pola-r-chop-in-high-risk-lbcl monthly 0.9 2025-11-06T16:02:00.000Z https://lymphomahub.com/medical-information/latest-updates-from-the-phase-iii-starglo-trial-2l-and-3l-data monthly 0.9 2025-10-15T15:34:00.000Z https://lymphomahub.com/medical-information/pilot-phase-ii-trial-final-results-lisocabtagene-maraleucel-for-rr-lbcl-in-patients-not-intended-for-hsct monthly 0.9 2025-10-02T16:15:00.000Z https://lymphomahub.com/medical-information/ub-vv111-granted-fda-fast-track-designation-for-the-treatment-of-rr-lbcl-and-cll monthly 0.9 2025-10-01T13:54:00.000Z https://lymphomahub.com/medical-information/sequoia-arm-d-results-zanubrutinib-venetoclax-in-patients-with-tn-cllsll monthly 0.9 2025-09-26T13:26:00.000Z https://lymphomahub.com/medical-information/hd21-phase-iii-trial-fertility-outcomes-in-chl-with-brecadd-vs-ebeacopp monthly 0.9 2025-09-25T10:13:00.000Z https://lymphomahub.com/medical-information/soho-2025-indolent-and-mantle-cell-nhl monthly 0.9 2025-10-22T09:19:00.000Z https://lymphomahub.com/medical-information/soho-2025-hodgkin-lymphoma-and-aggressive-b-cell-lymphoma monthly 0.9 2025-11-18T17:25:00.000Z https://lymphomahub.com/medical-information/early-rituximab-vs-watchful-waiting-in-low-tumor-burden-fl-long-term-results-of-a-phase-iii-trial monthly 0.9 2025-09-18T12:49:00.000Z https://lymphomahub.com/medical-information/soho-2025-live-congress-feed monthly 0.9 2025-10-22T09:19:00.000Z https://lymphomahub.com/medical-information/current-and-emerging-treatments-for-rr-mcl monthly 0.9 2025-09-11T13:26:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-symposium-customizing-therapy-for-mcl monthly 0.9 2026-01-06T11:06:00.000Z https://lymphomahub.com/medical-information/phase-iii-bruin-cll-321-trial-pirtobrutinib-vs-idelar-or-br-in-cbtki-pretreated-patients-with-cll monthly 0.9 2025-09-05T11:29:00.000Z https://lymphomahub.com/medical-information/pirtobrutinib-granted-conditional-marketing-authorization-by-the-uk-mhra-for-patients-with-rr-mcl-or-cll monthly 0.9 2025-11-19T14:37:00.000Z https://lymphomahub.com/medical-information/adx-2191-granted-orphan-drug-designation-by-the-ema-for-the-treatment-of-primary-lbcl-of-immune-privileged-sites monthly 0.9 2025-09-02T13:21:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-bendamustine-rituximab-in-high-risk-mcl-a-subgroup-analysis-of-the-phase-iii-echo-trial monthly 0.9 2025-08-29T08:39:00.000Z https://lymphomahub.com/medical-information/glofitamab-granted-approval-by-health-canada-for-the-treatment-of-rr-dlbcl monthly 0.9 2025-11-19T14:38:00.000Z https://lymphomahub.com/medical-information/tablet-formulation-of-zanubrutinib-granted-approval-by-the-ec-for-all-approved-indications monthly 0.9 2025-11-19T14:39:00.000Z https://lymphomahub.com/medical-information/odronextamab-for-patients-with-rr-fl-2-year-follow-up-results-from-the-phase-ii-elm-2-trial monthly 0.9 2025-08-21T16:50:00.000Z https://lymphomahub.com/medical-information/symposium-customizing-therapy-for-mcl-qa monthly 0.9 2025-09-04T11:08:00.000Z https://lymphomahub.com/medical-information/polargo-trial-pola-r-gemox-vs-r-gemox-in-patients-with-rr-dlbcl monthly 0.9 2025-08-13T16:41:00.000Z https://lymphomahub.com/medical-information/symposium-current-therapies-for-mcl-and-their-combinations-2 monthly 0.9 2026-01-06T11:05:00.000Z https://lymphomahub.com/medical-information/birelentinib-granted-fda-fast-track-designation-for-the-treatment-rr-cllsll monthly 0.9 2025-08-07T14:29:00.000Z https://lymphomahub.com/medical-information/shr2554-in-patients-with-rr-ptcl-results-from-a-phase-i-trial monthly 0.9 2025-08-06T13:35:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-granted-priority-review-by-the-fda-for-rr-mzl monthly 0.9 2025-08-05T15:53:00.000Z https://lymphomahub.com/medical-information/visual-abstract-latest-data-from-the-flair-and-captivate-trials-presented-at-eha-2025 monthly 0.9 2026-07-14T11:44:00.000Z https://lymphomahub.com/medical-information/final-analysis-of-the-gaiacll13-trial-venetoclax-combinations-vs-chemoimmunotherapy-in-cll monthly 0.9 2025-07-30T10:18:00.000Z https://lymphomahub.com/medical-information/symposium-sequencing-therapies-and-practical-management-of-adverse-events-in-mcl monthly 0.9 2025-08-19T13:01:00.000Z https://lymphomahub.com/medical-information/sonrotoclax-zanubrutinib-for-patients-with-rr-mcl-results-from-the-phase-i-bgb-11417-101-trial monthly 0.9 2025-07-24T10:00:00.000Z https://lymphomahub.com/medical-information/ibrutinib-granted-approval-by-the-ec-for-patients-with-previously-untreated-mcl-who-would-be-eligible-for-auto-hsct monthly 0.9 2025-07-24T08:25:00.000Z https://lymphomahub.com/medical-information/epi-rchop-phase-ii-results-tazemetostat-in-combination-with-r-chop-in-newly-diagnosed-dlbcl monthly 0.9 2025-07-17T17:25:00.000Z https://lymphomahub.com/medical-information/lisaftoclax-approved-by-chinas-nmpa-for-adult-patients-with-cllsll monthly 0.9 2025-11-19T14:36:00.000Z https://lymphomahub.com/medical-information/symposium-unmet-needs-in-the-treatment-of-mcl monthly 0.9 2025-08-14T09:38:00.000Z https://lymphomahub.com/medical-information/bexobrutideg-granted-orphan-drug-designation-by-the-ema-for-waldenstroms-macroglobulinemia monthly 0.9 2025-07-08T15:29:00.000Z https://lymphomahub.com/medical-information/improve-continued-btki-use-vs-a-3-week-pause-before-covid-19-vaccination-in-cll monthly 0.9 2025-07-04T13:57:00.000Z https://lymphomahub.com/medical-information/18th-international-conference-on-malignant-lymphoma-icml-congress-coverage monthly 0.9 2025-11-18T17:27:00.000Z https://lymphomahub.com/medical-information/18th-international-conference-on-malignant-lymphoma-icml-congress-coverage-indolent-and-mantle-cell-nhl monthly 0.9 2025-07-04T15:05:00.000Z https://lymphomahub.com/medical-information/18th-international-conference-on-malignant-lymphoma-icml-congress-coverage-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma monthly 0.9 2025-07-04T15:05:00.000Z https://lymphomahub.com/medical-information/18th-international-conference-on-malignant-lymphoma-icml-congress-coverage-hodgkin-lymphoma-and-t-cell-lymphoma monthly 0.9 2025-07-04T15:02:00.000Z https://lymphomahub.com/medical-information/anti-cd19-monoclonal-antibodies-for-the-treatment-of-dlbcl monthly 0.9 2025-07-08T13:50:00.000Z https://lymphomahub.com/medical-information/sgr-1505-granted-fda-fast-track-designation-for-the-treatment-of-patients-with-rr-waldenstrom-macroglobulinemia monthly 0.9 2025-07-03T09:42:00.000Z https://lymphomahub.com/medical-information/celmods-for-the-treatment-of-non-hodgkin-lymphoma monthly 0.9 2026-01-14T11:28:00.000Z https://lymphomahub.com/medical-information/swog-2308-phase-iii-protocol-mosunetuzumab-vs-rituximab-for-low-tumor-burden-fl monthly 0.9 2025-06-25T15:46:00.000Z https://lymphomahub.com/medical-information/eha-2025-live-congress-coverage monthly 0.9 2025-07-03T09:41:00.000Z https://lymphomahub.com/medical-information/eha-2025-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma monthly 0.9 2025-07-03T09:40:00.000Z https://lymphomahub.com/medical-information/eha-2025-indolent-and-mantle-cell-nhl monthly 0.9 2025-07-03T09:40:00.000Z https://lymphomahub.com/medical-information/eha-2025-hodgkin-lymphoma-and-t-cell-lymphoma monthly 0.9 2025-07-03T09:40:00.000Z https://lymphomahub.com/medical-information/ibrutinib-receives-positive-ema-chmp-opinion-for-an-extended-indication-in-frontline-mantle-cell-lymphoma monthly 0.9 2025-06-23T15:47:00.000Z https://lymphomahub.com/medical-information/icml-2025-what-do-the-initial-results-from-the-lotis-7-trial-suggest-for-loncastuximab-tesirine-plus-glofitamab-in-rr-dlbcl monthly 0.9 2025-06-30T17:20:00.000Z https://lymphomahub.com/medical-information/tafasitamab-in-combination-with-rituximab-and-lenalidomide-approved-by-the-fda-for-patients-with-rr-fl monthly 0.9 2025-06-19T17:57:00.000Z https://lymphomahub.com/medical-information/what-is-the-clinical-significance-of-the-long-term-results-from-the-epcore-nhl-2-trial-of-epcoritamab-r-chop-for-previously-untreated-high-risk-dlbcl monthly 0.9 2025-07-15T14:22:00.000Z https://lymphomahub.com/medical-information/eha-2025-what-are-the-latest-updates-from-the-starglo-trial-of-glofit-gemox-vs-r-gemox-in-rr-dlbcl monthly 0.9 2025-06-18T20:50:00.000Z https://lymphomahub.com/medical-information/eha-2025-how-effective-is-epcoritamab-r-ice-in-patients-with-rr-dlbcl-who-are-eligible-for-asct monthly 0.9 2025-06-17T17:24:00.000Z https://lymphomahub.com/medical-information/maplirpacept-for-the-treatment-of-dlbcl-mechanism-of-action-and-ongoing-trials monthly 0.9 2026-07-14T12:29:00.000Z https://lymphomahub.com/medical-information/eha-2025-top-abstracts-in-lymphoma-and-cll monthly 0.9 2025-07-03T09:42:00.000Z https://lymphomahub.com/medical-information/european-commission-approves-fixed-duration-acalabrutinib-venetoclax-obinutuzumab-for-adult-patients-with-previously-untreated-cll monthly 0.9 2025-06-06T14:14:00.000Z https://lymphomahub.com/medical-information/asco25-live-congress-coverage-from-the-lymphoma-hub monthly 0.9 2025-06-09T11:04:00.000Z https://lymphomahub.com/medical-information/fda-grants-breakthrough-therapy-designation-to-iopofosine-i-131-for-treatment-of-rr-wm monthly 0.9 2025-06-05T14:37:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-in-combination-with-ecadd-approved-by-the-ec-for-patients-with-nd-stage-iibiiiiv-hodgkin-lymphoma monthly 0.9 2025-06-06T09:16:00.000Z https://lymphomahub.com/medical-information/cll6-residuum-trial-impact-of-lenalidomide-consolidation-on-hrqol-in-cll monthly 0.9 2025-05-28T15:18:00.000Z https://lymphomahub.com/medical-information/visionho141-long-term-follow-up-of-mrd-guided-treatment-with-ibrutinib-and-venetoclax-in-rr-cll monthly 0.9 2025-05-23T13:06:00.000Z https://lymphomahub.com/medical-information/tafasitamab-in-combination-with-lenalidomide-approved-by-chinas-national-medical-products-administration-for-adult-patients-with-rr-dlbcl monthly 0.9 2025-05-23T12:56:00.000Z https://lymphomahub.com/medical-information/real-world-experience-of-tafasitamab-and-lenalidomide-for-the-treatment-of-rr-dlbcl monthly 0.9 2025-12-23T10:38:00.000Z https://lymphomahub.com/medical-information/how-effective-is-the-combination-of-tafasitamab-and-lenalidomide-in-treating-rr-dlbcl monthly 0.9 2025-12-23T10:38:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-spotlight-tafasitamab-for-the-treatment-of-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma monthly 0.9 2025-07-18T11:53:00.000Z https://lymphomahub.com/medical-information/nivolumab-for-patients-with-nd-fl-results-from-the-phase-ii-1st-flor-study monthly 0.9 2025-06-03T08:32:00.000Z https://lymphomahub.com/medical-information/np30179-phase-iii-study-fixed-duration-glofitamab-in-rr-mcl monthly 0.9 2025-05-07T16:11:00.000Z https://lymphomahub.com/medical-information/ema-approves-acalabrutinib-combination-for-patients-with-previously-untreated-mcl monthly 0.9 2025-05-06T15:34:00.000Z https://lymphomahub.com/medical-information/phase-iii-bruin-study-pirtobrutinib-monotherapy-in-cbtki-intolerant-patients-with-rr-b-cell-malignancies monthly 0.9 2025-05-06T15:25:00.000Z https://lymphomahub.com/medical-information/bi-1808-granted-fda-fast-track-designation-for-the-treatment-of-patients-with-cutaneous-t-cell-lymphoma monthly 0.9 2025-05-01T12:46:00.000Z https://lymphomahub.com/medical-information/fixed-duration-acalabrutinib-venetoclax-obinutuzumab-receives-positive-opinion-from-chmp-for-adults-with-previously-untreated-cll monthly 0.9 2025-04-30T14:54:00.000Z https://lymphomahub.com/medical-information/waldenstrom-s-macroglobulinemia-european-educational-forum-eef-2025 monthly 0.9 2025-04-30T11:02:00.000Z https://lymphomahub.com/medical-information/orelabrutinib-receives-china-s-national-medical-products-administration-approval-for-adult-patients-with-previously-untreated-cllsll monthly 0.9 2025-04-28T14:24:00.000Z https://lymphomahub.com/medical-information/talicabtagene-autoleucel-for-patients-with-rr-b-cell-malignancies-results-from-a-phase-iii-trial monthly 0.9 2025-04-24T14:07:00.000Z https://lymphomahub.com/medical-information/51st-annual-meeting-of-the-ebmt-congress-coverage-lymphoma-part-2 monthly 0.9 2025-09-04T09:49:00.000Z https://lymphomahub.com/medical-information/51st-annual-meeting-of-the-ebmt-congress-coverage-lymphoma-part-1 monthly 0.9 2025-09-04T09:48:00.000Z https://lymphomahub.com/medical-information/european-commission-approves-glofitamab-in-combination-with-gemcitabine-and-oxaliplatin-for-the-treatment-of-adult-patients-with-rr-dlbcl monthly 0.9 2025-04-14T13:57:00.000Z https://lymphomahub.com/medical-information/polarix-subgroup-analysis-pola-r-chp-for-older-patients-aged-60-years-with-untreated-dlbcl monthly 0.9 2025-04-10T14:57:00.000Z https://lymphomahub.com/medical-information/murano-final-analysis-and-substudy-results-of-venr-in-rr-cll monthly 0.9 2025-04-07T14:06:00.000Z https://lymphomahub.com/medical-information/phase-ii-study-mosunetuzumab-plus-pola-chp-vs-pola-r-chp-in-dlbcl monthly 0.9 2025-03-31T11:08:00.000Z https://lymphomahub.com/medical-information/zuma-12-3-year-follow-up-analysis-of-axi-cel-in-high-risk-large-b-cell-lymphoma monthly 0.9 2025-03-21T09:12:00.000Z https://lymphomahub.com/medical-information/phase-iii-inmind-trial-efficacy-and-safety-of-tafasitamab-plus-lenalidomide-and-rituximab-for-rr-fl monthly 0.9 2026-07-14T12:29:00.000Z https://lymphomahub.com/medical-information/azercabtagene-zapreleucel-granted-fda-fast-track-designation-for-the-treatment-of-patients-with-rr-dlbcl monthly 0.9 2025-03-24T11:45:00.000Z https://lymphomahub.com/medical-information/orphan-drug-designation-granted-to-nx-5948-for-the-treatment-of-patients-with-waldenstrom-s-macroglobulinemia monthly 0.9 2025-03-18T16:19:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-receives-european-commission-approval-for-the-treatment-of-adult-patients-with-rr-fl monthly 0.9 2025-03-17T16:33:00.000Z https://lymphomahub.com/medical-information/sympatico-ibrutinib-plus-venetoclax-in-relapsed-refractory-mcl monthly 0.9 2025-03-13T15:29:00.000Z https://lymphomahub.com/medical-information/ibrutinib-plus-nivolumab-for-relapsed-refractory-cns-lymphoma-phase-ii-results monthly 0.9 2025-03-13T15:30:00.000Z https://lymphomahub.com/medical-information/loncastuximab-tesirine-plus-rituximab-in-patients-with-rr-fl monthly 0.9 2025-03-11T07:39:00.000Z https://lymphomahub.com/medical-information/chmp-recommends-ema-approval-of-glofitamab-in-combination-with-gemcitabine-and-oxaliplatin monthly 0.9 2025-04-14T12:06:00.000Z https://lymphomahub.com/medical-information/pirtobrutinib-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-rr-cll-and-previous-btki-exposure monthly 0.9 2025-09-02T09:44:00.000Z https://lymphomahub.com/medical-information/sequoia-5-year-follow-up-zanubrutinib-vs-bendamustine-rituximab-in-patients-with-treatment-naive-cllsll monthly 0.9 2025-02-18T13:05:00.000Z https://lymphomahub.com/medical-information/zuma-5-5-year-follow-up-analysis-of-axicabtagene-ciloleucel-in-patients-with-rr-inhl monthly 0.9 2025-02-13T15:43:00.000Z https://lymphomahub.com/medical-information/epcoritamab-receives-approval-from-the-japanese-ministry-of-health-labour-and-welfare-for-rr-follicular-lymphoma monthly 0.9 2025-02-21T16:26:00.000Z https://lymphomahub.com/medical-information/mithic-fl1-mosunetuzumab-monotherapy-in-newly-diagnosed-follicular-lymphoma monthly 0.9 2025-03-03T15:02:00.000Z https://lymphomahub.com/medical-information/7th-european-car-t-cell-meeting-congress-coverage-catchup monthly 0.9 2025-11-18T17:25:00.000Z https://lymphomahub.com/medical-information/echelon-3-trial-brentuximab-vedotin-plus-lenalidomide-and-rituximab-for-patients-with-rr-dlbcl monthly 0.9 2026-07-14T12:29:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-obinutuzumab-and-venetoclax-boven-in-patients-with-treatment-naive-cll monthly 0.9 2025-02-05T13:41:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-in-combination-with-lenalidomide-and-rituximab-receives-u-s-fda-approval-for-the-treatment-of-rr-lbcl monthly 0.9 2025-02-13T15:41:00.000Z https://lymphomahub.com/medical-information/echelon-3-subgroup-analysis-brentuximab-vedotin-lenalidomide-rituximab-for-older-patients-with-rr-dlbcl monthly 0.9 2025-02-13T07:08:00.000Z https://lymphomahub.com/medical-information/polarix-5-year-follow-up-of-pola-r-chp-in-patients-with-intermediate-or-high-risk-dlbcl monthly 0.9 2025-02-03T06:02:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-spotlight-or-symphony-1-a-phase-ibiii-trial-of-taz-len-r-in-rr-fl monthly 0.9 2025-07-18T12:03:00.000Z https://lymphomahub.com/medical-information/elara-4-year-follow-up-of-tisagenlecleucel-in-patients-with-rr-fl monthly 0.9 2025-02-03T05:59:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-rr-fl monthly 0.9 2025-03-05T06:32:00.000Z https://lymphomahub.com/medical-information/novel-and-emerging-treatment-options-for-rr-dlbcl monthly 0.9 2025-11-27T17:49:00.000Z https://lymphomahub.com/medical-information/inmind-trial-tafasitamab-plus-lenalidomide-and-rituximab-for-rr-fl monthly 0.9 2025-04-01T07:04:00.000Z https://lymphomahub.com/medical-information/orphan-drug-designation-granted-to-mb-105-for-the-treatment-of-rr-t-cell-lymphoma monthly 0.9 2025-01-29T11:43:00.000Z https://lymphomahub.com/medical-information/aspen-5-8-year-follow-up-of-zanubrutinib-in-patients-with-wm monthly 0.9 2025-01-30T06:57:00.000Z https://lymphomahub.com/medical-information/flair-trial-mrd-directed-ibrutinib-venetoclax-vs-fcr-in-patients-with-cll monthly 0.9 2025-01-20T12:59:00.000Z https://lymphomahub.com/medical-information/allg-trial-ibrutinib-plus-r-mini-chop-in-older-patients-with-newly-diagnosed-dlbcl monthly 0.9 2025-01-20T07:45:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-plus-chemoimmunotherapy-receives-fda-approval-for-adult-patients-with-previously-untreated-mcl monthly 0.9 2025-01-20T11:41:00.000Z https://lymphomahub.com/medical-information/nccn-guidelines-updated-to-include-a-ctdna-mrd-testing-recommendation-for-b-cell-lymphoma monthly 0.9 2025-01-15T15:08:00.000Z https://lymphomahub.com/medical-information/triangle-trial-auto-hsct-in-ibrutinib-containing-first-line-treatment-for-mcl monthly 0.9 2025-01-15T09:26:00.000Z https://lymphomahub.com/medical-information/fixed-duration-acalabrutinib-venetoclax-with-or-without-obinutuzumab-in-cll-interim-analysis-of-the-amplify-trial monthly 0.9 2024-12-19T10:08:00.000Z https://lymphomahub.com/medical-information/jzp458-in-alllbl-complete-follow-up-results-from-aall1931-trial monthly 0.9 2024-12-19T10:06:00.000Z https://lymphomahub.com/medical-information/glofit-gemox-vs-r-gemox-for-rr-dlbcl-results-from-phase-iii-starglo-trial monthly 0.9 2024-12-19T10:06:00.000Z https://lymphomahub.com/medical-information/ash24-mantle-cell-lymphoma monthly 0.9 2025-01-15T14:13:00.000Z https://lymphomahub.com/medical-information/ash24-hodgkin-lymphoma monthly 0.9 2024-12-19T09:11:00.000Z https://lymphomahub.com/medical-information/ash24-indolent-b-cell-nhl monthly 0.9 2024-12-19T09:05:00.000Z https://lymphomahub.com/medical-information/how-to-treat-mcl-that-is-refractory-to-btk-inhibitors monthly 0.9 2025-08-05T13:39:00.000Z https://lymphomahub.com/medical-information/how-to-treat-older-patients-with-follicular-lymphoma-in-the-firstline-setting monthly 0.9 2025-08-05T13:41:00.000Z https://lymphomahub.com/medical-information/ash24-aggressive-b-cell-nhl monthly 0.9 2025-11-18T17:26:00.000Z https://lymphomahub.com/medical-information/ash24-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma monthly 0.9 2026-01-06T11:07:00.000Z https://lymphomahub.com/medical-information/valemetostat-for-rr-ptcl-results-from-phase-ii-valentine-ptcl01-trial monthly 0.9 2024-12-13T09:48:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-monotherapy-and-in-combination-with-rituximab-in-patients-with-fl monthly 0.9 2024-12-12T10:46:00.000Z https://lymphomahub.com/medical-information/echelon-3-trial monthly 0.9 2026-02-26T09:49:00.000Z https://lymphomahub.com/medical-information/fda-grants-regenerative-medicine-advanced-therapy-designation-to-acimtamig-and-ab101-combination-for-rr-hl monthly 0.9 2024-12-09T12:52:00.000Z https://lymphomahub.com/medical-information/symposium-or-targeted-therapies-in-classic-hodgkin-lymphoma-future-perspectives monthly 0.9 2024-12-04T05:58:00.000Z https://lymphomahub.com/medical-information/symposium-or-panel-discussion-or-how-to-sequence-targeted-therapies-in-classic-hodgkin-lymphoma monthly 0.9 2024-12-04T06:01:00.000Z https://lymphomahub.com/medical-information/fda-accepts-supplemental-biologics-license-application-for-glofitamab-gxbm-for-rr-dlbcl monthly 0.9 2024-12-05T15:37:00.000Z https://lymphomahub.com/medical-information/symposium-or-targeted-therapies-for-classic-hodgkin-lymphoma monthly 0.9 2024-12-04T07:14:00.000Z https://lymphomahub.com/medical-information/ash-2024-top-abstracts-in-lymphoma-and-cll monthly 0.9 2025-02-05T09:45:00.000Z https://lymphomahub.com/medical-information/iwwm-12-highlights-from-young-investigator-research monthly 0.9 2024-11-22T10:50:00.000Z https://lymphomahub.com/medical-information/iwwm-12-what-are-the-implications-of-istopmm-for-mm-and-wm monthly 0.9 2024-11-27T09:13:00.000Z https://lymphomahub.com/medical-information/glow-trial-5-year-follow-up-of-first-line-fixed-duration-ibrutinib-plus-venetoclax-in-older-adults-with-cllsll monthly 0.9 2026-01-30T13:09:00.000Z https://lymphomahub.com/medical-information/symposium-or-first-line-btk-inhibitors-in-clinical-practice-case-study-clinic monthly 0.9 2025-08-05T14:29:00.000Z https://lymphomahub.com/medical-information/iwwm-12-latest-updates-and-clinical-developments-in-novelemerging-therapies monthly 0.9 2024-11-22T10:48:00.000Z https://lymphomahub.com/medical-information/iwwm-12-what-insights-can-multi-omics-reveal-about-wm-subtypes monthly 0.9 2024-11-20T04:47:00.000Z https://lymphomahub.com/medical-information/symposium-or-first-line-btk-inhibitors-for-cll-current-and-future-perspectives monthly 0.9 2025-08-05T14:30:00.000Z https://lymphomahub.com/medical-information/iwwm-12-can-first-line-treatment-experience-of-wm-be-improved-by-btk-inhibitors monthly 0.9 2024-11-18T14:35:00.000Z https://lymphomahub.com/medical-information/symposium-or-customizing-first-line-btk-inhibitors-for-cll-unmet-needs-with-btk-inhibitors monthly 0.9 2025-08-05T14:30:00.000Z https://lymphomahub.com/medical-information/iwwm-12-management-of-igm-demyelinating-neuropathy monthly 0.9 2024-11-18T13:52:00.000Z https://lymphomahub.com/medical-information/addition-of-venetoclax-to-hyper-cvad-nelarabine-pegasp-for-t-alllbl-2-year-follow-up-from-the-phase-ii-trial monthly 0.9 2024-11-12T07:42:00.000Z https://lymphomahub.com/medical-information/mosunetuzumab-monotherapy-in-patients-with-rr-fl-after-2-prior-lines-of-therapies-3-year-follow-up-results-from-the-phase-ii-trial monthly 0.9 2024-11-12T07:45:00.000Z https://lymphomahub.com/medical-information/combination-therapies-for-cll-btki-bcl2i monthly 0.9 2026-05-28T09:40:00.000Z https://lymphomahub.com/medical-information/iwwm-12-what-are-the-future-perspectives-for-the-treatment-of-wm monthly 0.9 2024-11-18T17:24:00.000Z https://lymphomahub.com/medical-information/iwwm-12-what-were-the-key-takeaways monthly 0.9 2024-11-12T14:37:00.000Z https://lymphomahub.com/medical-information/tazemetostat-for-the-treatment-of-rr-fl monthly 0.9 2024-10-31T14:08:00.000Z https://lymphomahub.com/medical-information/intermittent-dosing-of-zandelisib-for-patients-with-rr-fl-results-from-the-phase-ii-tidal-trial monthly 0.9 2024-11-04T15:41:00.000Z https://lymphomahub.com/medical-information/first-line-treatment-with-ibrutinib-in-patients-with-cllsll-final-results-from-the-resonate-2-trial monthly 0.9 2024-11-04T15:40:00.000Z https://lymphomahub.com/medical-information/what-were-the-long-term-outcomes-of-fixed-duration-mosunetuzumab-in-b-nhl monthly 0.9 2024-10-28T16:01:00.000Z https://lymphomahub.com/medical-information/iwwm-12-live-congress-feed monthly 0.9 2024-10-25T13:48:00.000Z https://lymphomahub.com/medical-information/epcoritamab-plus-pola-r-chp-as-first-line-treatment-for-patients-with-dlbcl-results-from-the-phase-ibii-epcore-nhl-5-trial monthly 0.9 2024-11-04T15:39:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-vs-ibrutinib-for-rr-cllsll-final-comparative-analysis-results-from-the-alpine-trial monthly 0.9 2024-11-04T15:37:00.000Z https://lymphomahub.com/medical-information/characteristics-associated-with-response-in-patients-with-rr-cllsll-treated-with-liso-cel-transcend-cll-004-post-hoc-analysis monthly 0.9 2024-11-04T15:35:00.000Z https://lymphomahub.com/medical-information/real-world-outcomes-with-lisocabtagene-maraleucel-in-rr-lbcl monthly 0.9 2024-11-12T14:36:00.000Z https://lymphomahub.com/medical-information/outcomes-with-tafasitamab-lenalidomide-for-lbcl-pre-or-post-car-t-cell-therapy monthly 0.9 2024-10-15T09:23:00.000Z https://lymphomahub.com/medical-information/iach2024-lymphoma-and-chronic-lymphocytic-leukemia monthly 0.9 2024-10-01T14:56:00.000Z https://lymphomahub.com/medical-information/soho2024-mantle-cell-lymphoma monthly 0.9 2024-12-09T11:30:00.000Z https://lymphomahub.com/medical-information/mosunetuzumab-for-the-treatment-of-high-risk-heavily-pretreated-rr-follicular-lymphoma monthly 0.9 2024-11-04T15:30:00.000Z https://lymphomahub.com/medical-information/soho2024-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma monthly 0.9 2024-09-27T12:25:00.000Z https://lymphomahub.com/medical-information/soho2024-hodgkin-lymphoma-and-t-cell-lymphoma monthly 0.9 2024-09-27T12:24:00.000Z https://lymphomahub.com/medical-information/soho2024-indolent-b-cell-lymphoma monthly 0.9 2024-09-27T12:23:00.000Z https://lymphomahub.com/medical-information/treatment-options-for-patients-with-wm-in-the-thirdline-setting monthly 0.9 2024-11-22T08:57:00.000Z https://lymphomahub.com/medical-information/delphinus-daratumumab-plus-chemotherapy-in-pediatric-patients-with-rr-all-or-lbl monthly 0.9 2024-09-19T12:25:00.000Z https://lymphomahub.com/medical-information/transcend-cll-004-a-post-hoc-analysis-of-characteristics-associated-with-response-to-liso-cel monthly 0.9 2026-02-18T16:49:00.000Z https://lymphomahub.com/medical-information/soho2024-aggressive-b-cell-non-hodgkin-lymphoma monthly 0.9 2024-09-27T12:24:00.000Z https://lymphomahub.com/medical-information/options-for-the-treatment-of-second-line-dlbcl monthly 0.9 2024-09-23T07:22:00.000Z https://lymphomahub.com/medical-information/iach-2024-live-congress-feed monthly 0.9 2024-09-19T10:43:00.000Z https://lymphomahub.com/medical-information/ibrutinib-for-cll-mechanism-of-action-and-clinical-considerations monthly 0.9 2024-09-20T09:10:00.000Z https://lymphomahub.com/medical-information/long-term-results-from-a-phase-ibii-study-of-magrolimab-plus-rituximab-in-rr-inhl monthly 0.9 2024-09-18T06:16:00.000Z https://lymphomahub.com/medical-information/management-of-complications-of-car-t-cell-therapies-in-europe monthly 0.9 2024-09-11T12:57:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-vs-standard-of-care-as-second-line-therapy-for-lbcl-3-year-follow-up-from-the-phase-iii-transform-trial monthly 0.9 2024-09-05T09:58:00.000Z https://lymphomahub.com/medical-information/soho-2024-live-congress-feed monthly 0.9 2024-11-26T09:49:00.000Z https://lymphomahub.com/medical-information/outpatient-administration-of-car-t-cell-therapies-in-patients-with-hematological-malignancies monthly 0.9 2024-09-02T12:35:00.000Z https://lymphomahub.com/medical-information/efficacy-and-safety-of-rituximab-and-pembrolizumab-in-rr-wm-pembrowm-trial monthly 0.9 2024-08-30T13:54:00.000Z https://lymphomahub.com/medical-information/relmacabtagene-autoleucel-receives-china-nmpa-supplementary-biological-application-approval-for-rr-mcl monthly 0.9 2024-08-30T14:05:00.000Z https://lymphomahub.com/medical-information/odronextamab-receives-ec-approval-for-adult-patients-with-rr-fl-and-dlbcl monthly 0.9 2024-08-28T14:57:00.000Z https://lymphomahub.com/medical-information/pirtobrutinib-in-patients-with-richter-transformation-results-from-the-phase-iii-bruin-trial monthly 0.9 2024-09-02T13:12:00.000Z https://lymphomahub.com/medical-information/epcoritamab-for-patients-with-rr-fl-results-from-epcore-nhl-1 monthly 0.9 2024-08-21T16:01:00.000Z https://lymphomahub.com/medical-information/primary-endpoint-met-in-inmind-trial-of-tafasitamab-in-patients-with-rr-fl monthly 0.9 2024-08-21T11:38:00.000Z https://lymphomahub.com/medical-information/pet-guided-brecadd-for-the-treatment-of-advanced-stage-chl monthly 0.9 2024-08-14T15:09:00.000Z https://lymphomahub.com/medical-information/eha-esmo-clinical-practice-recommendations-for-pcnsl monthly 0.9 2024-08-13T17:17:00.000Z https://lymphomahub.com/medical-information/symposium-or-optimizing-outcomes-before-and-after-car-t-cell-therapy-in-patients-with-large-b-cell-lymphoma monthly 0.9 2024-11-12T14:44:00.000Z https://lymphomahub.com/medical-information/sequoia-trial-zanubrutinib-venetoclax-in-treatment-naive-patients-with-cllsll monthly 0.9 2024-11-12T14:44:00.000Z https://lymphomahub.com/medical-information/denileukin-diftitox-cxdl-receives-u-s-fda-approval-for-adult-patients-with-rr-cutaneous-t-cell-lymphoma monthly 0.9 2024-08-12T11:40:00.000Z https://lymphomahub.com/medical-information/orphan-drug-designation-granted-to-sls009-for-the-treatment-of-rr-peripheral-t-cell-lymphoma monthly 0.9 2024-08-07T16:48:00.000Z https://lymphomahub.com/medical-information/ibrutinib-plus-venetoclax-for-patients-with-mcl-and-tp53-mutations-results-from-the-sympatico-trial monthly 0.9 2024-08-05T06:35:00.000Z https://lymphomahub.com/medical-information/alpine-trial-pro-based-recurrent-symptomatic-deterioration-predicts-disease-progression monthly 0.9 2026-03-18T15:12:00.000Z https://lymphomahub.com/medical-information/esmo-guidelines-interim-update-on-new-targeted-therapies-for-cll monthly 0.9 2024-07-30T15:19:00.000Z https://lymphomahub.com/medical-information/6-year-time-to-next-treatment-extrapolation-curve-for-the-glow-study monthly 0.9 2026-02-18T17:16:00.000Z https://lymphomahub.com/medical-information/clover-wam-trial-iopofosine-i-131-exceeds-primary-endpoint-of-major-response-rate-in-patients-with-waldenstrom-s-macroglobulinemia monthly 0.9 2024-07-24T13:29:00.000Z https://lymphomahub.com/medical-information/echo-trial-acalabrutinib-plus-bendamustine-and-rituximab-for-newly-diagnosed-older-patients-with-mcl monthly 0.9 2024-07-22T08:52:00.000Z https://lymphomahub.com/medical-information/phase-iii-glow-trial-ibrutinib-plus-venetoclax-in-previously-untreated-cllsll monthly 0.9 2025-08-05T13:42:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-plus-lenalidomide-and-rituximab-for-rr-dlbcl-results-from-the-elechon-3-trial monthly 0.9 2024-11-29T10:18:00.000Z https://lymphomahub.com/medical-information/waldenstrom-s-macroglobulinemia-an-overview monthly 0.9 2025-12-23T10:39:00.000Z https://lymphomahub.com/medical-information/odronextamab-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-rr-fl-and-rr-dlbcl monthly 0.9 2024-07-03T08:08:00.000Z https://lymphomahub.com/medical-information/captivate-5-5-year-update-fixed-duration-ibrutinib-venetoclax-in-patients-with-cllsll-and-high-risk-genomic-features-or-progressive-disease monthly 0.9 2024-07-01T08:32:00.000Z https://lymphomahub.com/medical-information/eha2024 monthly 0.9 2024-07-31T09:11:00.000Z https://lymphomahub.com/medical-information/eha2024-4 monthly 0.9 2024-07-31T09:11:00.000Z https://lymphomahub.com/medical-information/visual-abstract-or-ibrutinib-venetoclax-in-untreated-wm monthly 0.9 2025-01-22T09:44:00.000Z https://lymphomahub.com/medical-information/eha2024-3 monthly 0.9 2024-07-31T09:12:00.000Z https://lymphomahub.com/medical-information/glofit-gemox-vs-r-gemox-for-rr-dlbcl-results-from-the-starglo-trial monthly 0.9 2024-06-28T09:14:00.000Z https://lymphomahub.com/medical-information/eha2024-2 monthly 0.9 2024-07-31T09:10:00.000Z https://lymphomahub.com/medical-information/epcoritamab-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-rr-fl monthly 0.9 2024-06-28T14:12:00.000Z https://lymphomahub.com/medical-information/epcoritamab-bysp-receives-accelerated-u-s-fda-approval-for-the-treatment-of-rr-fl monthly 0.9 2024-06-27T14:21:00.000Z https://lymphomahub.com/medical-information/what-is-the-role-of-treatment-line-and-duration-in-patients-with-lbcl-treated-with-car-t-cells monthly 0.9 2024-11-12T14:46:00.000Z https://lymphomahub.com/medical-information/chronic-lymphocytic-lymphoma-an-overview monthly 0.9 2025-12-23T10:39:00.000Z https://lymphomahub.com/medical-information/eha2024-congress-feed monthly 0.9 2024-07-02T20:50:00.000Z https://lymphomahub.com/medical-information/visual-abstract-or-auto-hsct-after-a-rituximabibrutinibara-c-containing-induction-in-generalized-mantle-cell-lymphoma-triangle-trial monthly 0.9 2024-06-11T10:51:00.000Z https://lymphomahub.com/medical-information/eha-2024-abstracts-what-s-hot-in-lymphoma-and-cll monthly 0.9 2024-06-10T15:07:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-receives-u-s-fda-approval-for-adult-patients-with-rr-mcl monthly 0.9 2024-05-31T13:30:00.000Z https://lymphomahub.com/medical-information/anti-cd30-car-t-cell-consolidation-after-auto-hsct-in-patients-with-high-risk-cd30-lymphoma-results-from-a-phase-i-trial monthly 0.9 2024-05-22T11:18:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-with-lenalidomide-and-rituximab-for-rr-aggressive-b-cell-non-hodgkin-lymphoma monthly 0.9 2024-05-17T14:19:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-receives-accelerated-u-s-fda-approval-for-adult-patients-with-rr-fl monthly 0.9 2024-05-17T08:14:00.000Z https://lymphomahub.com/medical-information/checkmate-436-nivolumab-plus-brentuximab-vedotin-for-rr-ptcl-and-ctcl monthly 0.9 2024-05-17T14:19:00.000Z https://lymphomahub.com/medical-information/machine-learning-based-survival-prediction-models-for-advanced-stage-hodgkin-lymphoma monthly 0.9 2024-05-14T17:23:00.000Z https://lymphomahub.com/medical-information/axi-cel-vs-chemoimmunotherapy-in-older-patients-with-rr-lbcl monthly 0.9 2024-05-08T08:03:00.000Z https://lymphomahub.com/medical-information/nivolumab-with-car-t-cell-therapy-in-progressive-dlbcl-final-analysis-of-a-phase-ii-study monthly 0.9 2024-05-08T07:53:00.000Z https://lymphomahub.com/medical-information/anti-cd19-car-t-cell-therapy-for-patients-with-primary-or-secondary-cns-lymphoma monthly 0.9 2024-05-02T16:18:00.000Z https://lymphomahub.com/medical-information/camrelizumab-plus-gemox-as-salvage-therapy-for-rr-chl-results-from-a-phase-ii-trial monthly 0.9 2024-04-29T09:53:00.000Z https://lymphomahub.com/medical-information/what-is-the-rationale-for-monitoring-secondary-malignancies-after-bcma-and-cd19-car-t-cell-therapy monthly 0.9 2024-11-12T14:47:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-as-a-second-line-treatment-for-rr-lbcl-pros-from-the-pilot-study monthly 0.9 2024-04-22T14:22:00.000Z https://lymphomahub.com/medical-information/correlation-between-mrd-at-the-end-of-induction-and-efs-in-pediatric-t-cell-lymphoblastic-lymphoma monthly 0.9 2024-04-26T08:39:00.000Z https://lymphomahub.com/medical-information/starglo-trial-of-glofitamab-primary-endpoint-met-in-rr-dlbcl monthly 0.9 2024-04-15T14:10:00.000Z https://lymphomahub.com/medical-information/what-are-the-strategies-to-manage-toxicities-with-car-t-cell-therapies monthly 0.9 2024-11-12T14:48:00.000Z https://lymphomahub.com/medical-information/venetoclax-monotherapy-for-patients-with-rr-cll-results-from-the-phase-iii-venice-1-trial monthly 0.9 2024-04-23T16:45:00.000Z https://lymphomahub.com/medical-information/polatuzumab-vedotin-in-combination-with-venetoclax-and-rituximab-for-patients-with-rr-dlbcl monthly 0.9 2024-03-26T15:05:00.000Z https://lymphomahub.com/medical-information/tarmac-trial-time-limited-ibrutinib-plus-car-t-cell-therapy-for-the-treatment-of-rr-mcl monthly 0.9 2024-03-26T14:43:00.000Z https://lymphomahub.com/medical-information/glow-trial-a-4-year-update-on-fixed-duration-ibrutinib-venetoclax-in-previously-untreated-cll monthly 0.9 2024-04-29T10:16:00.000Z https://lymphomahub.com/medical-information/venetoclax-for-del-17p-chronic-lymphocytic-leukemia-long-term-follow-up-data-from-the-m13-982-trial monthly 0.9 2024-03-13T14:45:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-granted-fda-approval-for-the-treatment-of-rr-cllsll monthly 0.9 2024-03-15T16:24:00.000Z https://lymphomahub.com/medical-information/tocilizumab-for-the-management-of-cytokine-release-syndrome-real-world-data monthly 0.9 2024-03-12T14:03:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-plus-obinutuzumab-receives-accelerated-u-s-fda-approval-for-adult-patients-with-rr-fl monthly 0.9 2024-03-08T13:40:00.000Z https://lymphomahub.com/medical-information/outcomes-of-subsequent-therapies-after-2l-axi-cel-or-soc-in-rr-lbcl-zuma-7-study monthly 0.9 2024-06-26T13:25:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-versus-acalabrutinib-in-rr-cll-an-indirect-comparison monthly 0.9 2024-03-01T16:04:00.000Z https://lymphomahub.com/medical-information/the-role-of-the-genetic-drivers-of-dlbcl-in-the-tumor-microenvironment monthly 0.9 2024-02-29T14:54:00.000Z https://lymphomahub.com/medical-information/impact-of-delayed-car-t-cell-infusion-on-clinical-outcomes-in-rr-lbcl monthly 0.9 2024-03-04T09:36:00.000Z https://lymphomahub.com/medical-information/ibrutinib-plus-fludarabine-cyclophosphamide-and-rituximab-as-initial-therapy-in-cll-a-5-year-follow-up-study monthly 0.9 2024-02-14T16:03:00.000Z https://lymphomahub.com/medical-information/hovon-nhl-24-trial-rituximab-plus-mbvp-in-pcnsl monthly 0.9 2024-02-08T16:02:00.000Z https://lymphomahub.com/medical-information/health-canada-approves-zanubrutinib-plus-obinutuzumab-for-adult-patients-with-rr-fl monthly 0.9 2024-02-08T15:32:00.000Z https://lymphomahub.com/medical-information/ash-2023-ctdna-in-lymphoma-management monthly 0.9 2024-02-06T10:20:00.000Z https://lymphomahub.com/medical-information/long-term-outcomes-of-inotuzumab-ozogamicin-plus-allo-hsct-conditioning-regimen-in-cd22-lymphoid-malignancies monthly 0.9 2024-01-31T16:25:00.000Z https://lymphomahub.com/medical-information/ash-2023-novel-treatment-options-for-patients-with-high-burden-newly-diagnosed-fl monthly 0.9 2024-01-31T16:50:00.000Z https://lymphomahub.com/medical-information/key-updates-from-ash-2023-novel-treatment-options-for-patients-with-rr-wm monthly 0.9 2024-01-26T10:40:00.000Z https://lymphomahub.com/medical-information/fda-issues-new-boxed-warning-for-car-t-cell-therapies monthly 0.9 2024-01-30T16:24:00.000Z https://lymphomahub.com/medical-information/car-t-cell-therapy-in-lbcl-key-updates-from-ash-2023 monthly 0.9 2024-01-24T14:51:00.000Z https://lymphomahub.com/medical-information/ash-2023-treatment-options-for-patients-with-high-risk-rr-mcl monthly 0.9 2024-01-18T16:09:00.000Z https://lymphomahub.com/medical-information/factors-associated-with-long-term-outcomes-of-cd19-car-t-cell-therapy-for-rr-cll monthly 0.9 2024-01-12T09:38:00.000Z https://lymphomahub.com/medical-information/primary-endpoint-met-in-clover-wam-trial-of-iopofosine-131-in-rr-wm monthly 0.9 2024-01-10T12:20:00.000Z https://lymphomahub.com/medical-information/sympatico-is-ibrutinib-combined-with-venetoclax-safe-and-effective-in-patients-with-rr-mcl monthly 0.9 2024-01-19T12:25:00.000Z https://lymphomahub.com/medical-information/swog1826-what-are-the-key-takeaways monthly 0.9 2024-01-19T12:26:00.000Z https://lymphomahub.com/medical-information/btk-inhibitors-discussion-how-do-they-work-and-what-do-patients-prefer monthly 0.9 2024-01-19T12:27:00.000Z https://lymphomahub.com/medical-information/iwmf-research-grant-program monthly 0.9 2024-01-10T17:34:00.000Z https://lymphomahub.com/medical-information/car-t-cell-therapy-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma-aged-65-years monthly 0.9 2023-12-06T16:32:00.000Z https://lymphomahub.com/medical-information/long-term-toxicities-associated-with-ibrutinib-in-patients-with-cll monthly 0.9 2023-12-07T17:25:00.000Z https://lymphomahub.com/medical-information/the-korean-ministry-of-food-and-drug-safety-approves-glofitamab-for-patients-with-rr-dlbcl monthly 0.9 2023-12-11T16:19:00.000Z https://lymphomahub.com/medical-information/the-role-of-the-tumor-microenvironment-on-car-t-cell-therapy-in-b-cell-lymphoma monthly 0.9 2026-05-28T09:39:00.000Z https://lymphomahub.com/medical-information/phase-iii-selene-trial-efficacy-and-safety-of-ibrutinib-plus-brr-chop-in-rr-fl-or-mzl monthly 0.9 2025-07-18T12:06:00.000Z https://lymphomahub.com/medical-information/fda-approves-pirtobrutinib-for-patients-with-relapsedrefractory-cllsll monthly 0.9 2023-12-05T17:05:00.000Z https://lymphomahub.com/medical-information/ash-2023-top-abstracts-in-lymphoma-and-cll monthly 0.9 2026-05-28T09:30:00.000Z https://lymphomahub.com/medical-information/how-to-treat-older-and-frail-patients-with-cll monthly 0.9 2025-08-05T13:42:00.000Z https://lymphomahub.com/medical-information/how-i-would-treat-patients-with-rr-dlbcl-in-2023-and-the-future monthly 0.9 2025-08-05T13:43:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-and-bendamustine-salvage-therapy-in-patients-with-relapsedrefractory-ptcl monthly 0.9 2026-05-28T09:39:00.000Z https://lymphomahub.com/medical-information/optimal-management-of-patients-with-rr-ptcl monthly 0.9 2023-11-22T10:24:00.000Z https://lymphomahub.com/medical-information/the-impact-of-crs-on-car-t-cell-outcomes-in-patients-with-aggressive-lbcl monthly 0.9 2026-05-28T09:38:00.000Z https://lymphomahub.com/medical-information/efficacy-and-safety-of-cd22cd19-dual-targeted-car-t-cell-therapy-in-b-cell-malignancies monthly 0.9 2026-05-28T09:37:00.000Z https://lymphomahub.com/medical-information/how-and-when-to-treat-patients-with-refractory-or-progressive-wm monthly 0.9 2024-09-18T10:26:00.000Z https://lymphomahub.com/medical-information/aspen-trial-long-term-follow-up-of-zanubrutinib-versus-ibrutinib-in-patients-with-wm monthly 0.9 2026-05-28T09:36:00.000Z https://lymphomahub.com/medical-information/fda-grants-lisocabtagene-maraleucel-priority-review-for-rr-cll-or-sll monthly 0.9 2023-11-13T11:22:00.000Z https://lymphomahub.com/medical-information/what-are-the-key-updates-from-esh-2nd-how-i-manage-car-t-therapies-and-bispecific-antibodies monthly 0.9 2023-10-26T09:29:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-in-relapsedrefractory-marginal-zone-lymphoma-final-results-from-the-magnolia-study monthly 0.9 2026-05-28T09:36:00.000Z https://lymphomahub.com/medical-information/how-to-choose-and-prepare-patients-for-car-t-cell-therapy monthly 0.9 2023-10-26T09:22:00.000Z https://lymphomahub.com/medical-information/glow-study-impact-of-mrd-on-pfs-in-older-and-frail-patients-with-cll-receiving-fixed-duration-ibrutinib-venetoclax-vs-chlorambucil-obinutuzumab monthly 0.9 2026-05-28T09:35:00.000Z https://lymphomahub.com/medical-information/what-are-the-new-therapeutic-strategies-in-mcl monthly 0.9 2023-10-17T10:38:00.000Z https://lymphomahub.com/medical-information/key-takeaways-and-updates-from-soho-2023 monthly 0.9 2023-10-13T11:05:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-combination-receives-ec-approval-for-the-treatment-of-adult-patients-with-untreated-stage-iii-hodgkin-lymphoma monthly 0.9 2023-10-19T15:32:00.000Z https://lymphomahub.com/medical-information/the-role-of-the-gut-microbiota-in-car-t-cell-therapy-outcomes monthly 0.9 2023-10-13T11:19:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-plus-obinutuzumab-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-rr-fl monthly 0.9 2023-10-16T15:05:00.000Z https://lymphomahub.com/medical-information/how-can-we-improve-care-for-elderly-patients-with-hl monthly 0.9 2023-10-13T11:05:00.000Z https://lymphomahub.com/medical-information/transcend-cll-004-trial-efficacy-and-safety-of-liso-cel-in-patients-with-rr-cll-or-sll monthly 0.9 2025-07-18T12:07:00.000Z https://lymphomahub.com/medical-information/what-constitutes-refractory-disease-in-the-context-of-wm monthly 0.9 2023-09-27T11:21:00.000Z https://lymphomahub.com/medical-information/epcoritamab-receives-approval-from-ec-and-japan-ministry-of-health-labour-and-welfare-for-rr-lbcl monthly 0.9 2023-09-26T14:36:00.000Z https://lymphomahub.com/medical-information/impact-of-bridging-therapy-on-car-t-cell-outcomes-in-patients-with-lbcl monthly 0.9 2026-05-28T09:34:00.000Z https://lymphomahub.com/medical-information/sls009-exhibits-favorable-data-in-rr-lymphomas-topline-results-from-phase-i-dose-escalation-trial monthly 0.9 2023-09-25T14:51:00.000Z https://lymphomahub.com/medical-information/keynote-087-5-year-follow-up-data-of-pembrolizumab-in-rr-classic-hodgkin-lymphoma monthly 0.9 2026-05-28T09:33:00.000Z https://lymphomahub.com/medical-information/alycante-axi-cel-exhibits-favorable-results-in-the-treatment-of-patients-with-lbcl monthly 0.9 2023-09-19T15:46:00.000Z https://lymphomahub.com/medical-information/iopofosine-i-131-receives-prime-designation-from-the-ema-for-patients-with-waldenstrom-s-macroglobulinemia monthly 0.9 2024-01-10T13:06:00.000Z https://lymphomahub.com/medical-information/efficacy-and-safety-of-obinutuzumab-versus-rituximab-in-patients-with-fl-gallium-trial monthly 0.9 2023-09-07T15:08:00.000Z https://lymphomahub.com/medical-information/pirtobrutinib-after-a-covalent-btk-inhibitor-in-cllsll monthly 0.9 2026-05-28T09:32:00.000Z https://lymphomahub.com/medical-information/pet-radiomics-vs-ipi-risk-score-model-performance-for-outcome-prediction-in-de-novo-dlbcl monthly 0.9 2025-07-18T12:07:00.000Z https://lymphomahub.com/medical-information/5-year-follow-up-trial-of-nivolumab-in-rr-classical-hodgkin-lymphoma-checkmate-205 monthly 0.9 2026-05-28T09:34:00.000Z https://lymphomahub.com/medical-information/key-highlights-from-a-descriptive-analysis-of-the-polarix-trial monthly 0.9 2023-08-14T11:02:00.000Z https://lymphomahub.com/medical-information/swog-s1826-nivolumab-avd-vs-brentuximab-vedotin-avd-in-patients-with-newly-diagnosed-advanced-stage-chl monthly 0.9 2026-05-28T09:31:00.000Z https://lymphomahub.com/medical-information/polarix-trial-is-pola-r-chp-effective-and-safe-in-elderly-patients-with-dlbcl monthly 0.9 2024-07-16T14:30:00.000Z https://lymphomahub.com/medical-information/new-nccn-guidelines-for-pediatric-patients-with-hodgkin-lymphoma-and-their-families monthly 0.9 2023-08-25T13:57:00.000Z https://lymphomahub.com/medical-information/pola-r-chp-vs-r-choep-in-young-patients-with-high-risk-dlbcl monthly 0.9 2023-08-14T10:39:00.000Z https://lymphomahub.com/medical-information/what-are-the-novel-treatment-options-for-patients-with-relapsed-or-refractory-wm monthly 0.9 2024-09-12T08:50:00.000Z https://lymphomahub.com/medical-information/novel-therapies-in-lbcl-key-updates-from-icml monthly 0.9 2026-05-28T09:30:00.000Z https://lymphomahub.com/medical-information/what-are-the-take-home-messages-from-17-icml monthly 0.9 2023-08-02T10:38:00.000Z https://lymphomahub.com/medical-information/captivate-4-year-update-fixed-duration-ibrutinib-venetoclax-in-cll-and-sll monthly 0.9 2026-05-28T09:29:00.000Z https://lymphomahub.com/medical-information/what-are-the-treatment-options-for-patients-with-mcl-who-relapse-after-btki-therapy monthly 0.9 2023-08-02T09:59:00.000Z https://lymphomahub.com/medical-information/novel-treatments-in-rr-cll-updates-from-eha-2023 monthly 0.9 2026-05-28T09:28:00.000Z https://lymphomahub.com/medical-information/transcend-cll004-might-car-t-cell-therapy-become-standard-of-care-for-cll monthly 0.9 2023-12-05T16:06:00.000Z https://lymphomahub.com/medical-information/6-year-follow-up-results-of-the-cll14-study-of-venetoclax-obinutuzumab-in-previously-untreated-cll monthly 0.9 2023-07-27T10:23:00.000Z https://lymphomahub.com/medical-information/novel-therapies-for-relapsedrefractory-follicular-lymphoma-key-updates-from-icml-2023 monthly 0.9 2026-05-28T09:28:00.000Z https://lymphomahub.com/medical-information/car-t-cell-case-study-sequencing-therapies-for-patients-with-high-risk-dlbcl monthly 0.9 2025-08-05T14:34:00.000Z https://lymphomahub.com/medical-information/understanding-biomarkers-and-patient-eligibility-for-car-t-cell-therapies-in-diffuse-large-b-cell-lymphoma monthly 0.9 2025-08-05T14:35:00.000Z https://lymphomahub.com/medical-information/answering-the-common-challenges-facing-real-world-car-t-cell-therapies monthly 0.9 2025-08-05T14:35:00.000Z https://lymphomahub.com/medical-information/fixed-duration-combinations-for-first-line-cll-treatmentwhat-do-the-long-term-trial-results-show monthly 0.9 2023-07-17T11:43:00.000Z https://lymphomahub.com/medical-information/ielsg37-trial-can-radiotherapy-be-avoided-in-patients-with-pmbcl monthly 0.9 2023-12-05T16:05:00.000Z https://lymphomahub.com/medical-information/targeting-unmet-needs-in-cll monthly 0.9 2023-07-04T11:49:00.000Z https://lymphomahub.com/medical-information/how-effective-is-car-t-cell-therapy-for-rr-mcl-in-a-standard-of-care-setting monthly 0.9 2024-06-25T14:47:00.000Z https://lymphomahub.com/medical-information/survival-analysis-of-axi-cel-versus-standard-of-care-in-patients-with-rr-lbcl-zuma-7-trial monthly 0.9 2023-06-28T11:48:00.000Z https://lymphomahub.com/medical-information/the-5th-edition-of-the-world-health-organization-classification-of-hematolymphoid-tumors-t-cell-lymphoma-part-3 monthly 0.9 2023-06-21T09:53:00.000Z https://lymphomahub.com/medical-information/prospective-geriatric-assessment-and-geriatric-consultation-in-car-t-cell-therapy-for-older-patients-with-lymphoma monthly 0.9 2024-07-16T14:28:00.000Z https://lymphomahub.com/medical-information/how-does-car-t-cell-therapy-compare-with-allo-sct-for-treating-rr-lbcl monthly 0.9 2023-06-27T14:12:00.000Z https://lymphomahub.com/medical-information/efficacy-and-safety-of-brexucabtagene-autoleucel-in-patients-with-rr-mcl-a-real-world-analysis monthly 0.9 2025-07-18T12:08:00.000Z https://lymphomahub.com/medical-information/what-insights-can-multi-omics-provide-into-the-mechanism-of-disease-progression-in-wm monthly 0.9 2023-06-23T09:56:00.000Z https://lymphomahub.com/medical-information/advanced-stage-chl-international-prognostication-index-a-hipi-a-modern-clinical-prediction-model-from-the-holistic-consortium monthly 0.9 2023-06-19T08:47:00.000Z https://lymphomahub.com/medical-information/glofitamab-receives-fda-approval-for-rr-dlbcl monthly 0.9 2025-11-19T14:38:00.000Z https://lymphomahub.com/medical-information/long-term-outcomes-following-car-t-cell-therapy-in-b-cell-malignancies monthly 0.9 2023-06-06T13:31:00.000Z https://lymphomahub.com/medical-information/polatuzumab-vedotin-in-previously-untreated-dlbcl-an-asia-subpopulation-analysis-from-polarix-trial monthly 0.9 2025-11-04T15:27:00.000Z https://lymphomahub.com/medical-information/eha-2023 monthly 0.9 2023-06-12T11:42:00.000Z https://lymphomahub.com/medical-information/the-emerging-role-of-mrd-in-the-treatment-of-chronic-lymphocytic-leukemia monthly 0.9 2023-06-01T09:08:00.000Z https://lymphomahub.com/medical-information/eha2023-abstracts-what-s-hot-in-lymphoma-and-cll monthly 0.9 2023-06-05T10:48:00.000Z https://lymphomahub.com/medical-information/asco23 monthly 0.9 2023-06-12T11:43:00.000Z https://lymphomahub.com/medical-information/time-limited-for-cll-and-lymphoma-who-what-and-how monthly 0.9 2025-08-05T13:44:00.000Z https://lymphomahub.com/medical-information/how-to-treat-newly-diagnosed-dlbcl monthly 0.9 2025-08-05T13:45:00.000Z https://lymphomahub.com/medical-information/5-year-outcomes-of-axicabtagene-ciloleucel-in-adults-with-refractory-lbcl-zuma-1-trial monthly 0.9 2023-05-12T10:00:00.000Z https://lymphomahub.com/medical-information/car-t-cell-therapy-associated-hlh-like-syndrome monthly 0.9 2023-05-10T10:01:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-receives-ec-approval-for-the-treatment-of-adult-patients-with-rr-lbcl-after-one-prior-therapy monthly 0.9 2023-05-05T10:59:00.000Z https://lymphomahub.com/medical-information/clinical-efficacy-of-ibrutinib-r-chop-in-untreated-non-gcb-dlbcl-co-expressing-myc-and-bcl2-subanalysis-of-the-phase-iii-phoenix-trial monthly 0.9 2025-07-18T12:09:00.000Z https://lymphomahub.com/medical-information/what-are-the-key-updates-to-the-nccn-guidelines-r-for-cllsll monthly 0.9 2024-07-16T14:13:00.000Z https://lymphomahub.com/medical-information/ebmt-2023 monthly 0.9 2023-04-19T10:12:00.000Z https://lymphomahub.com/medical-information/l-mind-rr-dlbcl-study-5-year-results monthly 0.9 2023-04-21T08:58:00.000Z https://lymphomahub.com/medical-information/polatuzumab-vedotin-in-combination-with-r-chp-granted-fda-approval-for-patients-with-untreated-dlbcl monthly 0.9 2023-06-05T11:08:00.000Z https://lymphomahub.com/medical-information/the-5th-edition-of-the-world-health-organization-classification-of-hematolymphoid-tumors-lymphoid-neoplasms-part-2 monthly 0.9 2023-04-13T12:00:00.000Z https://lymphomahub.com/medical-information/omidubicel-onlv-granted-fda-approval-for-patients-with-hematologic-malignancies-eligible-for-umbilical-cord-blood-transplantation monthly 0.9 2023-04-19T09:35:00.000Z https://lymphomahub.com/medical-information/clinical-implications-of-the-odac-vote-in-favor-of-polatuzumab-vedotin-for-untreated-dlbcl monthly 0.9 2023-04-20T09:17:00.000Z https://lymphomahub.com/medical-information/ibrutinib-voluntarily-withdrawn-in-u-s-for-lymphoma-indications monthly 0.9 2023-04-14T11:44:00.000Z https://lymphomahub.com/medical-information/dual-targeted-car-t-cell-therapy-key-updates-from-tct-2023 monthly 0.9 2023-03-24T11:20:00.000Z https://lymphomahub.com/medical-information/the-role-of-the-gut-microbiome-in-lymphoma-outcomes monthly 0.9 2023-03-23T10:25:00.000Z https://lymphomahub.com/medical-information/talking-to-your-patients-with-waldenstrom-macroglobulinemia monthly 0.9 2023-12-13T10:15:00.000Z https://lymphomahub.com/medical-information/educational-theme-or-tumor-intrinsic-resistance-mechanisms-to-car-t-cell-therapy-in-lymphomas monthly 0.9 2026-05-28T09:27:00.000Z https://lymphomahub.com/medical-information/common-genomic-diagnostic-tests monthly 0.9 2023-03-31T13:54:00.000Z https://lymphomahub.com/medical-information/visual-abstract-or-phase-ii-trial-of-glofitamab-following-obinutuzumab-pretreatment-in-patients-with-rr-dlbcl monthly 0.9 2024-07-16T14:41:00.000Z https://lymphomahub.com/medical-information/axicabtagene-ciloleucel-exhibits-improved-overall-survival-versus-soc-for-initial-treatment-of-adult-patients-with-rr-lbcl monthly 0.9 2023-03-23T13:53:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-as-second-line-therapy-for-adult-patients-with-lbcl-primary-analysis-of-the-phase-iii-transform-trial monthly 0.9 2023-03-01T12:35:00.000Z https://lymphomahub.com/medical-information/treatment-landscape-for-rr-wm monthly 0.9 2023-03-14T11:41:00.000Z https://lymphomahub.com/medical-information/descar-t-analysis-outcomes-following-anti-cd19-car-t-cell-failure monthly 0.9 2023-03-09T11:30:00.000Z https://lymphomahub.com/medical-information/a-phase-iii-trial-of-pirtobrutinib-in-patients-with-rr-waldenstrom-s-macroglobulinemia-bruin-trial monthly 0.9 2025-07-18T12:14:00.000Z https://lymphomahub.com/medical-information/novel-combinations-for-rr-mcl-key-updates-from-ash-2022 monthly 0.9 2023-02-13T11:34:00.000Z https://lymphomahub.com/medical-information/improving-safety-and-efficacy-of-brentuximab-vedotin-nivolumab-and-ad-for-advanced-stage-chl monthly 0.9 2023-02-03T10:36:00.000Z https://lymphomahub.com/medical-information/how-robust-is-pod24-as-a-predictor-of-survival-in-indolent-lymphomas monthly 0.9 2023-02-01T10:51:00.000Z https://lymphomahub.com/medical-information/treating-richter-transformation-in-cll monthly 0.9 2023-02-02T11:30:00.000Z https://lymphomahub.com/medical-information/what-do-the-elm-2-results-tell-us-about-the-efficacy-of-odronextamab-for-rr-dlbcl monthly 0.9 2023-02-01T10:43:00.000Z https://lymphomahub.com/medical-information/cart-2023 monthly 0.9 2023-02-07T11:46:00.000Z https://lymphomahub.com/medical-information/novel-combinations-for-the-frontline-treatment-of-patients-with-dlbcl monthly 0.9 2023-05-17T15:11:00.000Z https://lymphomahub.com/medical-information/how-to-treat-high-risk-follicular-lymphoma monthly 0.9 2023-03-27T15:45:00.000Z https://lymphomahub.com/medical-information/bispecific-antibodies-for-follicular-lymphoma-frontline-treatment-and-beyond monthly 0.9 2023-02-01T09:35:00.000Z https://lymphomahub.com/medical-information/primary-endpoint-met-in-transcend-cll-004-trial-of-liso-cel-in-rr-cll monthly 0.9 2023-01-31T10:42:00.000Z https://lymphomahub.com/medical-information/pirtobrutinib-granted-fda-approval-for-the-treatment-of-rr-mcl monthly 0.9 2025-11-19T14:37:00.000Z https://lymphomahub.com/medical-information/targeting-ror-1-with-zilovertamab-in-mcl-and-cll monthly 0.9 2023-01-30T12:39:00.000Z https://lymphomahub.com/medical-information/using-ctdna-analysis-in-risk-profiling-of-frontline-dlbcl-results-from-the-polarix-study monthly 0.9 2023-01-13T13:39:00.000Z https://lymphomahub.com/medical-information/the-neutrodiet-trial-is-a-protective-diet-necessary-after-sct monthly 0.9 2023-01-18T13:41:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-receives-fda-approval-for-cll-and-sll monthly 0.9 2023-01-23T13:01:00.000Z https://lymphomahub.com/medical-information/consolidative-hdc-asct-versus-non-myeloablative-immunochemotherapy-for-patients-with-primary-cns-lymphoma monthly 0.9 2023-01-23T14:10:00.000Z https://lymphomahub.com/medical-information/frontline-ibrutinib-for-younger-patients-with-mcl-results-from-the-phase-iii-triangle-trial monthly 0.9 2024-06-07T07:12:00.000Z https://lymphomahub.com/medical-information/symphony-1-a-trial-update monthly 0.9 2023-01-11T10:15:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-versus-ibrutinib-in-rr-cllsll-final-alpine-results monthly 0.9 2023-01-11T09:58:00.000Z https://lymphomahub.com/medical-information/novel-therapies-in-chronic-lymphocytic-leukemia-an-update monthly 0.9 2023-01-05T10:55:00.000Z https://lymphomahub.com/medical-information/tarmac-can-we-combine-targeted-therapy-with-car-t-cells-in-mcl monthly 0.9 2023-01-05T10:19:00.000Z https://lymphomahub.com/medical-information/mosunetuzumab-receives-fda-approval-for-the-treatment-of-rr-follicular-lymphoma monthly 0.9 2023-01-03T15:27:00.000Z https://lymphomahub.com/medical-information/what-are-the-car-t-cell-therapies-on-the-horizon-for-lymphoma monthly 0.9 2023-01-03T13:37:00.000Z https://lymphomahub.com/medical-information/predicting-response-to-bcr-and-bcl-2-therapies-using-mrd-assessment-in-patients-with-cll monthly 0.9 2022-12-22T12:00:00.000Z https://lymphomahub.com/medical-information/visual-abstract-or-a-real-world-comparison-of-treatment-with-tisagenlecleucel-and-axicabtagene-ciloleucel-in-patients-with-rr-dlbcl monthly 0.9 2024-07-16T14:41:00.000Z https://lymphomahub.com/medical-information/european-commission-grants-approval-to-loncastuximab-tesirine-for-the-treatment-of-adult-patients-with-rr-dlbcl-read-more-here-lymsm-leusm-medicalnews monthly 0.9 2022-12-22T14:19:00.000Z https://lymphomahub.com/medical-information/what-factors-explain-inferior-survival-for-eu-vs-us-patients-with-dlbcl-after-car-t-cell-therapy monthly 0.9 2022-12-19T13:48:00.000Z https://lymphomahub.com/medical-information/can-frontline-treatment-of-dlbcl-be-improved-by-combining-novel-agents-with-r-chop monthly 0.9 2022-12-19T13:34:00.000Z https://lymphomahub.com/medical-information/educational-theme-or-targeted-treatment-for-elderly-patients-with-cll monthly 0.9 2024-07-16T13:52:00.000Z https://lymphomahub.com/medical-information/ash-2022 monthly 0.9 2022-12-07T11:13:00.000Z https://lymphomahub.com/medical-information/educational-theme-disease-management-of-elderly-patients-with-aggressive-b-cell-lymphoma-in-the-modern-era monthly 0.9 2024-07-16T13:52:00.000Z https://lymphomahub.com/medical-information/umrd-as-a-surrogate-endpoint-for-clinical-trials-regulatory-approvals-and-therapy-decisions-in-cll monthly 0.9 2026-05-28T09:26:00.000Z https://lymphomahub.com/medical-information/how-do-you-choose-among-different-btk-inhibitors-for-treating-cll monthly 0.9 2023-01-06T09:05:00.000Z https://lymphomahub.com/medical-information/ash-2022-top-abstracts-in-lymphoma-and-cll monthly 0.9 2023-02-09T12:01:00.000Z https://lymphomahub.com/medical-information/managing-common-and-uncommon-complications-of-wm monthly 0.9 2022-11-16T12:44:00.000Z https://lymphomahub.com/medical-information/when-and-how-should-treatment-be-modified-for-older-patients-with-hl monthly 0.9 2024-07-16T14:28:00.000Z https://lymphomahub.com/medical-information/what-are-the-latest-advances-in-basal-petct-for-hodgkin-and-non-hodgkin-lymphoma monthly 0.9 2022-11-17T14:43:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-receives-ec-approval-for-the-treatment-of-adult-patients-with-cll monthly 0.9 2022-11-23T09:21:00.000Z https://lymphomahub.com/medical-information/how-does-the-prognostic-outlook-for-patients-with-double-hit-lymphoma-impact-disease-management monthly 0.9 2022-11-10T16:13:00.000Z https://lymphomahub.com/medical-information/the-5th-edition-of-the-world-health-organization-classification-of-hematolymphoid-tumors-lymphoid-neoplasms-part-1 monthly 0.9 2022-11-17T15:01:00.000Z https://lymphomahub.com/medical-information/irene-g-a-prospective-rct-of-nutritional-support-following-allo-hsct monthly 0.9 2022-11-10T16:11:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-combination-therapy-receives-fda-approval-for-high-risk-chl-in-patients-aged-2-years monthly 0.9 2022-11-18T10:52:00.000Z https://lymphomahub.com/medical-information/the-role-of-cns-prophylaxis-in-the-frontline-setting-for-patients-with-dlbcl monthly 0.9 2022-11-02T10:37:00.000Z https://lymphomahub.com/medical-information/is-cns-prophylaxis-warranted-in-dlbcl monthly 0.9 2022-11-08T15:28:00.000Z https://lymphomahub.com/medical-information/what-are-the-current-treatment-options-for-double-hit-lymphoma monthly 0.9 2022-11-08T15:27:00.000Z https://lymphomahub.com/medical-information/what-does-data-from-the-brazilian-prospective-hl-registry-tell-us-about-outcomes-for-older-patients monthly 0.9 2022-10-28T14:03:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-receives-ec-approval-for-the-treatment-of-rr-marginal-zone-lymphoma monthly 0.9 2022-11-04T12:22:00.000Z https://lymphomahub.com/medical-information/cd3-t-cells-as-biomarkers-of-frailty-in-elderly-patients-with-hematologic-malignancies monthly 0.9 2022-10-25T11:18:00.000Z https://lymphomahub.com/medical-information/what-are-the-latest-advances-in-the-treatment-of-nkt-cell-lymphoma monthly 0.9 2022-10-24T14:38:00.000Z https://lymphomahub.com/medical-information/the-effect-of-lisocabtagene-maraleucel-vs-standard-of-care-on-health-related-quality-of-life-in-patients-with-rr-lbcl monthly 0.9 2022-10-28T14:41:00.000Z https://lymphomahub.com/medical-information/visual-abstract-final-analysis-of-the-phase-iii-illuminate-trial-in-patients-with-cllsll monthly 0.9 2024-07-31T10:46:00.000Z https://lymphomahub.com/medical-information/axi-cel-receives-european-marketing-authorization-for-the-treatment-of-adult-patients-with-rr-dlbcl-and-hgbl-lymphoma-lymsm-mednews monthly 0.9 2022-10-27T08:54:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-exhibits-pfs-benefit-in-relapsedrefractory-cllsll-topline-results-from-the-alpine-trial monthly 0.9 2022-10-17T09:33:00.000Z https://lymphomahub.com/medical-information/ishl-2022 monthly 0.9 2022-10-24T11:07:00.000Z https://lymphomahub.com/medical-information/genomic-pathways-and-treatment-strategies-for-patients-with-waldenstrom-s-macroglobulinemia monthly 0.9 2022-10-14T14:39:00.000Z https://lymphomahub.com/medical-information/educational-theme-treatment-considerations-for-elderly-patients-with-lymphoma monthly 0.9 2024-07-16T13:52:00.000Z https://lymphomahub.com/medical-information/how-can-we-improve-care-for-elderly-patients-with-aggressive-lymphomas monthly 0.9 2024-07-16T14:31:00.000Z https://lymphomahub.com/medical-information/colym-2022 monthly 0.9 2022-10-17T16:21:00.000Z https://lymphomahub.com/medical-information/cost-effectiveness-of-axicabtagene-ciloleucel-in-rr-dlbcl monthly 0.9 2022-10-03T14:43:00.000Z https://lymphomahub.com/medical-information/rehabilitation-strategies-for-patients-undergoing-car-t-cell-therapy monthly 0.9 2022-09-27T14:59:00.000Z https://lymphomahub.com/medical-information/soho-2022 monthly 0.9 2022-09-29T09:22:00.000Z https://lymphomahub.com/medical-information/patient-preferences-for-the-treatment-of-waldenstrom-s-macroglobulinemia monthly 0.9 2022-09-22T14:27:00.000Z https://lymphomahub.com/medical-information/patient-reported-outcomes-in-phase-iii-zuma-7-trial-axicabtagene-versus-standard-of-care-in-rr-lbcl monthly 0.9 2022-10-18T08:26:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-mzl monthly 0.9 2022-09-20T15:34:00.000Z https://lymphomahub.com/medical-information/loncastuximab-tesirine-receives-positive-chmp-opinion-for-the-treatment-of-patients-with-rr-dlbcl monthly 0.9 2022-09-20T15:21:00.000Z https://lymphomahub.com/medical-information/axi-cel-receives-positive-chmp-opinion-for-the-treatment-of-adult-patients-with-dlbcl-and-high-grade-bcl monthly 0.9 2022-10-18T08:34:00.000Z https://lymphomahub.com/medical-information/visual-abstract-a-phase-iii-study-of-zanubrutinib-vs-bendamustine-rituximab-in-cll-and-sll monthly 0.9 2024-07-16T14:41:00.000Z https://lymphomahub.com/medical-information/esmo-congress-2022 monthly 0.9 2022-09-22T08:36:00.000Z https://lymphomahub.com/medical-information/educational-theme-latest-advances-in-the-treatment-for-patients-with-hodgkin-lymphoma monthly 0.9 2024-07-16T13:52:00.000Z https://lymphomahub.com/medical-information/is-car-t-cell-therapy-an-option-for-transplant-ineligible-patients-with-dlbc monthly 0.9 2022-09-23T14:15:00.000Z https://lymphomahub.com/medical-information/mrd-guided-venetoclax-plus-ibrutinib-for-rr-cll-results-from-the-phase-ii-hovon141vision-trial monthly 0.9 2022-08-30T10:46:00.000Z https://lymphomahub.com/medical-information/three-year-follow-up-of-kte-x19-in-rr-mantle-cell-lymphoma-zuma-2-trial monthly 0.9 2022-08-30T09:24:00.000Z https://lymphomahub.com/medical-information/emerging-novel-therapies-for-the-treatment-of-patients-with-aggressive-rr-nhl monthly 0.9 2022-08-30T09:24:00.000Z https://lymphomahub.com/medical-information/what-is-on-the-horizon-for-treating-peripheral-t-cell-lymphoma monthly 0.9 2022-11-14T12:40:00.000Z https://lymphomahub.com/medical-information/phase-i-data-of-golidocitinib-rr-peripheral-t-cell-lymphoma-jackpot8-trial monthly 0.9 2022-09-16T14:26:00.000Z https://lymphomahub.com/medical-information/what-are-the-latest-treatment-advances-for-hodgkin-lymphoma monthly 0.9 2022-08-09T10:53:00.000Z https://lymphomahub.com/medical-information/is-peripheral-neuropathy-in-patients-with-dlbcl-more-severe-after-pola-r-chp-vs-r-chop-treatment monthly 0.9 2024-06-25T14:47:00.000Z https://lymphomahub.com/medical-information/asct-in-dlbcl-is-it-over monthly 0.9 2022-08-03T16:31:00.000Z https://lymphomahub.com/medical-information/fixed-duration-ibrutinib-venetoclax-receives-ec-approval-as-first-line-treatment-for-chronic-lymphocytic-leukemia monthly 0.9 2022-08-05T12:50:00.000Z https://lymphomahub.com/medical-information/circulating-micrornas-in-cerebrospinal-fluid-and-plasma-a-new-diagnostic-modality-in-lymphoma-treatment monthly 0.9 2022-07-28T13:36:00.000Z https://lymphomahub.com/medical-information/emerging-treatment-strategies-in-rr-classical-hodgkin-lymphoma monthly 0.9 2025-08-05T13:46:00.000Z https://lymphomahub.com/medical-information/treating-primary-refractory-chl-that-is-refractory-to-salvage-chemotherapy monthly 0.9 2025-08-05T13:47:00.000Z https://lymphomahub.com/medical-information/liso-cel-as-a-second-line-treatment-for-patients-with-rr-lbcl-not-intended-for-hsct monthly 0.9 2022-07-26T08:54:00.000Z https://lymphomahub.com/medical-information/what-is-on-the-horizon-for-the-frontline-treatment-of-mcl monthly 0.9 2022-09-16T14:28:00.000Z https://lymphomahub.com/medical-information/polarix-how-does-myc-and-bcl2-expression-impact-outcomes-post-frontline-treatment-with-pv-in-dlbcl monthly 0.9 2022-07-22T09:25:00.000Z https://lymphomahub.com/medical-information/latest-advances-in-the-treatment-of-mantle-cell-lymphoma monthly 0.9 2022-07-19T07:57:00.000Z https://lymphomahub.com/medical-information/bispecific-antibodies-for-patients-with-rr-b-cell-lymphoma-latest-updates-from-phase-ii-trials monthly 0.9 2022-07-14T08:47:00.000Z https://lymphomahub.com/medical-information/article-title-required-captivate-3-year-update-fixed-duration-ibrutinib-venetoclax-in-cllsll monthly 0.9 2022-09-16T14:29:00.000Z https://lymphomahub.com/medical-information/what-are-the-key-considerations-for-car-t-cell-therapy-in-elderly-patients-with-lymphoma monthly 0.9 2024-07-16T14:31:00.000Z https://lymphomahub.com/medical-information/axicabtagene-ciloleucel-receives-ec-approval-as-a-third-line-treatment-of-follicular-lymphoma monthly 0.9 2022-06-30T10:40:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-receives-fda-approval-for-the-second-line-treatment-of-large-b-cell-lymphoma monthly 0.9 2022-06-28T15:21:00.000Z https://lymphomahub.com/medical-information/mb-106-granted-orphan-drug-designation-for-the-treatment-of-waldenstrom-s-macroglobulinemia monthly 0.9 2022-06-27T14:17:00.000Z https://lymphomahub.com/medical-information/efficacy-and-safety-of-ibrutinib-br-in-the-treatment-of-elderly-patients-with-mcl-primary-analysis-from-shine-iii monthly 0.9 2022-06-29T13:41:00.000Z https://lymphomahub.com/medical-information/mosunetuzumab-receives-european-commission-approval-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma monthly 0.9 2022-06-17T09:50:00.000Z https://lymphomahub.com/medical-information/genomic-features-of-car-t-treatment-failure-in-patients-with-lymphoma monthly 0.9 2022-06-14T14:01:00.000Z https://lymphomahub.com/medical-information/the-rapidly-evolving-role-of-car-t-cell-therapy-in-the-treatment-of-relapsedrefractory-hodgkin-lymphoma monthly 0.9 2022-06-09T09:10:00.000Z https://lymphomahub.com/medical-information/eha-2022 monthly 0.9 2022-07-07T09:24:00.000Z https://lymphomahub.com/medical-information/eha-2022-abstracts-what-s-hot-in-lymphoma-and-cll monthly 0.9 2022-06-06T12:31:00.000Z https://lymphomahub.com/medical-information/asco-2022 monthly 0.9 2022-09-02T10:08:00.000Z https://lymphomahub.com/medical-information/tisagenlecleucel-receives-fda-approval-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma monthly 0.9 2022-06-01T08:51:00.000Z https://lymphomahub.com/medical-information/article-title-required-treatment-patterns-and-survival-outcomes-in-patients-with-rr-follicular-lymphoma-a-multicenter-cohort-study monthly 0.9 2022-05-30T13:28:00.000Z https://lymphomahub.com/medical-information/preparing-for-car-t-cell-therapy-patient-selection-bridging-therapies-and-lymphodepletion monthly 0.9 2022-05-23T13:25:00.000Z https://lymphomahub.com/medical-information/a-safety-efficacy-and-pharmacokinetic-study-of-mosunetuzumab-in-non-hodgkin-lymphoma monthly 0.9 2024-07-16T14:42:00.000Z https://lymphomahub.com/medical-information/resource-stratified-guidelines-for-the-management-of-classical-hodgkin-lymphoma monthly 0.9 2024-07-16T14:13:00.000Z https://lymphomahub.com/medical-information/visual-abstract-or-odronextamab-phase-1-trial monthly 0.9 2024-07-16T14:42:00.000Z https://lymphomahub.com/medical-information/tisagenlecleucel-receives-ec-approval-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma monthly 0.9 2022-05-06T15:19:00.000Z https://lymphomahub.com/medical-information/two-year-follow-up-of-transcend-nhl-001-suggests-lisocabtagene-maraleucel-maintains-a-durable-response-in-rr-large-b-cell-lymphoma monthly 0.9 2022-05-12T11:20:00.000Z https://lymphomahub.com/medical-information/outcomes-of-elderly-patients-with-primary-cns-lymphoma-in-different-socioeconomic-settings-a-12-year-population-based-analysis-of-combined-modality-treatment monthly 0.9 2024-07-16T14:31:00.000Z https://lymphomahub.com/medical-information/dual-targeting-of-p13k-and-bcl-2-in-ibrutinib-resistant-mcl-a-preclinical-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/challenges-and-future-directions-for-access-to-cell-therapies-a-global-perspective monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/zuma-12-primary-analysis-axi-cel-for-the-frontline-treatment-for-high-risk-lbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/updated-clinical-data-from-phase-iii-study-of-afm13-complexed-with-preactivated-and-expanded-cord-blood-derived-nk-cells-for-patients-with-rr-cd30-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ctdna-serves-as-a-prognostic-marker-throughout-induction-therapy-in-patients-with-previously-untreated-mcl monthly 0.9 2022-04-11T14:38:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-receives-european-commission-approval-as-third-line-treatment-for-certain-forms-of-relapsed-or-refractory-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/minimal-residual-disease-mrd-guided-venetoclax-consolidation-following-fixed-duration-combination-treatment-in-previously-untreated-patients-with-chronic-lymphocytic-leukemia-cll-latest-updates-from-the-phase-ii-hovon-139give-trial monthly 0.9 2026-07-06T08:31:00.000Z https://lymphomahub.com/medical-information/does-prior-use-of-checkpoint-inhibitors-impact-allo-sct-outcomes-for-patients-with-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/axicabtagene-ciloleucel-receives-us-fda-approval-as-second-line-treatment-for-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-novel-therapies-for-the-treatment-of-first-relapse-and-primary-refractory-disease-in-patients-with-classical-hodgkin-lymphoma monthly 0.9 2024-07-16T13:52:00.000Z https://lymphomahub.com/medical-information/ema-recommends-eu-approval-of-polatuzumab-vedotin-combination-for-untreated-diffuse-large-b-cell-lymphoma monthly 0.9 2022-04-04T16:42:00.000Z https://lymphomahub.com/medical-information/what-treatment-options-are-there-for-patients-with-cll-who-are-resistant-to-both-btki-and-bcl2i monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/car-t-or-stem-cell-transplant-for-second-line-treatment-of-aggressive-b-cell-nhl monthly 0.9 2022-05-12T11:21:00.000Z https://lymphomahub.com/medical-information/safety-and-efficacy-of-tisagenlecleucel-in-primary-cns-lymphoma-a-phase-iii-clinical-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-do-you-decide-between-continuous-or-time-limited-therapy-for-cll monthly 0.9 2022-08-09T10:55:00.000Z https://lymphomahub.com/medical-information/approaches-to-disease-progression-in-fl-following-front-line-treatment monthly 0.9 2022-03-24T13:49:00.000Z https://lymphomahub.com/medical-information/ebmt-2022-what-are-the-highlights-for-the-treatment-of-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/responses-to-the-sars-cov-2-booster-vaccination-in-patients-with-lymphoid-malignancies monthly 0.9 2022-03-22T10:38:00.000Z https://lymphomahub.com/medical-information/educational-theme-first-line-management-of-patients-with-chl-a-british-society-for-haematology-guideline monthly 0.9 2024-07-16T13:53:00.000Z https://lymphomahub.com/medical-information/management-of-short-medium-and-long-term-complications-in-patients-receiving-car-t-cell-therapy monthly 0.9 2022-03-17T16:39:00.000Z https://lymphomahub.com/medical-information/orphan-drug-designation-granted-to-dt2216-for-the-treatment-of-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/healthcare-inequalities-in-bone-marrow-transplants monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-common-are-cardiotoxic-events-in-patients-receiving-cd19-car-t-cells-what-are-the-risk-factors monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/when-is-car-t-a-good-option-for-patients-with-follicular-and-marginal-zone-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-might-car-t-cells-change-the-treatment-landscape-for-patients-with-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/which-patients-with-aggressive-b-cell-nhl-do-not-qualify-for-car-t monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ibrutinib-rituximab-combinations-for-frontline-use-in-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-do-car-t-cell-recipients-respond-to-covid-19-vaccination monthly 0.9 2024-06-25T14:46:00.000Z https://lymphomahub.com/medical-information/what-supportive-care-is-needed-for-patients-receiving-car-t-cell-therapy monthly 0.9 2024-07-16T14:24:00.000Z https://lymphomahub.com/medical-information/what-does-the-first-line-data-for-polatuzumab-vedotin-tell-us-about-its-role-in-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/axi-cel-vs-soc-for-rr-lbcl-zuma-7-primary-analysis monthly 0.9 2024-09-18T09:57:00.000Z https://lymphomahub.com/medical-information/fda-grants-priority-review-to-liso-cel-as-a-second-line-therapy-for-rr-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-places-clinical-hold-on-car-t-cell-therapy-lb1901-phase-i-trial-in-rr-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-is-the-rationale-behind-the-combination-of-glofitamab-polatuzumab-in-patients-with-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/parsaclisib-new-drug-application-withdrawn-for-relapsedrefractory-mcl-mzl-and-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-places-partial-clinical-hold-on-umbralisib-and-ublituximab-trials-in-cll-and-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-receives-a-positive-opinion-from-the-ema-chmp-for-the-treatment-of-rr-dlbcl-pmbcl-and-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/mrd-growth-decelerated-with-venetoclax-combined-with-either-rituximab-or-obinutuzumab-in-patients-with-rr-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/visual-abstract-transform monthly 0.9 2024-09-18T09:58:00.000Z https://lymphomahub.com/medical-information/high-dose-methotrexate-does-not-reduce-cns-relapse-in-patients-with-dlbclhgbcl-findings-from-two-retrospective-cohort-studies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/outcomes-in-patients-with-comorbidities-treated-with-ublituximab-umbralisib-a-unity-cll-retrospective-analysis monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/chemo-free-combination-of-lenalidomide-rituximab-in-elderlyfrail-patients-with-mcl-and-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/orphan-drug-designation-granted-to-bi-1206-antibody-for-the-treatment-of-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/follicular-lymphoma-a-summary-of-the-hot-topics-presented-at-the-63rd-american-society-of-hematology-annual-meeting-and-exposition monthly 0.9 2025-02-20T16:39:00.000Z https://lymphomahub.com/medical-information/idelalisib-withdrawn-from-u-s-market-for-relapsed-fl-and-relapsed-sll-indications monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/treatment-with-loncastuximab-tesirine-in-patients-with-rr-dlbcl-health-related-qol-symptoms-and-tolerability-data monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/parsaclisib-a-potent-and-highly-selective-next-generation-pi3kd-inhibitor-a-summary-of-data-from-the-three-citadel-trials-203-204-and-205 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-lifts-clinical-hold-on-allogeneic-car-t-cell-therapy-trials monthly 0.9 2026-07-30T15:59:00.000Z https://lymphomahub.com/medical-information/what-impact-does-trial-eligibility-have-on-the-generalizability-of-survival-data monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-did-you-use-propensity-score-matching-to-compare-real-world-results-from-axi-cel-and-tisa-cel monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/polatuzumab-vedotin-r-chp-vs-r-chop-for-frontline-treatment-of-dlbcl-results-from-the-phase-iii-polarix-trial monthly 0.9 2025-11-04T15:25:00.000Z https://lymphomahub.com/medical-information/fda-agrees-to-design-and-major-details-of-zilo-301-a-phase-iii-study-of-zilovertamab-in-rr-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/covid-19-severity-mortality-and-mrna-vaccine-responses-in-patients-with-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-iii-belinda-tisa-cel-vs-standard-of-care-as-second-line-treatment-of-aggressive-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-i-dose-expansion-trial-of-brentuximab-vedotin-and-lenalidomide-in-patients-with-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-is-the-rationale-behind-step-up-dosing-of-glofitamab-in-patients-with-mcl monthly 0.9 2024-06-25T14:45:00.000Z https://lymphomahub.com/medical-information/what-results-have-you-seen-with-mosunetuzumab-in-patients-with-high-risk-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/comparison-of-auto-hct-and-car-t-cell-therapy-in-patients-with-relapsed-dlbcl-in-partial-remission monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-are-the-benefits-of-adding-anti-cd20-therapy-to-treatment-with-targeted-agents-in-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/humoral-and-cellular-responses-in-patients-with-lymphoid-malignancies-receiving-sars-cov-2-vaccination monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/polatuzumab-vedotinbased-therapy-as-third-line-or-beyond-treatment-for-patients-with-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2021-abstracts-what-s-hot-in-lymphoma-and-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/practice-patterns-and-outcomes-in-older-patients-with-dlbcl-in-england-a-real-world-data-analysis monthly 0.9 2024-07-16T14:29:00.000Z https://lymphomahub.com/medical-information/sympatico-study-safety-run-in-simultaneous-ibrutinib-plus-venetoclax-for-rr-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-or-aitl-pathophysiology-diagnostic-challenges-and-current-and-future-treatment-of-a-rare-t-cell-lymphoma-subtype monthly 0.9 2024-07-16T13:53:00.000Z https://lymphomahub.com/medical-information/what-role-is-there-for-allogeneic-sct-in-the-treatment-of-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-can-we-address-treatment-disparities-in-patients-with-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-does-ethnogeographic-diversity-tell-us-about-the-cause-of-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/survival-outcomes-in-patients-with-hodgkin-transformation-of-cll-a-multicenter-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/orphan-drug-designation-granted-to-zandelisib-for-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/risk-of-transformation-to-aggressive-b-cell-lymphoma-in-patients-with-primary-refractory-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-accepts-new-drug-application-for-parsaclisib-for-rr-fl-mzl-and-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/clinical-factors-predictive-of-pod24-a-robust-early-clinical-endpoint-of-poor-survival-in-patients-with-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/cpi-613-r-devimistat-receives-orphan-drug-designation-for-the-treatment-of-patients-with-relapsed-or-refractory-burkitt-lymphoma-by-the-european-medicines-agency monthly 0.9 2022-10-28T16:11:00.000Z https://lymphomahub.com/medical-information/what-does-the-future-of-t-cell-lymphoma-management-look-like monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-efficacy-and-safety-of-the-jak-12-inhibitor-ruxolitinib-in-tcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/efficacy-and-safety-of-pembro-gvd-as-second-line-therapy-for-patients-with-rr-chl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/efficacy-of-ibrutinib-plus-venetoclax-as-first-line-treatment-in-patients-with-cllsll-primary-analysis-from-the-mrd-cohort-of-captivate-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-grants-priority-review-to-tisagenlecleucel-for-relapsedrefractory-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/hodgkin-lymphoma-and-adoptive-immunotherapy-an-overview-of-current-research monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-ii-magnolia-trial-efficacy-and-safety-of-zanubrutinib-in-marginal-zone-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/humoral-and-cellular-responses-to-tisagenlecleucel monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/geriatric-hematology-in-low-resource-settings-improving-care-for-older-people-through-the-implementation-of-geriatric-hematology-programs monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-do-you-use-mrd-to-guide-treatment-decisions monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/efficacy-and-safety-of-the-triplet-regimen-obinutuzumab-atezolizumab-lenalidomide-for-patients-with-rr-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/outcomes-of-patients-with-cll-that-develop-dual-resistance-to-btki-and-venetoclax monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ema-approves-shorter-infusion-time-for-obinutuzumab-for-patients-with-treateduntreated-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/understanding-the-mutational-landscape-of-plasmablastic-lymphoma-a-genomic-analysis monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-approves-phase-i-clinical-trial-to-evaluate-xl114-in-patients-with-non-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-places-a-clinical-hold-on-allogeneic-car-t-cell-trials monthly 0.9 2026-07-30T16:01:00.000Z https://lymphomahub.com/medical-information/umbralisib-demonstrates-favorable-long-term-safety-for-patients-with-rr-lymphoid-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-is-the-most-promising-novel-agent-for-the-treatment-of-aggressive-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/efficacy-of-hyper-cvad-r-in-preventing-cns-relapse-in-aggressive-b-cell-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-do-you-approach-the-treatment-of-untreated-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/overall-survival-and-ezh2-expression-in-mantle-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-are-the-best-strategies-for-long-term-management-of-hematotoxicity-associated-with-car-t monthly 0.9 2024-07-16T14:25:00.000Z https://lymphomahub.com/medical-information/re-mind-a-study-comparing-tafasitamab-lenalidomide-versus-a-real-world-lenalidomide-monotherapy-cohort-of-patients-with-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-can-we-select-the-best-targeted-agent-s-for-patients-with-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/loncastuximab-tesirine-granted-orphan-drug-designation-in-the-european-union-for-the-treatment-of-patients-with-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/safety-and-efficacy-of-oral-azacitidine-cc-486-plus-r-chop-in-patients-with-previously-untreated-intermediate-to-high-risk-dlbcl-a-phase-i-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/clonal-hematopoiesis-and-car-t-cell-therapy-outcomes monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-do-we-select-a-patient-with-rr-dlbcl-for-car-t monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-granted-accelerated-approval-by-the-fda-for-the-treatment-of-patients-with-rr-mzl monthly 0.9 2025-02-20T16:20:00.000Z https://lymphomahub.com/medical-information/clinical-practice-guidelines-for-transplant-and-cellular-therapies-in-mantle-cell-lymphoma-recommendations-from-astct-cibmtr-and-ebmt monthly 0.9 2024-07-16T14:14:00.000Z https://lymphomahub.com/medical-information/what-is-the-most-promising-new-targetable-pathway-in-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-predicts-disease-progression-on-venetoclax monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/predicting-long-term-cardiovascular-risk-in-patients-with-early-stage-hodgkin-lymphoma-treated-with-involved-field-radiotherapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/does-current-reporting-on-car-t-cell-therapy-in-clinical-trials-overestimate-efficacy-why-the-distinction-between-itt-and-mitt-populations-is-important monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/alpha2-is-allo-501a-a-promising-alternative-to-autologous-car-t-cells monthly 0.9 2026-07-30T16:04:00.000Z https://lymphomahub.com/medical-information/fda-approval-of-zanubrutinib-for-adult-patients-with-waldenstrom-s-macroglobulinemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/development-of-a-novel-prognostic-scoring-system-for-risk-stratification-of-patients-with-angioimmunoblastic-t-cell-lymphoma monthly 0.9 2021-08-27T09:23:00.000Z https://lymphomahub.com/medical-information/risk-scores-for-monoclonal-b-cell-lymphocytosis-in-patients-with-european-ancestry-and-chronic-lymphocytic-leukemia-in-african-americans monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/using-pet-to-guide-the-therapeutic-approach-for-patients-with-follicular-lymphoma monthly 0.9 2025-02-20T16:39:00.000Z https://lymphomahub.com/medical-information/ctdna-surveillance-to-detect-early-relapse-in-patients-with-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/epicovideha-registry-epidemiology-and-outcomes-in-patients-with-hematologic-malignancies-infected-with-covid-19 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/severity-of-sars-cov-2-infection-and-the-safety-of-covid-19-vaccination-in-patients-receiving-hsct monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/mogamulizumab-versus-vorinostat-in-patients-with-mycosis-fungoides-and-sezary-syndrome-efficacy-and-safety-based-on-baseline-blood-involvement monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/autologous-vs-allogeneic-hematopoietic-cell-transplantation-for-the-treatment-of-patients-with-ptcl-nos-or-aitl-who-have-failed-first-line-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/is-frontline-r-chop-still-the-standard-of-care-for-dlbcl monthly 0.9 2021-08-19T09:45:00.000Z https://lymphomahub.com/medical-information/expression-pattern-and-role-of-circular-rnas-in-the-prognosis-of-mantle-cell-lymphoma-in-younger-patients monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/a-new-analytical-tool-to-assess-the-adverse-event-burden-in-older-patients-with-cll-treated-with-bendamustine-plus-rituximab-or-ibrutinib-regimens-based-on-the-alliance-a041202-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-car-hematotox-model-for-car-t-cell-hematotoxicity-in-rr-lbcl monthly 0.9 2024-07-16T14:25:00.000Z https://lymphomahub.com/medical-information/dzd4205-an-oral-jak-inhibitor-for-the-treatment-of-rr-ptcl-jackpot8-phase-i-trial-results monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-from-the-french-descar-t-registry-study-use-of-cancer-databases-for-the-management-of-data-from-patients-undergoing-car-t-cell-therapy-for-the-treatment-of-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fixed-duration-or-mrd-guided-venetoclax-maintenance-treatment-in-patients-with-cll-unfit-for-first-line-fcr-results-from-hovon-139give-trial monthly 0.9 2026-07-06T08:31:00.000Z https://lymphomahub.com/medical-information/fixed-duration-treatment-with-ibrutinib-and-venetoclax-in-patients-with-cllsll-findings-from-the-glow-and-captivate-trials monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/updated-efficacy-data-from-the-phase-i-dose-escalation-trial-of-glofitamab-in-patients-with-rr-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-impact-of-genomic-markers-on-survival-outcomes-in-patients-with-cll-treated-with-obinutuzumab-plus-either-venetoclax-or-chlorambucil monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/factors-associated-with-prolonged-length-of-in-hospital-stay-and-higher-mortality-in-patients-with-covid-19-and-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-s-new-in-mantle-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/first-interim-results-from-a-phase-iii-randomized-trial-of-zanubrutinib-vs-ibrutinib-in-patients-with-relapsedrefractory-cllsll-alpine-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/updated-results-from-the-zuma-5-trial-of-axi-cel-for-patients-with-relapsedrefractory-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/bms-withdraws-romidepsin-s-ptcl-indication-from-the-u-s-market-following-failure-of-confirmatory-phase-iii-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-or-efficacy-and-safety-of-camidanlumab-tesirine-in-patients-with-rr-classical-hodgkin-lymphoma monthly 0.9 2024-07-16T13:53:00.000Z https://lymphomahub.com/medical-information/role-of-activated-mapk-pathway-in-mediating-resistance-to-pi3k-inhibitors-in-patients-with-chronic-lymphocytic-leukemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fungal-superinfections-and-covid-19-in-the-icu monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/does-the-addition-of-romidepsin-to-duvelisib-enhance-tumor-responses-in-peripheral-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/first-mind-trial-safety-of-tafasitamab-plus-r-chop-for-newly-diagnosed-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/when-is-it-safe-to-schedule-an-allo-hsct-after-covid-19-infection monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-in-combination-with-standard-chemotherapy-for-pediatric-patients-with-newly-diagnosed-alk-alcl monthly 0.9 2024-07-16T13:58:00.000Z https://lymphomahub.com/medical-information/what-are-the-recent-advances-in-antibody-drug-conjugates-for-lymphoma-treatment monthly 0.9 2021-07-21T15:53:00.000Z https://lymphomahub.com/medical-information/educational-theme-or-the-long-term-efficacy-and-safety-outcomes-of-anti-pd-1-inhibitors-for-the-treatment-of-rr-chl monthly 0.9 2024-07-16T13:53:00.000Z https://lymphomahub.com/medical-information/which-emerging-therapies-are-likely-to-shape-treatment-approaches-for-relapsed-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/can-ctdna-be-used-to-detect-mrd-in-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-for-the-treatment-of-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lacutamab-for-advanced-mycosis-fungoides-are-the-early-results-promising monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-is-the-role-of-genetic-classification-in-the-diagnosis-of-dlbcl monthly 0.9 2021-07-07T13:28:00.000Z https://lymphomahub.com/medical-information/do-the-results-of-the-lysa-lnh-09-1b-trial-support-a-pet-adapted-treatment-strategy-for-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/frontline-ibrutinib-venetoclax-in-cll-results-from-a-fixed-duration-cohort-of-the-captivate-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-have-radiotherapy-fractionation-schemes-evolved-for-the-treatment-of-indolent-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/updates-from-the-phase-i-dose-escalation-trial-of-tg-1701-a-novel-covalent-btki-for-cll-and-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/do-early-clinical-data-show-synergy-between-mosunetuzumab-and-polatuzumab-vedotin-in-rr-b-cell-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-s-new-in-peripheral-t-cell-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/foll12-trial-does-response-adapted-therapy-after-induction-benefit-patients-with-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-does-real-world-data-tell-us-about-frontline-treatment-strategies-for-mcl monthly 0.9 2021-06-29T11:29:00.000Z https://lymphomahub.com/medical-information/how-do-cell-of-origin-and-molecular-features-influence-outcomes-in-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/which-factors-help-guide-therapy-choice-for-rr-diffuse-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/which-new-therapeutics-are-generating-excitement-at-this-year-s-icml-2021 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/elara-trial-does-tisa-cel-car-t-cell-therapy-hold-promise-for-patients-with-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/a-pet-adapted-approach-for-the-treatment-of-early-stage-bulky-classic-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-iii-echelon-1-study-updated-results-of-brentuximab-vedotin-chemotherapy-for-untreated-chl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-factors-should-be-considered-when-deciding-whether-to-refer-a-patient-for-car-t-cell-therapy monthly 0.9 2021-07-05T09:36:00.000Z https://lymphomahub.com/medical-information/cd20-directed-car-t-cell-therapies-in-the-treatment-of-relapsedrefractory-non-hodgkin-lymphoma-results-from-two-phase-i-trials monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-is-the-optimal-frontline-immunochemotherapy-for-primary-mediastinal-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-are-the-latest-advances-in-targeted-therapies-for-chronic-lymphocytic-leukemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-satellite-symposium-2021-summary-and-roundtable-discussion monthly 0.9 2025-08-05T14:41:00.000Z https://lymphomahub.com/medical-information/tafasitamab-receives-a-positive-opinion-from-the-ema-chmp-for-the-treatment-of-rr-dlbcl monthly 0.9 2021-07-01T11:46:00.000Z https://lymphomahub.com/medical-information/glow-trial-is-fixed-duration-ibrutinib-venetoclax-a-feasible-frontline-treatment-option-for-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/glofitamab-in-rr-nhl-how-does-step-up-dosing-compare-with-fixed-dosing monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/updates-to-the-esmo-guidelines-for-the-treatment-of-mantle-cell-lymphoma monthly 0.9 2024-07-16T14:15:00.000Z https://lymphomahub.com/medical-information/is-tisa-cel-a-car-t-cell-therapy-safe-and-effective-for-patients-with-rr-follicular-lymphoma-visit-link-to-find-out-more-lymsm monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/satellite-symposium-or-sequencing-of-therapy-for-a-patient-with-tp53-mutated-mcl monthly 0.9 2025-08-05T14:41:00.000Z https://lymphomahub.com/medical-information/symposium-test monthly 0.9 2025-08-05T14:40:00.000Z https://lymphomahub.com/medical-information/satellite-symposium-or-treatment-options-for-a-patient-with-ibrutinib-resistant-cll monthly 0.9 2025-08-05T14:40:00.000Z https://lymphomahub.com/medical-information/satellite-symposium-or-how-to-treat-early-relapse-in-a-patient-with-fl monthly 0.9 2025-08-05T14:40:00.000Z https://lymphomahub.com/medical-information/satellite-symposium-or-welcome-and-introductions monthly 0.9 2025-08-05T14:39:00.000Z https://lymphomahub.com/medical-information/first-results-of-a-head-to-head-trial-of-acalabrutinib-versus-ibrutinib-in-patients-with-high-risk-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-does-covid-19-impact-patients-with-lymphoma-receiving-b-cell-depleting-immunotherapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/combining-bsabs-with-antibody-drug-conjugates-can-we-improve-efficacy-in-patients-with-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/preliminary-results-for-the-allogeneic-off-the-shelf-car-t-cell-product-pbcar0191-positive-news monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-is-early-data-telling-us-about-the-potential-of-oncolytic-virotherapy-for-patients-with-tcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-factors-should-be-considered-when-choosing-between-novel-treatment-options-for-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/is-acalabrutinib-superior-to-ibrutinib-for-the-treatment-of-rr-cll monthly 0.9 2024-08-30T14:50:00.000Z https://lymphomahub.com/medical-information/loncastuximab-tesirine-in-relapsed-or-refractory-dlbcl-results-from-a-phase-ii-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-new-chemo-free-treatment-options-are-emerging-for-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/attenuated-responses-to-covid-19-vaccination-in-patients-with-hematologic-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/treatment-landscape-for-mantle-cell-lymphoma-an-update monthly 0.9 2025-08-05T14:39:00.000Z https://lymphomahub.com/medical-information/what-novel-targeted-therapies-are-currently-under-investigation-for-rr-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ema-grants-marketing-authorization-to-duvelisib-monotherapy-for-rr-cll-or-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/bruin-trial-phase-iii-of-pirtobrutinib-a-novel-reversible-btk-inhibitor-for-relapsed-b-cell-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/does-upfront-treatment-with-venetoclax-lenalidomide-and-rituximab-enhance-tumor-responses-in-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2021-abstracts-what-s-hot-in-lymphoma-and-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/targeted-agents-for-patients-with-follicular-lymphoma monthly 0.9 2025-08-05T14:38:00.000Z https://lymphomahub.com/medical-information/educational-themeor-treatment-of-elderly-patients-with-follicular-lymphoma monthly 0.9 2024-07-16T13:53:00.000Z https://lymphomahub.com/medical-information/positive-effect-on-hrqol-and-symptom-severity-with-liso-cel-in-patients-with-rr-lbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/when-is-a-second-car-t-cell-infusion-feasible-following-unsuccessful-prior-car-t-cell-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/chronos-3-copanlisib-plus-rituximab-in-patients-with-relapsed-indolent-non-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-targeted-therapies-are-showing-promise-for-the-treatment-of-patients-with-pediatric-lymphoma monthly 0.9 2024-07-16T13:58:00.000Z https://lymphomahub.com/medical-information/immunological-effects-of-ibrutinib-for-patients-with-cll-and-covid-19 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-passing-of-anton-hagenbeek-a-key-contributor-to-the-lymphoma-community monthly 0.9 2021-05-24T09:57:00.000Z https://lymphomahub.com/medical-information/the-management-of-toxicities-associated-with-targeted-agents-in-cll monthly 0.9 2025-08-05T14:37:00.000Z https://lymphomahub.com/medical-information/fda-lifts-partial-clinical-hold-on-odronextamab-trials-in-b-cell-non-hodgkin-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-granted-priority-review-by-the-fda-for-the-treatment-of-adult-patients-with-rr-mzl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/covid-19-vaccination-for-hematopoietic-stem-cell-transplant-patients monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-clears-investigational-new-drug-application-for-cd20-directed-car-t-cell-therapy-mb-106 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-approval-of-cd19-targeted-adc-loncastuximab-tesirine-ipyl-for-patients-with-rr-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-are-the-major-challenges-for-car-t-cell-therapies-in-europe-during-the-covid-19-pandemic monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-clears-investigational-new-drug-application-for-cd19-directed-car-nk-therapy-nkx019 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/updated-results-from-zuma-2-trial-investigating-kte-x19-in-rr-mantle-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-meets-primary-endpoint-in-alpine-trial-for-patients-with-rr-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-or-r-minichop-plus-lenalidomide-for-elderly-patients-with-dlbcl-results-from-the-phase-iii-senior-trial monthly 0.9 2024-07-16T13:53:00.000Z https://lymphomahub.com/medical-information/treatment-with-ublituximab-plus-ibrutinib-versus-ibrutinib-alone-a-phase-iii-randomised-trial-genuine-for-patients-with-relapsed-or-refractory-high-risk-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/zuma-2-how-does-prior-btk-inhibitor-treatment-affect-the-efficacy-of-kte-x19-in-patients-with-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/zuma-1-4-year-follow-up-polyclonal-b-cell-recovery-and-survival-outcomes-with-axi-cel-in-rr-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-or-efficacy-and-safety-of-car-t-cell-therapy-in-older-patients-a-multicenter-matched-control-cohort-study monthly 0.9 2024-07-16T13:53:00.000Z https://lymphomahub.com/medical-information/why-is-the-german-experience-with-commercial-car-t-inferior-to-published-study-data monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/are-we-nearer-to-effective-management-of-elderly-patients-with-lymphoma monthly 0.9 2024-07-16T14:31:00.000Z https://lymphomahub.com/medical-information/antibiotic-treatment-is-associated-with-decreased-response-to-car-t-cell-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/progress-in-immunotherapy-for-hematologic-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/drss-a-new-disease-risk-stratification-system-for-hematologic-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/outpatient-administration-of-liso-cel-preliminary-results-from-the-outreach-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/real-world-outcomes-in-germany-with-standard-of-care-axi-cel-and-tisa-cel-in-patients-with-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/duvelisib-receives-a-positive-opinion-from-the-ema-chmp-for-the-treatment-of-rr-cll-and-refractory-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-biologics-license-application-of-ublituximab-plus-umbralisib-for-the-treatment-of-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-ii-study-of-lenalidomide-and-r-chop-in-patients-with-diffuse-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/japanese-approval-of-lisocabtagene-maraleucel-for-the-treatment-of-rr-lbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-5hmc-profiles-of-cfdna-predict-r-chop-treatment-response-in-patients-with-dlbcl monthly 0.9 2024-07-16T13:54:00.000Z https://lymphomahub.com/medical-information/fda-clears-investigational-new-drug-application-for-oncomimic-based-immunotherapy-eo2463 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-good-are-we-in-generating-car-t-cells-in-a-virus-free-environment monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/a-four-factor-prognostic-model-predicts-outcome-in-patients-with-cll-treated-with-ibrutinib monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ec-approval-of-pembrolizumab-for-adult-and-pediatric-patients-with-rr-chl monthly 0.9 2025-02-20T16:30:00.000Z https://lymphomahub.com/medical-information/nice-recommendation-of-acalabrutinib-for-patients-with-treatment-naive-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/novel-targeted-therapies-for-rr-marginal-zone-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-are-the-options-for-cell-based-therapies-in-mantle-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/nccn-covid-19-vaccination-recommendations-for-patients-with-hematologic-malignancies monthly 0.9 2024-07-16T14:19:00.000Z https://lymphomahub.com/medical-information/will-car-t-cell-therapy-change-the-treatment-landscape-for-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/venetoclax-plus-r-chop-as-first-line-treatment-for-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/preliminary-results-from-phase-i-studies-of-cd20-cd3-bispecific-antibodies-in-rr-b-cell-non-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lymphoma-and-covid-19-management-guidelines monthly 0.9 2024-07-16T14:15:00.000Z https://lymphomahub.com/medical-information/fda-approval-of-axicabtagene-ciloleucel-for-patients-with-rr-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/esmo-guidelines-newly-diagnosed-relapsed-follicular-lymphoma monthly 0.9 2024-07-16T14:15:00.000Z https://lymphomahub.com/medical-information/educational-theme-csf-analysis-of-ctdna-for-lymphoma-with-cns-involvement monthly 0.9 2024-07-16T13:54:00.000Z https://lymphomahub.com/medical-information/phase-ii-results-matrix-rice-therapy-and-asct-in-dlbcl-with-secondary-cns-involvement monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/updated-consensus-recommendations-for-the-treatment-of-waldenstrm-s-macroglobulinemia monthly 0.9 2024-07-16T14:20:00.000Z https://lymphomahub.com/medical-information/bl-ipi-to-support-risk-stratification-and-targeted-novel-treatment-approaches-for-burkitt-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/is-cd47-a-good-target-for-immunotherapy-in-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-fda-accepts-an-investigational-new-drug-application-for-nx-2127-for-rr-b-cell-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-fda-accepts-a-supplemental-new-drug-application-for-zanubrutinib-in-waldenstrom-s-macroglobulinemia monthly 0.9 2025-02-20T16:20:00.000Z https://lymphomahub.com/medical-information/juliet-what-factors-predict-response-to-tisa-cel monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/hematopoietic-stem-cell-transplantation-in-waldenstrom-s-macroglobulinemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/can-cd30-car-t-cell-consolidation-improve-outcomes-after-asct-for-patients-with-cd30-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/zuma-12-is-car-t-cell-therapy-effective-in-high-risk-dlbcl-as-first-line-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/liso-cel-updates-from-transcend-cll-004-and-trancend-nhl-001-trials monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-monitoring-treatment-response-in-lymphoma-using-cfdna monthly 0.9 2024-07-16T13:54:00.000Z https://lymphomahub.com/medical-information/what-are-the-critical-issues-to-address-for-outpatient-administration-of-car-t-cell-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2020-or-practice-changing-abstracts-in-lymphoma-and-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/epidemiology-pathology-and-clinical-features-of-dlbcl monthly 0.9 2026-09-21T10:30:00.000Z https://lymphomahub.com/medical-information/the-fda-clears-an-investigational-new-drug-application-for-cap-100 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/car-t-cell-updates-from-zuma-5-and-elara-trials monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-accelerated-approval-of-umbralisib-for-rr-mzl-and-rr-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-approves-lisocabtagene-maraleucel-for-rr-large-b-cell-lymphoma monthly 0.9 2024-07-16T13:42:00.000Z https://lymphomahub.com/medical-information/educational-theme-the-role-of-ctdna-in-lymphoma-management monthly 0.9 2024-07-16T13:54:00.000Z https://lymphomahub.com/medical-information/does-ctdna-add-value-to-current-prognostic-markers-for-identifying-high-risk-patients monthly 0.9 2021-02-05T09:48:00.000Z https://lymphomahub.com/medical-information/can-ctdna-help-inform-on-the-suitability-of-auto-sct-in-patients-with-dlbcl monthly 0.9 2021-02-06T09:15:00.000Z https://lymphomahub.com/medical-information/is-targeting-irak4-in-patients-with-lymphoma-promising monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-progress-is-being-made-in-the-treatment-options-for-patients-with-richter-s-transformation monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/why-should-we-use-ctdna-assessments-in-lymphoma-diagnostics-in-the-future monthly 0.9 2021-02-06T09:18:00.000Z https://lymphomahub.com/medical-information/ash-2020-overview-of-the-current-advances-in-treating-aggressive-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/combining-car-t-cell-therapy-with-targeted-drugscan-we-improve-efficacy-in-patients-with-rr-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/pembrolizumab-receives-positive-ema-chmp-opinion-for-extended-approval-in-patients-with-rr-chl monthly 0.9 2025-02-20T16:31:00.000Z https://lymphomahub.com/medical-information/how-should-we-manage-toxicities-associated-with-btk-inhibitors-in-cll monthly 0.9 2024-07-16T14:26:00.000Z https://lymphomahub.com/medical-information/what-data-are-available-to-help-guide-sequencing-of-therapy-for-relapsed-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/umbralisib-and-ublituximab-combination-is-superior-to-current-standard-of-care-for-patients-with-untreated-relapsed-or-refractory-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/captivate-trial-results-show-that-12-cycles-of-combined-ibrutinib-venetoclax-may-allow-treatment-free-remission-in-patients-with-undetectable-mrd monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/does-polatuzumab-vedotin-venetoclax-and-rituximab-combined-enhance-tumor-responses-in-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-meets-primary-endpoint-in-elevate-rr-trial-for-patients-with-rr-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/mosunetuzumab-in-heavily-pretreated-follicular-lymphoma-phase-i-dose-escalation-trial-updates monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/japanese-approval-of-axicabtagene-ciloleucel-for-the-treatment-of-rr-large-b-cell-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/cft7455-receives-clearance-of-investigational-new-drug-application-by-fda-for-the-treatment-of-multiple-myeloma-and-non-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-novel-therapies-are-showing-promise-for-patients-with-heavily-pretreated-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-factors-should-be-considered-when-sequencing-therapy-in-rr-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-effective-is-nivolumab-brentuximab-vedotin-as-a-consolidation-therapy-for-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/a-summary-the-findings-from-the-final-analysis-of-the-phase-iii-innovate-trial-of-ibrutinib-in-wm monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-accepts-investigational-new-drug-application-for-pbcar19b-for-the-treatment-of-rr-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/nice-recommends-kte-x19-for-the-treatment-of-rr-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ema-grants-prime-designation-to-anti-cd30-car-t-cell-therapy-for-the-treatment-of-patients-with-rr-chl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/5-year-results-of-the-murano-phase-iii-trial-of-venetoclax-rituximab-vs-bendamustine-rituximab-in-patients-with-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-approval-of-crizotinib-for-the-treatment-of-pediatric-patients-and-young-adults-with-alk-positive-rr-alcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/tandem-cd20cd19-car-t-cell-therapy-for-relapsed-b-cell-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/nccn-recommendation-of-zanubrutinib-as-first-line-and-second-line-therapy-in-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-places-partial-clinical-hold-on-odronextamab-trials-in-b-cell-non-hodgkin-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-approval-of-rituximab-arrx-for-the-treatment-of-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/final-analysis-of-the-innovate-study-or-five-year-follow-up-of-ibrutinib-plus-rituximab-versus-placebo-plus-rituximab-in-wm monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/expansion-of-the-phase-ib-study-of-zandelisib-me-401-in-combination-with-zanubrutinib-to-include-disease-specific-b-cell-malignancy-cohorts monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/cd19-expression-in-brain-cells-may-be-associated-with-immunotherapy-related-neurotoxicity monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-provides-positive-feedback-in-end-of-phase-ii-meeting-for-bnz-1-for-patients-with-refractory-cutaneous-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/orelabrutinib-receives-approval-in-china-for-the-treatment-of-rr-cll-sll-and-rr-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/interim-results-from-zuma-12-axi-cel-as-frontline-treatment-for-high-risk-lbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/outcomes-with-tisagenlecleucel-in-non-hodgkin-lymphoma-in-real-world-settings monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/real-world-experience-with-axicabtagene-ciloleucel-and-tisagenlecleucel-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/why-should-we-use-the-bl-ipi-for-prognosis-of-patients-with-burkitt-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-is-the-role-of-allo-hct-in-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/is-mosunetuzumab-safe-and-effective-for-elderly-patients-with-untreated-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/is-a-response-adapted-treatment-strategy-feasible-for-patients-with-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-clears-investigational-new-drug-application-for-car-t-cell-therapy-lb1901-for-relapsedrefractory-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/kte-x19-receives-conditional-approval-in-europe-for-the-treatment-of-relapsedrefractory-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/is-there-a-role-for-pet-ct-directed-therapy-in-dlbcl monthly 0.9 2020-12-17T13:29:00.000Z https://lymphomahub.com/medical-information/obinutuzumab-and-the-lyma-101-trial-expert-discussion monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-from-the-phase-i-study-of-a-novel-cd19cd20-tandem-car-t-cell-therapy-in-rr-b-cell-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/is-odronextamab-a-feasible-option-for-patients-with-nhl-who-are-refractory-to-car-t-cell-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-are-the-challenges-faced-when-selecting-frontline-treatment-for-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-factors-guide-treatment-decisions-in-the-frontline-treatment-of-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/patterns-and-characteristics-of-infection-episodes-in-the-first-year-following-cd19-car-t-cell-treatment-for-diffuse-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/genetic-dysregulation-of-b-cell-lymphoma-a-focus-on-epigenetic-modifiers-in-dlbcl-and-fl-from-esh-2020 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2020-abstracts-what-s-hot-in-lymphoma-and-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/preparing-for-ash-2020or-advances-in-ctdna-for-lymphoma-prognosis monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-can-we-better-treat-patients-with-early-relapsing-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/zanubrutinib-shows-significant-activity-in-high-risk-treatment-naive-patients-with-del-17p-cllsll-in-a-global-phase-iii-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-satellite-symposiumsummary-and-roundtable-discussion monthly 0.9 2024-07-16T13:46:00.000Z https://lymphomahub.com/medical-information/satellite-symposium-or-patient-with-rr-cll-latin-american-perspective monthly 0.9 2025-08-05T14:44:00.000Z https://lymphomahub.com/medical-information/clinical-and-infusion-product-characteristics-influencing-the-outcomes-and-toxicity-of-car-t-cell-treatment-with-axicabtagene-ciloleucel-for-lbcl monthly 0.9 2024-07-16T14:26:00.000Z https://lymphomahub.com/medical-information/satellite-symposium-or-patient-with-rr-cll-european-perspective monthly 0.9 2025-08-05T14:45:00.000Z https://lymphomahub.com/medical-information/loncastuximab-tesirine-granted-priority-review-status-by-the-fda monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2019-or-practice-changing-abstracts-in-lymphoma-and-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-role-of-auto-hsct-in-pet-positive-chemosensitive-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/satellite-symposium-or-patient-with-rr-dlbcl-european-perspective monthly 0.9 2025-08-05T14:45:00.000Z https://lymphomahub.com/medical-information/satellite-symposium-or-patient-with-rr-dlbcl-us-perspective monthly 0.9 2025-08-05T14:46:00.000Z https://lymphomahub.com/medical-information/highlights-of-the-lymphoma-hub-satellite-symposium monthly 0.9 2025-08-05T14:46:00.000Z https://lymphomahub.com/medical-information/relapsedrefractory-cll-following-treatment-with-venetoclax-rituximab-what-to-do-next monthly 0.9 2025-08-05T14:47:00.000Z https://lymphomahub.com/medical-information/challenges-in-the-management-and-treatment-of-patients-with-relapsedrefractory-dlbcl monthly 0.9 2025-08-05T14:48:00.000Z https://lymphomahub.com/medical-information/phase-ib-trial-of-zanubrutinib-plus-obinutuzumab-in-cllsll-and-rr-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/when-will-we-be-seeing-changes-in-the-frontline-treatment-of-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-are-the-recent-advances-in-the-treatment-of-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-delays-decision-on-lisocabtagene-maraleucel-for-adult-patients-with-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ublituximab-umbralisib-granted-fda-fast-track-designation-for-the-treatment-of-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/can-we-eliminate-auto-sct-for-patients-with-mcl monthly 0.9 2020-11-13T12:01:00.000Z https://lymphomahub.com/medical-information/nice-recommends-venetoclax-obinutuzumab-for-frontline-treatment-of-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-receives-approval-in-europe-for-the-treatment-of-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/can-we-avoid-chemotherapy-entirely-in-follicular-lymphoma monthly 0.9 2020-11-13T12:01:00.000Z https://lymphomahub.com/medical-information/predictive-factors-of-mortality-in-patients-with-hematological-malignancies-diagnosed-with-covid-19 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/safety-profiles-of-venetoclax-obinutuzumab-vs-chlorambucil-obinutuzumab-in-patients-with-cll-and-comorbidities-cll14-long-term-results monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/efficacy-and-safety-of-tazemetostat-in-patients-with-rr-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/francesc-bosch-outlines-what-he-will-be-discussing-at-the-virtual-lymphoma-hub-satellite-symposium monthly 0.9 2025-08-05T14:48:00.000Z https://lymphomahub.com/medical-information/challenges-in-rr-cll-and-dlbcl-overcoming-drug-resistance monthly 0.9 2025-08-05T14:48:00.000Z https://lymphomahub.com/medical-information/marie-jose-kersten-invites-you-to-join-the-virtual-lymphoma-hub-satellite-symposium-on-nov-8-2020 monthly 0.9 2025-08-05T14:49:00.000Z https://lymphomahub.com/medical-information/challenges-in-rr-cll-and-dlbcl-how-to-maintain-good-quality-of-life monthly 0.9 2025-08-05T14:49:00.000Z https://lymphomahub.com/medical-information/4-year-results-from-the-phase-iii-murano-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-clears-investigational-new-drug-application-for-adi-001 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/kieron-dunleavy-invites-you-to-join-the-virtual-lymphoma-hub-satellite-symposium-on-nov-8-2020 monthly 0.9 2025-08-05T14:50:00.000Z https://lymphomahub.com/medical-information/lyma-101-trial-update-obinutuzumab-for-the-treatment-of-mantle-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-i-trial-of-the-triplet-therapy-ipilimumab-nivolumab-and-brentuximab-vedotin-for-patients-with-relapsedrefractory-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-prognostic-value-of-pet-scan-in-the-treatment-of-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/pembrolizumab-receives-fda-approval-for-extended-indications-in-classical-hodgkin-lymphoma monthly 0.9 2025-02-20T16:31:00.000Z https://lymphomahub.com/medical-information/kte-x19-receives-chmp-positive-opinion-for-the-treatment-of-patients-with-rr-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-symposium-or-the-value-of-btk-inhibitors-for-the-treatment-of-patients-with-rr-cll monthly 0.9 2025-08-05T14:50:00.000Z https://lymphomahub.com/medical-information/astrid-pavlovsky-explains-why-you-should-join-the-virtual-lymphoma-hub-satellite-symposium monthly 0.9 2025-08-05T14:51:00.000Z https://lymphomahub.com/medical-information/phase-iii-chronos-3-study-evaluating-copanlisib-and-rituximab-combination-meets-primary-endpoint monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ascend-final-results-acalabrutinib-compared-with-idelalisib-r-or-bendamustine-r-in-rr-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lymphodepletion-optimization-for-car-t-cell-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/liso-cel-for-relapsedrefractory-large-b-cell-lymphoma-results-from-transcend-nhl-001 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/us-population-based-cohort-study-on-the-mortality-causes-of-patients-with-chl-between-20002016 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/educational-theme-mutational-profile-and-treatment-of-waldenstrom-s-macroglobulinemia monthly 0.9 2024-07-16T13:54:00.000Z https://lymphomahub.com/medical-information/phase-iii-sympatico-study-on-ibrutinib-plus-venetoclax-in-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/gilles-salles-explains-why-you-should-join-the-virtual-lymphoma-hub-satellite-symposium monthly 0.9 2025-08-05T14:51:00.000Z https://lymphomahub.com/medical-information/phase-iii-study-of-omidubicel-in-patients-with-high-risk-hematologic-malignancies-meets-all-3-secondary-endpoints monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/car-t-cell-therapy-limitations-and-strategies-to-overcome-them-from-asco-and-eha-2020 monthly 0.9 2022-09-02T09:44:00.000Z https://lymphomahub.com/medical-information/fda-grants-fast-track-designation-to-novel-combination-car-t-cell-therapy-clbr001-swi019-for-b-cell-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/antibody-based-therapies-add-weight-to-immunotherapy-concepts-for-rr-dlbcl monthly 0.9 2025-08-05T14:52:00.000Z https://lymphomahub.com/medical-information/update-from-soho-2020-on-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/tucidinostat-received-orphan-drug-designation-in-japan-for-the-treatment-of-rr-atl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/tafasitamab-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-grants-priority-review-for-crizotinib-in-pediatric-alk-positive-rr-alcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/bla-submitted-to-fda-for-loncastuximab-tesirine-in-relapsedrefractory-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-s-current-and-what-s-next-in-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/european-approval-for-ibrutinib-plus-rituximab-for-frontline-therapy-in-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/a-new-prognostic-model-is-proposed-for-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-impact-of-extra-copies-of-myc-bcl2-and-bcl6-on-outcome-in-patients-with-diffuse-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-microbiome-and-its-effects-on-the-immune-system monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-i-results-suggest-a-tolerable-safety-profile-for-avadomide-and-obinutuzumab-in-patients-with-rr-b-cell-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-are-the-chemotherapy-free-treatment-options-for-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-impact-of-second-line-regimens-on-outcomes-in-younger-patients-with-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/use-of-ruxolitinib-in-patients-with-severe-covid-19 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/why-should-we-use-checkpoint-inhibitors-with-car-t-therapy-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-does-biology-affect-treatment-strategy-in-waldenstrom-s-macroglobulinemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/which-patients-with-rr-mcl-benefit-from-car-t-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/update-from-eha-2020-targeted-therapy-in-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/study-of-tandem-cd19cd20-car-engineered-t-cells monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/update-in-hl-from-eha-2020 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-fda-accepts-a-supplemental-biologics-license-application-for-axicabtagene-ciloleucel-in-patients-with-rr-fl-or-mzl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-patient-characteristics-t-cell-starting-material-and-drug-product-attributes-affect-car-t-cell-therapy-outcomes monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/anti-cd30-car-t-cell-therapy-in-patients-with-heavily-pretreated-rr-hl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/a-novel-composite-scoring-system-to-predict-mortality-after-auto-hsct monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-grants-fast-track-and-orphan-drug-designations-to-vls-101-for-the-treatment-of-patients-with-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/tolinapant-receives-orphan-drug-designation-from-the-fda-for-the-treatment-of-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ibrutinib-with-bendamustine-and-rituximab-in-relapsedrefractory-cllsll-final-5-year-results-from-the-helios-trial monthly 0.9 2025-07-18T12:15:00.000Z https://lymphomahub.com/medical-information/liso-cel-treatment-in-the-outpatient-setting monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-from-the-alpha-study-on-allo-501-and-lymphodepleting-allo-647-in-rr-dlbcl-or-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-fda-accepts-investigational-new-drug-application-for-nt-i7-in-combination-with-tisagenlecleucel-for-patients-with-rr-lbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/relevance-study-first-line-lenalidomide-plus-rituximab-induces-high-molecular-responses-in-patients-with-naive-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/nice-recommends-polatuzumab-vedotin-with-rituximab-and-bendamustine-for-rr-diffuse-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/aspen-trial-or-comparison-of-zanubrutinib-vs-ibrutinib-in-wm-with-myd88-mutation-and-zanubrutinib-monotherapy-in-myd88-wild-type-wm monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lenalidomide-combined-with-tafasitamab-in-relapsedrefractory-diffuse-large-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-grants-priority-review-to-umbralisib-for-mzl-and-standard-review-for-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-advances-in-treating-waldenstrom-s-macroglobulinemia monthly 0.9 2024-07-16T13:54:00.000Z https://lymphomahub.com/medical-information/a-retrospective-study-of-the-clinical-and-pathological-features-of-peripheral-t-cell-lymphomas-in-a-spanish-population monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/irc-recommends-to-focus-on-one-dosage-arm-to-complete-the-paradigme-phase-iib-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-ii-study-of-tisagenlecleucel-in-patients-with-rr-fl-meets-its-primary-endpoint monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-approves-tafasitamab-in-combination-with-lenalidomide-as-second-line-treatment-for-patients-with-rr-dlbcl monthly 0.9 2024-07-16T13:42:00.000Z https://lymphomahub.com/medical-information/ixazomib-rituximab-and-dexamethasone-in-patients-with-relapsed-or-progressive-waldenstrom-s-macroglobulinemia-final-analysis-of-the-hovon124ecwm-r2-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/venetoclax-and-navitoclax-for-rr-all-and-lymphoblastic-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-from-phase-i-alexander-study-investigating-the-first-car-t-cell-therapy-auto3-plus-pembrolizumab-to-target-both-cd19-and-cd22-in-the-treatment-of-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-receives-chmp-positive-opinion-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/brexucabtagene-autoleucel-receives-fda-approval-for-the-treatment-of-relapsedrefractory-mantle-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-grants-orphan-drug-designation-to-cobomarsen-for-the-treatment-of-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/interim-data-from-the-phase-iii-study-on-bnz-1-in-patients-with-refractory-cutaneous-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-from-the-oasis-phase-iii-trial-on-ibrutinib-venetoclax-plus-obinutuzumab-in-patients-with-newly-diagnosed-mantle-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lisocabtagene-maraleucel-as-a-second-line-treatment-or-interim-results-of-phase-ii-pilot-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ema-validates-marketing-authorization-application-for-lisocabtagene-maraleucel-for-the-treatment-of-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-primary-mediastinal-b-cell-lymphoma-and-follicular-lymphoma-grade-3b monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/practice-changing-abstracts-in-indolent-lymphoma-at-eha-2020 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/selinexor-for-rr-dlbcl-latest-updates-and-data monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-grants-breakthrough-therapy-designation-to-mosunetuzumab-for-the-treatment-of-adult-patients-with-rr-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/an-update-in-cll-from-eha-2020 monthly 0.9 2020-08-26T12:45:00.000Z https://lymphomahub.com/medical-information/nice-recommends-brentuximab-vedotin-in-combination-with-chemotherapy-as-frontline-treatment-for-systemic-anaplastic-large-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/a-retrospective-analysis-of-allogeneic-stem-cell-transplantation-for-peripheral-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-grants-priority-review-to-second-line-pembrolizumab-for-the-treatment-of-rr-hodgkin-lymphoma monthly 0.9 2025-02-20T16:31:00.000Z https://lymphomahub.com/medical-information/fda-lifts-partial-hold-on-the-phase-ii-trial-of-camidanlumab-tesirine-in-patients-with-rr-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/interim-analysis-of-the-phase-ii-zuma-5-study-of-axicabtagene-ciloleucel-in-patients-with-rr-inhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ixazomib-in-combination-with-rituximab-and-dexamethasone-in-patients-with-relapsed-wm monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/alemtuzumab-plus-chop-in-elderly-patients-with-ptcl-results-from-a-phase-iii-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/review-or-therapies-available-or-in-clinical-development-for-patients-with-aggressive-mantle-cell-lymphoma-in-2020 monthly 0.9 2025-02-20T16:23:00.000Z https://lymphomahub.com/medical-information/177-lu-lilotomab-satetraxetan-receives-fast-track-designation-from-the-fda-for-marginal-zone-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/u-s-prescribing-information-for-ibrutinib-in-waldenstrom-s-macroglobulinemia-to-be-reviewed-and-potentially-updated-by-the-fda-following-long-term-data monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-2-study-of-loncastuximab-tesirine-a-novel-antibodydrug-conjugate-in-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-ii-clinical-trial-of-ceopivegdp-alternating-therapy-for-peripheral-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/retreatment-of-patients-with-refractory-large-b-cell-lymphoma-with-axicabtagene-ciloleucel-in-zuma-1 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-approves-selinexor-for-the-treatment-of-patients-with-rr-dlbcl monthly 0.9 2024-07-16T13:42:00.000Z https://lymphomahub.com/medical-information/what-was-new-in-aggressive-nhl-at-asco-and-eha-2020 monthly 0.9 2022-09-02T09:44:00.000Z https://lymphomahub.com/medical-information/chemotherapy-free-treatment-of-indolent-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-was-new-in-mcl-at-asco-and-eha-2020 monthly 0.9 2022-09-02T09:47:00.000Z https://lymphomahub.com/medical-information/tazemetostat-receives-fda-supplemental-new-drug-application-approval-for-adult-patients-with-relapsedrefractory-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/update-in-emerging-agents-presented-at-asco-and-eha monthly 0.9 2022-09-02T09:47:00.000Z https://lymphomahub.com/medical-information/update-in-car-t-cell-therapies-presented-at-asco-and-eha monthly 0.9 2022-09-02T09:47:00.000Z https://lymphomahub.com/medical-information/belinostat-in-patients-with-rr-angioimmunoblastic-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-was-new-in-indolent-nhl-at-asco-and-eha monthly 0.9 2022-09-02T09:48:00.000Z https://lymphomahub.com/medical-information/how-can-we-use-the-microbiome-to-improve-cancer-immunotherapy-and-alleviate-side-effect-such-as-graft-versus-host-disease monthly 0.9 2020-08-26T12:45:00.000Z https://lymphomahub.com/medical-information/phase-i-study-of-cd20-tcb-a-novel-t-cell-engaging-bispecific-antibody-in-rr-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/alpha-study-first-in-human-data-of-allo-501-and-allo-647-in-rr-large-b-cell-or-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/asco-recommendations-for-pathologic-diagnosis-of-breast-implant-associated-anaplastic-large-cell-lymphoma monthly 0.9 2022-09-02T09:48:00.000Z https://lymphomahub.com/medical-information/the-efficacy-and-safety-of-mogamulizumab-for-advanced-mycosis-fungoides-and-sezary-syndrome monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/transplant-brave-trial-or-brentuximab-vedotin-in-combination-with-dhap-for-patients-with-relapsedrefractory-classical-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/atezolizumab-obinutuzumab-venetoclax-in-patients-with-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/china-s-national-medical-products-administration-grants-zanubrutinib-approval-for-patients-with-rr-cllsll-and-rr-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/primary-analysis-of-phase-iii-of-the-zuma-6-trial-axicabtagene-ciloleucel-plus-atezolizumab-for-patients-with-refractory-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lenalidomide-as-maintenance-therapy-in-patients-with-relapsed-dlbcl-not-eligible-for-transplantation-phase-ii-final-results monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/aspen-trial-zanubrutinib-versus-ibrutinib-for-patients-with-waldenstrom-macroglobulinemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/alexander-study-cd1922-dual-targeting-car-t-cell-therapy-with-pembrolizumab-in-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/keynote-204-pembrolizumab-versus-brentuximab-vedotin-rr-classic-hodgkin-lymphoma monthly 0.9 2025-02-20T16:31:00.000Z https://lymphomahub.com/medical-information/fda-grants-clr-131-fast-track-designation-for-the-treatment-of-patients-with-lymphoplasmacytic-lymphomawaldenstrom-s-macroglobulinemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/nivolumab-plus-avd-as-first-line-treatment-for-high-risk-classic-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/positive-interim-results-announced-for-trph-222-in-patients-with-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/177-lu-lilotomab-satetraxetan-receives-positive-opinion-for-orphan-drug-designation-from-ema-for-mzl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-plus-chp-is-approved-by-the-european-commission-and-china-for-the-treatment-of-adult-patients-with-salcl monthly 0.9 2024-07-16T13:42:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-for-untreated-cll-delving-into-elevate-tn-phase-iii-trial-results monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/safety-of-trial-participants-is-fda-s-top-priority-in-ongoing-clinical-trials-during-the-covid-19-outbreak monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-iii-study-of-omidubicel-in-patients-with-high-risk-hematologic-malignancies-meets-primary-endpoint monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/aacr-2020-or-or-preliminary-results-of-the-embolden-and-durability-phase-i-studies-on-the-combination-of-immune-checkpoint-inhibitors-with-epigenetic-therapy-in-patients-with-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/nice-backs-obinutuzumab-plus-bendamustine-chemotherapy-for-patients-with-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/acalabrutinib-for-relapsed-or-refractory-cllsll-updated-results-of-a-phase-ii-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-fda-accepts-supplemental-new-drug-application-for-selinexor-as-a-treatment-for-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-rationale-of-combining-pd1-blockade-with-two-epigenetic-modifiers-for-t-cell-lymphoma-treatment monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-advances-in-t-cell-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/positive-topline-results-announced-from-the-unity-cll-phase-iii-study-evaluating-the-combination-of-umbralisib-and-ublituximab-u2-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/a-subset-of-dlbcl-cases-with-9p24-1-amplication-reveals-molecular-and-genetic-features-similar-to-pmbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/aacr-2020or-the-efficacy-and-safety-of-geptanolimab-gb226-in-patients-with-rr-ptcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/sgx301-for-cutaneous-t-cell-lymphoma-or-positive-results-from-phase-iii-flash-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/covid-heme-forum-supports-hematologists-during-covid-19-pandemic monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ibrutinib-plus-rituximab-as-a-first-line-treatment-for-patients-with-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-fda-approves-pembrolizumab-for-use-at-an-additional-recommended-dose-of-400-mg-every-six-weeks-for-all-previously-approved-adult-indications monthly 0.9 2024-07-16T13:42:00.000Z https://lymphomahub.com/medical-information/bortezomib-consolidation-or-maintenance-after-immunochemotherapy-and-transplant-in-patients-with-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/zuma-1-or-should-age-limit-the-use-of-axicabtagene-ciloleucel monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/management-of-covid-19-outbreak-on-transplant-wards monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/long-term-follow-up-of-chlorambucil-mitoxantrone-and-dexamethasone-vs-fludarabine-mitoxantrone-and-dexamethasone-in-patients-with-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/potential-biomarkers-in-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-prognostic-value-of-18f-fdg-pet-metabolic-heterogeneity-in-dlbcl-after-first-line-immunochemotherapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ibrutinib-plus-rituximab-approved-by-the-fda-for-frontline-cllsll monthly 0.9 2024-07-16T13:42:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-regenerative-medicine-advanced-therapy-rmat-designation-to-tisagenlecleucel-for-patients-with-relapsed-or-refractory-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/kte-x19-granted-priority-review-by-us-fda-for-rr-mantle-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-from-the-phase-ii-hovon-75-trial-in-patients-with-newly-diagnosed-mantle-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/caring-for-patients-with-hematological-malignancies-during-the-covid-19-pandemic-recommendations-from-iach-eha-and-ebmt monthly 0.9 2024-07-16T14:20:00.000Z https://lymphomahub.com/medical-information/meta-analysis-of-cardiovascular-adverse-events-in-patients-receiving-frontline-treatment-for-non-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/an-overview-of-the-use-of-fdg-pet-in-hodgkin-lymphoma-and-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-impact-of-targeted-treatment-and-immunotherapies-on-the-role-of-hematopoietic-stem-cell-transplantation-in-the-treatment-of-blood-cancers monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-grants-orphan-drug-designation-to-afm13-and-fast-track-designation-to-tipifarnib-for-t-cell-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/tafasitamab-plus-lenalidomide-granted-priority-review-by-us-fda monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-grants-fast-track-designation-to-me-401-and-orphan-drug-designation-to-umbralisib-for-the-treatment-of-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/international-t-cell-project-a-subgroup-analysis-of-patients-with-extranodal-natural-killer-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/update-on-cll-induction-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-receives-positive-chmp-opinion-in-combination-with-chp-as-treatment-for-adult-patients-with-previously-untreated-salcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/nivolumab-treatment-followed-by-consolidation-with-allo-hsct-is-associated-with-favorable-outcomes-in-patients-with-relapsedrefractory-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-persistent-immune-dysregulation-in-survivors-of-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/covid-19-and-ebmt-recommendations-for-patients-with-hematological-malignancies monthly 0.9 2024-07-16T14:20:00.000Z https://lymphomahub.com/medical-information/the-effect-of-covid-19-on-the-management-of-patients-with-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/depth-of-remission-following-first-line-therapy-or-a-prognostic-marker-in-gastric-mucosa-associated-lymphoid-tissue-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-iii-clinical-trial-with-car-nk-cells-against-cd19-positive-non-hodgkin-lymphoma-or-chronic-lymphocytic-leukemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/review-or-breast-implant-associated-anaplastic-large-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/long-term-outcomes-of-the-zuma-1-study-assessing-axicabtagene-ciloleucel-for-the-treatment-of-refractory-b-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-or-pet-as-a-prognostic-tool-in-lymphoma monthly 0.9 2024-07-16T13:55:00.000Z https://lymphomahub.com/medical-information/non-myeloablative-haploidentical-or-unrelated-cord-blood-hematopoietic-transplant-for-hodgkin-and-non-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/car-t-2020-or-cytopenia-in-cart-the-prolonged-threat-of-infection monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/tirabrutinib-shows-significant-activity-for-rr-mcl-without-major-drug-related-toxicities-in-a-3-year-follow-up-study monthly 0.9 2023-05-16T16:08:00.000Z https://lymphomahub.com/medical-information/long-term-follow-up-supports-r-chop-and-rituximab-maintenance-for-the-treatment-of-mantle-cell-lymphoma-in-elderly-patients monthly 0.9 2023-05-16T15:55:00.000Z https://lymphomahub.com/medical-information/car-t-cell-approaches-for-the-treatment-of-patients-with-b-and-t-cell-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/nice-recommends-lenalidomide-in-combination-with-rituximab-for-patients-with-previously-treated-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/nice-denies-funding-for-polatuzumab-vedotin-combination-in-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/third-generation-car-cd30-t-cell-therapy-for-cd30-positive-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/implementation-of-car-t-cell-therapy-in-the-real-world-a-round-table-discussion monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ebmt-and-jacie-recommendations-for-the-management-of-car-t-cell-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ror1-car-t-cell-therapy-for-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/new-prognostic-model-for-survival-in-patients-with-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/axi-cel-for-secondary-cns-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ema-extends-the-license-indications-for-rituximab-and-venetoclax monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/pet-in-dlbcl-or-interim-pet-as-a-biomarker-for-response-and-pet-directed-therapy-for-limited-stage-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prognostic-value-of-measurable-residual-disease-detection-after-a-fixed-duration-chemotherapy-free-treatment-a-prospective-analysis-of-the-cll14-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-from-the-phase-ii-zuma-2-trial-car-t-therapy-for-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/kte-x19-marketing-authorization-application-fully-validated-by-the-ema monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/has-the-implementation-of-car-t-in-the-real-world-happened-as-expected monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-does-the-ebmt-support-the-development-of-car-t-therapies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/full-efficacy-and-safety-analysis-from-go29834-or-polatuzumab-vedotin-obinutuzumab-and-lenalidomide-for-rr-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-impact-does-car-t-therapy-have-on-patient-quality-of-life monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-new-technologies-are-available-in-the-field-of-car-t-manufacturing monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-will-car-t-therapy-for-lymphoma-be-used-in-the-future monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-successful-is-a-country-wide-selection-algorithm-for-patients-receiving-car-t-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/why-should-we-use-car30-memory-t-cells-to-treat-hodgkin-and-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/the-impact-of-early-relapse-on-outcome-in-patients-with-mantle-cell-lymphoma-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/why-do-we-need-registries-for-patients-treated-with-car-t-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-can-third-generation-anti-cd30-cars-improve-treatment-of-cd30-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/mayo-clinic-lymphoma-etumor-board-or-transformed-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/mayo-clinic-lymphoma-etumor-board-or-breast-implant-associated-anaplastic-large-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/regn1979-for-relapsedrefractory-b-cell-non-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/management-of-patients-with-cll-after-venetoclax-discontinuation monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ec-approval-of-polatuzumab-vedotin-in-combination-with-bendamustine-and-rituximab-for-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-ii-study-update-of-tazemetostat-in-patients-with-relapsedrefractory-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/does-the-use-of-bridging-therapy-impact-patient-outcomes-whilst-awaiting-axi-cel-manufacturing monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-improving-front-line-treatment-in-cll monthly 0.9 2024-07-16T13:55:00.000Z https://lymphomahub.com/medical-information/geographical-diversity-in-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/assessment-of-response-by-recil-2017-versus-lugano-2014-criteria-in-patients-with-previously-untreated-cd20-positive-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lacutamab-phase-ii-trial-in-advanced-t-cell-lymphomas-placed-on-partial-hold-by-the-fda monthly 0.9 2021-05-13T15:13:00.000Z https://lymphomahub.com/medical-information/efficacy-and-safety-of-liso-cel-in-patients-with-nhl-and-cllsll-update-from-ash-2019-annual-meeting monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fda-grants-clr-131-orphan-drug-designation-in-lymphoplasmacytic-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-from-a-phase-iib-dose-escalation-study-of-mosunetuzumab-in-high-risk-non-hodgkin-lymphoma-patients monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ema-approval-of-lenalidomide-plus-rituximab-for-adult-patients-with-rr-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/obinutuzumab-plus-lenalidomide-is-effective-and-well-tolerated-in-patients-with-indolent-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-from-the-phase-iii-elevate-tn-trial-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-can-we-tackle-immune-evasion-in-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-has-the-presentation-of-the-elevate-tn-trial-taught-us monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-are-the-promising-updates-in-lymphoma-at-ash-2019 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/vitamin-d-deficiency-linked-to-poor-outcome-in-patients-with-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ibrutinib-and-venetoclax-combination-therapy-for-first-line-treatment-of-cll-updated-results-from-a-phase-ii-study monthly 0.9 2025-01-10T10:44:00.000Z https://lymphomahub.com/medical-information/which-patients-with-dlbcl-may-benefit-from-pet-directed-induction-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/which-population-of-patients-with-cll-might-benefit-most-from-venetoclax-plus-ibrutinib monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/should-we-treat-patients-with-high-tumor-burden-fl-with-a-chemo-free-regimen monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-is-the-impact-of-bridging-therapy-on-the-outcomes-of-patients-receiving-car-t-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/new-data-about-btk-inhibitors-in-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-can-predicting-survival-in-patients-with-relapsed-dlbcl-improve-treatment-decisions monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/sequoia-trial-which-subset-of-patients-with-cllsll-benefits-the-most-from-zanubritinib-treatment monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/could-nanoparticles-help-to-deliver-bh3-mimetics-more-effectively-in-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/practice-changing-abstracts-in-indolent-lymphoma-presented-at-ash-2019 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-can-we-maximize-patient-quality-of-life-within-clinical-trials monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/practice-changing-abstracts-in-mcl-from-ash-2019 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/augment-is-the-combination-of-lenalidomide-and-rituximab-efficacious-in-elderly-patients-with-inhl monthly 0.9 2023-05-16T15:47:00.000Z https://lymphomahub.com/medical-information/why-is-an-elderly-prognostic-index-required-for-patients-with-dlbcl monthly 0.9 2023-05-16T15:47:00.000Z https://lymphomahub.com/medical-information/when-should-patients-with-rr-nhl-receive-the-bispecific-antibody-regn1979 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-should-we-use-geriatric-assessment-to-guide-treatment-decisions-for-elderly-patients-with-dlbcl monthly 0.9 2023-05-16T15:47:00.000Z https://lymphomahub.com/medical-information/transcend-cll-004-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/should-we-treat-newly-diagnosed-patients-with-cll-differently-after-ash-2019 monthly 0.9 2024-07-30T09:12:00.000Z https://lymphomahub.com/medical-information/metabolic-response-prediction-to-abvd-from-diagnostic-biopsy-analysis monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-approval-of-acalabrutinib-for-adult-patients-with-cll-or-sll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-i-study-of-oral-5-azacytidine-and-romidepsin-in-patients-with-ptcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/a-17-gene-expression-signature-to-distinguish-patients-who-are-likely-to-achieve-long-term-remissions-following-front-line-fcr-chemoimmunotherapy-from-those-who-might-benefit-from-alternative-regimens monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/response-adapted-therapy-of-stage-iii-iv-hodgkin-lymphoma-using-pet-imaging-a-five-year-follow-up-of-the-swog-s0816-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/chmp-recommends-ema-approval-of-polatuzumab-vedotin-for-the-treatment-of-adult-patients-with-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lenalidomide-plus-rituximab-receives-chmp-s-positive-opinion-for-the-treatment-of-adult-patients-with-rr-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-approves-zanubrutinib-for-the-treatment-of-adult-patients-with-rr-mcl monthly 0.9 2024-07-16T13:43:00.000Z https://lymphomahub.com/medical-information/nanatinostat-plus-valganciclovir-granted-fast-track-designation-by-the-fda-for-the-treatment-of-patients-with-ebv-associated-lymphomas monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/cd19cd22-targeted-car-t-therapy-for-relapsedrefractory-b-cell-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/t-cell-antigen-coupler-tac-therapy-tac01-cd19-granted-fast-track-designation-by-the-fda-for-the-treatment-of-patients-with-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/educational-theme-prognostic-factors-in-lymphoma monthly 0.9 2024-07-16T13:56:00.000Z https://lymphomahub.com/medical-information/impact-of-donor-type-on-outcomes-of-allogeneic-transplant monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ublituximab-and-umbralisib-for-rr-b-cell-nhl-and-cllsll monthly 0.9 2021-03-03T13:46:00.000Z https://lymphomahub.com/medical-information/ihc-algorithm-reliably-predicts-gata3-and-tbx21-subtypes-of-ptcl-nos monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-ii-trial-clarity-demonstrates-efficacy-and-safety-of-ibrutinib-plus-venetoclax-in-rr-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/gene-expression-profiling-more-sensitive-than-fish-for-identifying-double-hit-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/population-based-study-association-of-secondary-primary-malignancies-and-dlbcl-stage-at-diagnosis monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/resonate-final-analysis-confirms-efficacy-of-ibrutinib-in-patients-with-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/will-car-t-cell-therapy-be-used-in-patients-with-other-than-dlbcl-types-of-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/bispecific-antibodies-in-lymphoma-myeloma-and-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/keynote-087-2-year-follow-up-of-pembrolizumab-in-rr-classic-hodgkin-lymphoma monthly 0.9 2025-02-20T16:32:00.000Z https://lymphomahub.com/medical-information/new-insights-into-the-molecular-pathogenesis-of-t-cell-lymphomas monthly 0.9 2021-05-13T15:17:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-a-standard-of-care-soc-update-for-chronic-lymphocytic-leukemia-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/duvelisib-receives-orphan-drug-designation-from-the-fda-for-the-treatment-of-t-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-standard-of-care-in-mantle-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-the-future-of-cellular-therapy-in-hematological-malignancies monthly 0.9 2021-05-13T15:57:00.000Z https://lymphomahub.com/medical-information/abexinostat-granted-fda-s-fast-track-designation-for-the-treatment-of-patients-with-relapsed-or-refractory-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-the-investigational-new-drug-designation-for-pbcar20a-a-car-t-cell-therapy monthly 0.9 2021-03-04T10:26:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-what-would-you-recommend-as-a-frontline-treatment-for-mantle-cell-lymphoma-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-what-is-the-current-standard-of-care-for-frontline-treatment-of-chronic-lymphocytic-leukemia-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-how-do-we-currently-understand-the-pathogenesis-of-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-beyond-ibrutinib-and-venetoclax-what-are-other-novel-targeted-therapies-for-cll-treatment monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-what-is-the-role-of-car-t-cell-therapy-in-chronic-lymphocytic-leukemia-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-what-is-in-the-pipeline-for-the-treatment-of-t-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-what-are-the-novel-prognostic-factors-for-the-treatment-of-patients-with-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-will-car-t-cell-therapy-become-standard-of-care-for-patients-with-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/soho-2019-what-are-the-current-unanswered-questions-in-indolent-non-hodgkin-lymphoma-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/soho-2019-how-could-patients-benefit-from-point-of-care-car-t-cell-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/soho-2019-or-what-are-the-current-unanswered-questions-in-chronic-lymphocytic-leukemia-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-should-patients-with-t-cell-lymphoma-be-treated-in-2019 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/soho-2019-how-to-treat-double-hit-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/reasons-for-car-t-cell-therapy-failure-and-potential-management-strategies monthly 0.9 2023-01-13T16:45:00.000Z https://lymphomahub.com/medical-information/educational-theme-high-risk-patients-with-lymphoid-malignancies monthly 0.9 2024-07-16T13:56:00.000Z https://lymphomahub.com/medical-information/rituximab-maintenance-in-follicular-lymphoma-fl-nine-year-follow-up-of-the-prima-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/what-is-the-familial-risk-of-developing-a-hematological-malignancy monthly 0.9 2021-05-13T14:40:00.000Z https://lymphomahub.com/medical-information/mayo-clinic-lymphoma-etumor-board-or-splenic-marginal-zone-lymphoma-with-massive-splenomegaly monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/tisagenlecleucel-in-secondary-cns-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-priority-review-of-zanubrutinib-for-rr-mcl monthly 0.9 2025-02-20T16:21:00.000Z https://lymphomahub.com/medical-information/tisagenlecleucel-in-patients-with-rr-dlbcl-without-measurable-disease-at-infusion monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-breakthrough-therapy-designation-to-acalabrutinib-for-adult-patients-with-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/meta-analysis-and-systematic-review-of-plerixafor-for-stem-cell-mobilization-for-autologous-stem-cell-transplant-asct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/galen-trial-phase-ii-results-obinutuzumab-lenalidomide-for-relapsedrefractory-follicular-lymphoma monthly 0.9 2021-03-04T10:12:00.000Z https://lymphomahub.com/medical-information/medicare-announces-coverage-of-chimeric-antigen-receptor-car-t-cell-therapy-in-the-united-states-us monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/car-t-versus-asct-for-rr-b-cell-nhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-potential-role-of-liquid-biopsy-in-nhl-and-its-current-limitations monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prevalence-of-btk-and-plcg2-mutations-in-a-cll-cohort-still-on-ibrutinib-after-three-years monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rituximab-and-dose-dense-cyclophosphamide-vincristine-prednisone-plus-interferon-in-patients-with-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/educational-theme-chimeric-antigen-receptor-car-t-cell-therapies-in-dlbcl-and-cll monthly 0.9 2024-07-16T13:56:00.000Z https://lymphomahub.com/medical-information/fda-requests-recall-of-allergan-s-biocell-textured-breast-implants-and-tissue-expanders monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/anti-pd1-agents-as-consolidation-in-relapsedrefractory-classical-hodgkin-lymphoma monthly 0.9 2021-03-04T10:17:00.000Z https://lymphomahub.com/medical-information/new-chemotherapy-free-approaches-for-the-treatment-of-lymphoid-malignancies monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-satellite-symposium-2019-dlbcl-chemotherapy-free-regimens-professor-ulrich-jager monthly 0.9 2024-07-16T13:47:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-satellite-symposium-2019-cll-chemotherapy-free-regimens-professor-michael-hallek monthly 0.9 2024-06-25T14:40:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-satellite-symposium-2019-chemo-free-approaches-for-the-treatment-of-lymphoid-malignancies-professor-nathan-fowler monthly 0.9 2024-06-25T14:43:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-satellite-symposium-2019-or-chemo-free-approaches-in-mcl-professor-simon-rule monthly 0.9 2024-07-16T13:47:00.000Z https://lymphomahub.com/medical-information/impact-of-treatment-regimen-on-risk-of-secondary-malignancies-in-patients-with-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/cd19-car-t-cell-immunotherapy-plus-ibrutinib-results-in-durable-responses-in-rr-cll monthly 0.9 2025-02-20T16:40:00.000Z https://lymphomahub.com/medical-information/fda-approves-rituximab-pvvr-ruxience-r-a-rituximab-biosimilar-for-the-treatment-of-patients-with-cd20-positive-nhl-and-cll monthly 0.9 2022-10-28T16:12:00.000Z https://lymphomahub.com/medical-information/eha-2019-or-two-year-follow-up-of-checkmate-205-nivolumab-plus-doxorubicin-vinblastine-and-dacarbazine-in-newly-diagnosed-advanced-stage-chl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-clr-131-fast-track-designation-for-the-treatment-of-patients-with-relapsed-or-refractory-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/chemotherapy-free-approaches-for-indolent-nhl-and-mcl monthly 0.9 2025-02-20T16:27:00.000Z https://lymphomahub.com/medical-information/icml-2019-randomized-phase-iii-study-of-lenalidomider-chop-r2-chop-vs-placebor-chop-in-previously-untreated-abc-type-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/epigenetics-in-peripheral-t-cell-lymphoma-ptcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-safety-concerns-halt-actr087-b-cell-non-hodgkin-lymphoma-clinical-trial monthly 0.9 2021-03-04T10:14:00.000Z https://lymphomahub.com/medical-information/advances-in-treatments-for-follicular-lymphoma-results-of-the-foll12-and-nct01865617-studies monthly 0.9 2025-02-20T16:09:00.000Z https://lymphomahub.com/medical-information/emerging-clinical-activity-of-regn1979-in-relapsedrefractory-b-cell-non-hodgkin-lymphoma monthly 0.9 2020-12-03T16:33:00.000Z https://lymphomahub.com/medical-information/venetoclax-in-chronic-lymphocytic-leukemia-cll monthly 0.9 2025-01-10T10:45:00.000Z https://lymphomahub.com/medical-information/eha-2019-or-anti-cd47-antibody-hu5f9-g4-with-rituximab-in-relapsedrefractory-diffuse-large-b-cell-lymphoma-dlbcl-and-indolent-non-hodgkin-lymphoma-inhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/icml-2019-can-car-t-therapy-deliver-long-term-benefits-for-patients-with-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-randomized-r2-chop-studies-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-which-patients-with-mcl-could-benefit-most-from-ibrutinib-plus-rituximab-in-the-front-line-setting monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-is-response-oriented-maintenance-based-on-mrd-and-pet-feasible-in-patients-with-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-the-revised-role-of-targeted-approaches-in-indolent-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-rg6146-and-venetoclax-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-have-we-improved-the-management-of-car-t-toxicities monthly 0.9 2023-05-16T16:15:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-practice-changing-abstracts monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-what-are-the-latest-advances-in-the-treatment-of-t-cell-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-in-which-patients-with-rr-chl-is-camidanlumab-tesirine-most-effective monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-magnify-study-will-patients-with-relapsed-fl-benefit-from-r2 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-overview-of-the-phase-ii-smart-start-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-cll14-trial-do-certain-patients-benefit-more-from-venetoclax-plus-obinutuzumab-in-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2019-or-investigating-liso-cel-in-rr-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/echelon-2-trial-response-by-cd30-expression monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-how-is-me-401-a-new-pi3k-inhibitor-different-from-existing-pi3k-inhibitors monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-has-the-combination-of-zanubrutinib-plus-obinutuzumab-improved-response-rates-in-cllsll-and-rr-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2019-or-ibrutinib-in-early-and-late-cll-news-from-eha monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-how-could-azacitidine-with-romidepsin-be-integrated-into-the-treatment-pathway-of-t-cell-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-the-rise-of-car-t-cell-therapy-where-are-we-in-the-us-and-europe monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-transcend-cll04-are-the-responses-to-jcar017-sustained-in-patients-with-rr-cllsll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-efficacy-of-novel-t-cell-bispecific-engaging-antibody-cd20-tcb-rg6026-for-rr-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-comments-on-the-addition-of-lenalidomide-to-r-chop-in-two-studies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-robust-study-why-did-it-not-meet-its-primary-endpoint-a-subgroup-analysis monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-cll12-study-should-we-treat-asymptomatic-treatment-naive-patients-with-ibrutinib monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-how-will-front-line-use-of-polatuzumab-vedotin-influence-patient-outcomes-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-autologous-or-allogeneic-stem-cell-transplant-for-consolidation-therapy-in-t-cell-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2019-or-real-world-data-from-the-first-french-cohort-of-patients-treated-with-car-t-cell-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-of-the-l-mind-trial-in-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/how-will-the-results-of-the-phase-iii-ascend-trial-change-treatment-practice-of-rr-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/long-term-outcomes-of-patients-with-waldenstrom-s-macroglobulinemia-treated-with-ibrutinib monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/interpretation-of-r2-chop-in-large-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-are-the-latest-advances-in-car-t-cell-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-what-are-the-latest-advances-in-the-treatment-of-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-checkmate-205-does-nivolumab-improve-the-long-term-outcomes-of-patients-with-advanced-stage-chl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-highlights-of-icml-2019 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2019-or-what-are-the-latest-advances-in-the-treatment-of-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2019-or-results-of-the-phase-ii-lyma-101-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2019-mabcute-study-extended-maintenance-with-subcutaneous-rituximab-vs-observation-in-inhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2019-how-will-the-sequencing-of-treatments-for-dlbcl-change-in-the-future monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2019-how-can-fdg-pet-guide-the-treatment-of-patients-with-follicular-lymphoma monthly 0.9 2024-06-25T14:44:00.000Z https://lymphomahub.com/medical-information/eha-2019-augment-study-post-hoc-analysis-in-mzl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2019-goya-trial-prognostic-value-of-metabolic-tumor-volume-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2019-or-access-and-implementation-of-car-t-treatment-in-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2019-first-line-therapy-in-fl-and-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lymphoma-hub-satellite-symposium-at-15-icml-new-chemotherapy-free-approaches-for-the-treatment-of-lymphoid-malignancies monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2019-smart-start-phase-2-trial-rituximab-lenalidomide-and-ibrutinib-combination-for-naive-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2019-or-polatuzumab-vedotin-obinutuzumab-lenalidomide-for-rr-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-approval-granted-to-polatuzumab-vedotin-in-combination-with-bendamustine-and-rituximab-for-rr-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/polatuzumab-vedotin-for-naive-dlbcl-results-from-a-phase-1b-2-trial monthly 0.9 2021-03-03T13:44:00.000Z https://lymphomahub.com/medical-information/asco-2019-or-allo-sct-versus-auto-sct-as-first-line-consolidation-in-ptcl-aatt-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/mayo-clinic-lymphoma-etumor-board-or-follicular-lymphoma-stage-ia-observation-versus-treatment monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/asco-2019-obinutuzumab-plus-venetoclax-is-superior-than-combination-with-chlorambucil-in-naive-cll-with-comorbidities monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/what-is-the-future-of-maintenance-therapy-in-relapsed-hodgkin-s-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/impact-of-novel-treatment-options-on-long-term-outcomes-in-cll-and-wm monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/cost-effective-lymphoma-treatment-for-developing-countries monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/turning-the-corner-on-rr-cns-lymphoma-applying-precision-and-immune-based-treatments monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/consolidation-strategies-for-cns-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/overall-strategies-for-primary-cns-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/sequencing-of-targeted-therapies-in-relapsed-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/what-should-be-done-for-elderly-patients-with-primary-central-nervous-system-lymphoma monthly 0.9 2024-06-20T09:46:00.000Z https://lymphomahub.com/medical-information/pre-transplant-salvage-options-bringing-conventional-versus-novel-combinations-to-practice monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/fast-and-furious-looking-ahead-to-next-generation-treatments-and-new-combinations-in-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/neurotoxicity-from-car-t-cell-therapy-how-can-it-be-managed-and-who-is-at-risk monthly 0.9 2023-05-16T16:15:00.000Z https://lymphomahub.com/medical-information/neurotoxicity-from-car-t-cell-therapy-why-does-it-happen monthly 0.9 2023-05-16T16:15:00.000Z https://lymphomahub.com/medical-information/what-are-the-driving-forces-in-patient-selection-for-car-t-cell-therapy-in-aggressive-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/lenalidomide-plus-rituximab-versus-rituximab-monotherapy-in-previously-untreated-fl-results-from-a-phase-ii-trial monthly 0.9 2021-03-03T13:23:00.000Z https://lymphomahub.com/medical-information/lenalidomide-approved-by-the-fda-for-follicular-and-marginal-zone-lymphoma monthly 0.9 2024-07-16T13:43:00.000Z https://lymphomahub.com/medical-information/long-term-efficacy-of-bexarotene-for-cutaneous-t-cell-lymphoma-results-from-a-phase-ii-trial monthly 0.9 2021-05-13T14:57:00.000Z https://lymphomahub.com/medical-information/decreased-mitochondrial-fitness-correlates-with-impaired-car-t-cell-persistence-and-poorer-responses-in-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/alisertib-and-romidepsin-combination-for-aggressive-rr-t-cell-and-b-cell-lymphomas monthly 0.9 2021-03-03T13:41:00.000Z https://lymphomahub.com/medical-information/checkmate-205-nivolumab-monotherapy-followed-by-avd-combination-for-naive-aggressive-chl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dose-adjusted-epoch-with-or-without-rituximab-for-nhl-associated-hlh-results-from-a-phase-ii-trial monthly 0.9 2021-05-13T14:01:00.000Z https://lymphomahub.com/medical-information/venetoclax-approved-by-fda-for-untreated-cll-and-sll monthly 0.9 2024-07-16T13:43:00.000Z https://lymphomahub.com/medical-information/prognostic-value-of-nk-cell-count-on-dlbcl-outcomes-following-immunochemotherapy monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/bendamustine-plus-ofatumumab-for-naive-elderly-patients-with-dlbcl-results-from-a-phase-ii-trial monthly 0.9 2021-03-03T13:35:00.000Z https://lymphomahub.com/medical-information/mayo-clinic-lymphoma-etumor-board-or-ovarian-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/meta-analysis-of-teaes-associated-with-pd-1-and-pd-l1-inhibitors monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/intratumor-heterogeneity-as-a-predictor-of-disease-progression-in-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/patient-outcomes-following-ibrutinib-discontinuation-for-cll-in-a-real-world-setting monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/pembrolizumab-for-rr-t-cell-lymphoma-results-from-a-phase-ii-trial monthly 0.9 2025-02-20T16:12:00.000Z https://lymphomahub.com/medical-information/risk-of-subsequent-neoplasms-following-allo-hsct-with-different-conditioning-regimens monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/car-t-therapy-with-or-without-conditioning-chemotherapy-results-from-a-phase-i-trial monthly 0.9 2025-02-20T16:18:00.000Z https://lymphomahub.com/medical-information/long-term-follow-up-of-90y-ibritumomab-tiuxetan-consolidation-in-mcl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ofatumumab-plus-idelalisib-as-front-line-therapy-for-cll-results-from-a-phase-ii-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/pembrolizumab-consolidation-after-asct-for-rr-chl-results-from-a-phase-ii-trial monthly 0.9 2025-02-20T16:16:00.000Z https://lymphomahub.com/medical-information/bortezomib-plus-r-chop-for-distinct-molecular-dlbcl-subtypes-results-from-the-phase-iii-trial-remodl-b monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/r-chop-versus-da-epoch-r-as-frontline-therapy-for-dlbcl-results-from-a-phase-iii-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ibrutinib-plus-r-chop-for-non-germinal-center-dlbcl-results-from-a-phase-iii-trial monthly 0.9 2021-03-03T13:40:00.000Z https://lymphomahub.com/medical-information/polatuzumab-or-pinatuzumab-vedotin-plus-rituximab-for-rr-nhl-results-from-the-romulus-phase-ii-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-from-the-augment-phase-iii-trial-lenalidomide-rituximab-for-rr-mzl-and-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ebmt-debate-session-how-to-treat-rr-dlbcl-in-2019-or-part-3-car-t monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ebmt-debate-session-how-to-treat-rr-dlbcl-in-2019-or-part-2-allo-sct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ebmt-debate-session-or-how-to-treat-rr-dlbcl-in-2019-or-part-1-asct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ebmt-2019-or-a-consensus-grading-system-for-toxicities-in-car-t-trials monthly 0.9 2023-05-16T16:09:00.000Z https://lymphomahub.com/medical-information/chiara-de-philippis-or-ebmt-2019-or-impact-of-checkpoint-inhibitors-on-haploidentical-transplant-in-rr-hl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ebmt-2019-or-donor-lymphocyte-infusion-monotherapy-for-hl-after-allo-sct-relapse monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ebmt-2019-or-preliminary-in-human-evaluation-of-a-cd19cd22-dual-car-t-construct-for-b-nhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/marie-jose-kersten-ebmt-2019-or-car-t-cells-vs-autologous-sct-vs-allogeneic-sct-in-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ebmt-2019-or-tandem-autologous-reduced-intensity-allogeneic-sct-for-rr-hl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/martin-dreyling-or-ebmt-2019-or-combining-cellular-and-targeted-therapies-in-mcl-treatment monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/richard-maziarz-or-ebmt-2019-or-grading-cytokine-release-syndrome-and-neurotoxicity-in-car-t-trials monthly 0.9 2023-05-16T16:15:00.000Z https://lymphomahub.com/medical-information/stephen-robinson-or-ebmt-2019-or-allogeneic-stem-cell-transplant-or-car-t-for-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/christian-gisselbrecht-or-ebmt-2019-or-autologous-stem-cell-transplant-versus-car-t-in-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/venetoclax-and-obinutuzumab-combination-for-rr-or-naive-cll-patients monthly 0.9 2021-03-03T13:37:00.000Z https://lymphomahub.com/medical-information/spanish-lymphoma-oncology-group-report-on-tfl-predictors monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/jude-fitzgibbon-eli-6th-workshop-2019-or-current-understanding-of-transformed-fl-biology monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/venetoclax-combination-with-r-or-g-chop-in-nhl-results-from-the-phase-ib-cavalli-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/gapdh-is-a-predictor-of-response-to-r-chop-in-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/high-dose-methotrexate-plus-temozolomide-with-or-without-rituximab-for-naive-pcnsl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/pentostatin-cyclophosphamide-and-rituximab-combination-for-advanced-stage-inhl monthly 0.9 2021-03-03T13:18:00.000Z https://lymphomahub.com/medical-information/tct-meeting-2019-or-nicotinamide-expanded-related-donor-natural-killer-cells-for-the-treatment-of-relapsedrefractory-multiple-myeloma-and-non-hodgkin-lymphoma-results-from-the-first-in-human-phase-i-study monthly 0.9 2021-03-04T10:16:00.000Z https://lymphomahub.com/medical-information/response-to-lymphodepleting-regimen-is-associated-with-pfs-in-car-t-infused-nhl-patients monthly 0.9 2025-02-20T16:40:00.000Z https://lymphomahub.com/medical-information/fda-grants-breakthrough-therapy-designation-to-venetoclax-and-obinutuzumab-for-adult-patients-with-previously-untreated-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/parsaclisib-for-rr-b-cell-malignancies-results-of-a-phase-i-ii-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/mass-cytometry-reveals-that-specific-intratumoral-cd4-t-cell-subsets-correlate-with-patient-survival-in-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/daratumumab-in-rr-mcl-dlbcl-and-fl-results-of-a-phase-ii-trial monthly 0.9 2021-03-03T13:49:00.000Z https://lymphomahub.com/medical-information/lenalidomide-and-rituximab-combination-activates-anti-tumor-immunity-and-tumor-cell-death-in-ex-vivo-and-in-vitro-fl-samples monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-priority-review-to-lenalidomide-and-rituximab-combination-for-the-treatment-of-indolent-nhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/reduced-cycles-of-high-dose-methotrexate-prior-to-whole-brain-irradiation-for-pcnsl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/alemtuzumab-and-chop-for-aggressive-t-cell-lymphoma monthly 0.9 2021-05-13T14:46:00.000Z https://lymphomahub.com/medical-information/r-chop-average-relative-dose-intensity-as-an-independent-outcome-predictor-in-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-ii-dynamo-trial-duvelisib-in-heavily-pre-treated-rr-inhl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-polatuzumab-vedotin-priority-review-for-the-treatment-of-relapsedrefractory-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/car-t-cell-meeting-2019-or-car-t-cell-therapy-in-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/meta-analysis-of-nivolumab-outcomes-in-hodgkin-lymphoma-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/lenalidomide-and-rituximab-combination-for-rr-pcnsl-dlbcl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/mayo-clinic-lymphoma-etumor-board-or-low-grade-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ofatumumab-monotherapy-in-naive-fl-patients-results-from-a-phase-ii-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/alisertib-monotherapy-for-ptcl-patients-results-from-a-phase-iii-trial monthly 0.9 2021-05-13T14:52:00.000Z https://lymphomahub.com/medical-information/ibrutinib-and-nivolumab-combination-in-rr-nhl-and-cllsll-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/da-epoch-r-versus-r-chop-for-double-hit-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-orphan-drug-designation-to-bi-1206-for-patients-with-previously-treated-mcl monthly 0.9 2021-03-04T10:22:00.000Z https://lymphomahub.com/medical-information/breshap-as-second-line-therapy-for-rr-hl-patients monthly 0.9 2021-03-03T13:47:00.000Z https://lymphomahub.com/medical-information/asct-consolidation-does-not-improve-aggressive-t-nhl-patient-outcomes monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/nice-grants-approval-to-tisagenlecleucel-kymriah-r-for-patients-with-previously-treated-dlbcl monthly 0.9 2022-10-28T16:13:00.000Z https://lymphomahub.com/medical-information/combination-of-coo-and-cns-ipi-improves-cns-relapse-prognosis-in-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-ibrutinib-plus-rituximab-provide-superior-outcomes-than-fcr-in-naive-cll-patients-results-from-the-ecog-acrin-phase-iii-trial-e1912 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-approval-to-ibrutinib-imbruvica-r-in-combination-with-obinutuzumab-gazyva-r-for-patients-with-previously-untreated-cllsll monthly 0.9 2022-10-28T16:10:00.000Z https://lymphomahub.com/medical-information/ash-2018-secondary-analysis-of-the-phase-iii-goya-trial-chop6-versus-chop8-for-first-line-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-plus-chemotherapy-for-cd30-ptcl-results-from-the-phase-iii-echelon-2-trial monthly 0.9 2021-05-13T15:39:00.000Z https://lymphomahub.com/medical-information/fda-grants-breakthrough-therapy-designation-to-umbralisib-tgr-1202-for-adult-patients-with-previously-treated-mzl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/novel-bcl2-mutation-leads-to-venetoclax-resistance-in-progressive-cll-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/mayo-clinic-lymphoma-etumor-board-or-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/pet-adapted-chemotherapy-for-advanced-stage-hl-results-from-a-phase-iii-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-breakthrough-therapy-designation-to-zanubrutinib-bgb-3111-for-adult-patients-with-previously-treated-mcl monthly 0.9 2025-02-20T16:25:00.000Z https://lymphomahub.com/medical-information/sintilimab-for-rr-classical-hl-patients-results-from-the-orient-1-phase-ii-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-iii-results-on-rituximab-addition-to-high-dose-methotrexate-chemotherapy-for-newly-diagnosed-pcnsl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-rituximab-ibrutinib-and-lenalidomide-combination-promising-for-previously-untreated-mzl-and-fl-patients monthly 0.9 2021-05-13T14:24:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-primary-analysis-of-the-phase-iii-complement-a-b-trial-ofatumumab-plus-bendamustine-for-indolent-nhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/a-great-visionary-leaves-the-lymphoma-community-bertrand-coiffier-dies-aged-71 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-eight-year-follow-up-of-galgb-50403-alliance-phase-ii-trial-post-transplant-bortezomib-in-mcl monthly 0.9 2026-09-11T16:26:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-results-from-the-phase-iii-augment-trial-lenalidome-plus-rituximab-for-rr-fl-and-mzl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-long-term-outcomes-of-the-murano-phase-iii-trial-venetoclax-plus-rituximab-leads-to-prolonged-outcomes-in-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-pembrolizumab-for-rr-pmbcl-patients-results-from-the-phase-ii-keynote-170-trial-and-updated-data-from-the-phase-ib-keynote-013 monthly 0.9 2025-02-20T16:32:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-mor208-and-lenalidomide-in-rr-dlbcl-results-from-the-phase-ii-l-mind-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-results-from-the-flyer-trial-on-the-efficacy-of-four-r-chop-cycles-versus-six-in-young-nhl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-phase-iii-results-from-r-chop-and-ibrutinib-in-untreated-non-gcb-dlbcl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-phase-iii-alliance-a041202-results-on-ibrutinib-alone-or-with-rituximab-as-front-line-therapy-in-older-cll-patients monthly 0.9 2023-05-16T16:01:00.000Z https://lymphomahub.com/medical-information/loretta-nastoupil-or-ash-2018-or-real-world-outcomes-of-axi-cel monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/john-seymour-or-ash-2018-or-updated-results-from-the-phase-iii-murano-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/carlos-ramos-or-ash-2018-or-cd30-car-t-therapy-for-hl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/catherine-diefenbach-or-ash-2018-or-new-checkpoint-blockade-therapy-from-china-with-interesting-data monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/catherine-diefenbach-ash-2018-or-novel-checkpoint-bv-combination-shows-durable-responses-in-hl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/frederick-locke-or-ash-2018-or-ash-2018-car-t-updates-in-b-cell-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/yuqin-song-or-ash-18-or-zanubrutinib-bgb-3111-in-relapsedrefractory-mantle-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/yuqin-song-or-ash-2018-or-tislelizumab-bgb-a317-in-relapsedrefractory-classical-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/nathan-fowler-or-ash-2018-or-long-term-updates-on-lenalidomide-plus-rituximab-in-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/marco-davila-ash-2018-or-car-t-related-toxicities-in-rr-dlbcl-patients monthly 0.9 2023-05-16T16:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-results-from-the-phase-iii-illuminate-trial-on-chemotherapy-free-first-line-treatment-for-cllsll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/martin-dreyling-or-ash-2018-or-targeted-therapy-in-relapsed-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/gilles-salles-or-ash-2018-or-mor208-combined-with-lenalidomide-in-patients-with-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2018-results-from-the-hovon-130-trial-lenalidomide-and-r-chop-for-b-cell-lymphoma-with-myc-rearrangements monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-car-t-and-ibrutinib-combination-for-the-treatment-of-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/raul-cordoba-or-ash-2018-or-peripheral-t-cell-lymphomas-in-spain monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/christiane-pott-or-ash-2018-or-updated-outcomes-from-the-phase-iii-gallium-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/sattva-neelapu-or-ash-2018-or-results-from-the-two-year-follow-up-of-zuma-1 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/anthony-mato-or-ash-2018-or-cll-treatment-updates-and-prognostic-testing monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-late-car-t-effects-in-rr-nhl-and-cll-patients monthly 0.9 2025-02-20T16:41:00.000Z https://lymphomahub.com/medical-information/stefano-luminari-or-ash-2018-or-outcome-predictors-in-mzl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/pierluigi-porcu-or-ash-2018-or-updates-on-t-nk-cell-lymphoma-treatment-strategies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-results-from-the-clarity-phase-ii-trial-on-ibrutinib-and-venetoclax-combo-in-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-approves-rituximab-abbs-truxima-r-for-the-treatment-of-adult-patients-with-cd20-positive-b-cell-nhl monthly 0.9 2022-10-28T16:13:00.000Z https://lymphomahub.com/medical-information/ema-grants-approval-to-mogamulizumab-poteligeo-r-for-patients-with-previously-treated-cutaneous-t-cell-lymphoma monthly 0.9 2022-10-28T16:13:00.000Z https://lymphomahub.com/medical-information/andreas-engert-or-ash-2018-or-final-phase-iii-results-of-combined-modality-treatment-in-early-stage-hl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-mrd-and-pfs-correlation-analysis-of-the-phase-iii-murano-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-efficacy-and-safety-outcomes-of-axi-cel-in-patients-with-relapsedrefractory-large-b-cell-lymphoma-comparable-between-patients-who-were-aged-less-65-years-versus-65-years monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2018-or-real-world-efficacy-and-safety-outcomes-with-axi-cel-in-patients-with-relapsedrefractory-large-b-cell-lymphoma-comparable-to-the-zuma-1-clinical-trial monthly 0.9 2021-05-14T16:33:00.000Z https://lymphomahub.com/medical-information/french-and-us-pooled-analysis-on-cause-of-death-in-fl-during-the-rituximab-era monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/real-world-outcomes-of-very-elderly-lymphoma-patients-in-sweden monthly 0.9 2023-05-16T15:54:00.000Z https://lymphomahub.com/medical-information/comorbidity-index-as-a-negative-prognostic-factor-for-survival-in-mcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/safety-and-efficacy-of-beac-conditioning-in-hl-and-nhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-ii-brismaielsg36-results-on-bendamustine-and-rituximab-in-splenic-mzl monthly 0.9 2021-05-13T14:29:00.000Z https://lymphomahub.com/medical-information/prognostic-value-of-cll-ipi-in-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-approval-to-brentuximab-vedotin-adcetris-r-for-frontline-ptcl monthly 0.9 2022-10-28T16:15:00.000Z https://lymphomahub.com/medical-information/allo-sct-outcomes-in-rr-t-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-breakthrough-therapy-designation-to-brentuximab-vedotin-adcetris-r-for-frontline-ptcl monthly 0.9 2022-10-28T16:16:00.000Z https://lymphomahub.com/medical-information/uk-real-world-gene-expression-profiling-for-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/long-term-follow-up-of-r-chop21-and-lenalidomide-in-dlbcl-analysis-of-two-phase-ii-trials monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/mycig-rearrangements-are-not-responsible-for-poor-survival-in-double-triple-hit-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-selinexor-fast-track-designation-for-the-treatment-of-patients-with-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-dexamethasone-high-dose-cytarabine-and-cisplatin-for-rr-chl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-iii-comparative-results-on-rituximab-and-ct-p10-in-low-tumor-burden-fl monthly 0.9 2025-02-20T16:08:00.000Z https://lymphomahub.com/medical-information/ten-year-follow-up-of-the-jcog0203-trial-on-r-chop-in-fl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/venetoclax-venclyxto-r-plus-rituximab-granted-approval-by-the-european-commission-for-the-treatment-of-cll-patients monthly 0.9 2022-10-28T16:16:00.000Z https://lymphomahub.com/medical-information/entospletinib-monotherapy-for-inhl-and-mcl-patients-results-from-a-phase-ii-trial monthly 0.9 2021-03-03T13:38:00.000Z https://lymphomahub.com/medical-information/the-long-term-effect-of-intensive-first-line-treatment-in-advanced-stage-hl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-ii-trial-of-lenalidomide-and-dexamethasone-combination-in-naive-cll-patients monthly 0.9 2021-03-03T13:19:00.000Z https://lymphomahub.com/medical-information/final-phase-iii-trial-analysis-on-vr-cap-versus-r-chop-for-newly-diagnosed-mcl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/updated-results-from-the-phase-iii-helios-trial-for-relapsed-or-refractory-cllsll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prognostic-value-of-pet-based-response-assessment-in-fl-secondary-analysis-of-the-phase-iii-gallium-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/mayo-clinic-lymphoma-etumor-board-in-situ-follicular-neoplasia-in-two-anatomical-sites monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-from-the-phase-iii-duo-trial-on-duvelisib-for-relapsedrefractory-cllsll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-accepts-supplemental-new-drug-application-and-grants-priority-review-status-to-ibrutinib-in-combination-with-obinutuzumab-for-the-treatment-of-previously-untreated-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-effects-of-chemotherapy-free-treatment-for-advanced-indolent-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-advisory-committee-recommends-approval-of-ct-p10-for-the-treatment-of-non-hodgkin-lymphoma monthly 0.9 2025-02-20T16:10:00.000Z https://lymphomahub.com/medical-information/obinutuzumab-and-chop-combination-for-advanced-dlbcl-results-from-the-phase-ii-gather-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-orphan-drug-designation-to-cerdulatinib-for-the-treatment-of-peripheral-t-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/five-year-follow-up-of-the-aethera-phase-iii-trial-brentuximab-vedotin-for-chl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-mavoric-phase-iii-trial-vorinostat-versus-mogamulizumab-for-previously-treated-ctcl monthly 0.9 2021-05-13T14:56:00.000Z https://lymphomahub.com/medical-information/soho-2018-virtual-coverage-or-angiogenesis-related-polymorphism-as-a-prognostic-marker-in-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/duvelisib-to-be-developed-and-commercialized-for-all-oncology-indications-in-china monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iach-2018-lenalidomide-and-rituximab-versus-chemotherapy-and-rituximab-in-patients-with-untreated-follicular-lymphoma-the-relevance-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iach-2018-or-treatment-of-adult-t-cell-leukemialymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-ii-study-finds-entospletinib-has-limited-activity-in-patients-with-rr-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/duvelisib-has-been-approved-by-the-fda-for-rr-cll-or-sll monthly 0.9 2024-07-16T13:43:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-approved-in-japan-for-frontline-treatment-of-hl monthly 0.9 2024-07-16T13:43:00.000Z https://lymphomahub.com/medical-information/soho-2018-virtual-coverage-or-new-approaches-to-the-management-of-ctcl monthly 0.9 2021-05-13T14:55:00.000Z https://lymphomahub.com/medical-information/safety-and-efficacy-phase-iii-study-of-forodesine-in-japanese-patients-with-relapsed-ptcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-meeting-on-lymphoma-biology-2018-or-virtual-congress-coverage monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/moxetumomab-pasudotox-tdfk-approved-by-fda-for-the-treatment-of-hcl monthly 0.9 2024-07-16T13:43:00.000Z https://lymphomahub.com/medical-information/safety-analysis-finds-venetoclax-monotherapy-is-well-tolerated-in-patients-with-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/long-term-follow-up-ibrutinib-and-rituximab-combination-in-patients-with-rr-mcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ibrutinib-did-not-meet-the-primary-efficacy-endpoint-in-patients-with-rr-fl-in-the-phase-ii-dawn-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/tisagenlecleucel-approved-by-the-ec-for-the-treatment-of-dlbcl monthly 0.9 2024-07-16T13:43:00.000Z https://lymphomahub.com/medical-information/axicabtagene-ciloleucel-approved-by-the-ec-for-the-treatment-of-dlbcl-and-pmbcl monthly 0.9 2024-07-16T13:44:00.000Z https://lymphomahub.com/medical-information/mayo-clinic-lymphoma-etumor-board-or-spontaneous-regression-in-a-dlbcl-ebv-patient monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/outcomes-of-the-phase-iii-revlirit-cll-5-agmt-study-in-patients-with-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/obinutuzumab-in-combination-with-lenalidomide-in-relapsedrefractory-follicular-lymphoma-results-of-an-open-label-multicenter-phase-ib-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-iii-study-of-obinutuzumab-in-japanese-patients-with-previously-untreated-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/efficacy-and-safety-analysis-of-obinutuzumab-or-rituximab-with-chemotherapy-for-previously-untreated-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/mayo-clinic-case-studies-a-new-feature-of-the-lymphoma-hub monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/mayo-clinic-lymphoma-etumor-board-or-lymphomatoid-papulosis monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/mogamulizumab-kpkc-approved-by-the-fda-for-mycosis-fungoides-or-sezary-syndrome monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/combination-of-ofatumumab-and-afuresertib-is-well-tolerated-with-moderate-activity-in-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-of-a-phase-ii-study-on-panobinostat-combined-with-rituximab-in-heavily-pre-treated-dlbcl monthly 0.9 2021-03-03T13:22:00.000Z https://lymphomahub.com/medical-information/asco-2018-the-highlights monthly 0.9 2025-02-20T16:27:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-impact-on-outcomes-of-dlbcl-patients-with-concurrent-fl-or-other-low-grade-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-venetoclax-monotherapy-in-patients-with-rr-mcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-durable-responses-seen-with-moxetumomab-pasudotox-in-rr-hcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-outcomes-by-prior-lines-of-therapy-from-the-zuma-1-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-venetoclax-safety-and-efficacy-in-patients-with-previously-treated-wm monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-results-from-the-phase-iii-trial-of-ibrutinibrituximab-versus-placeborituximab-in-wm monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-atezolizumab-plus-r-chop-in-previously-untreated-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-updated-results-from-the-phase-ii-juliet-trial-of-tisagenlecleucel-in-patients-with-rr-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-phase-i-study-of-the-synergistic-effects-of-cc-122-and-obinutuzumab monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-genetic-mutations-identify-patients-with-poor-prognosis-in-splenic-mzl monthly 0.9 2021-05-13T14:29:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-efficacy-of-2-year-rituximab-maintenance-vs-observation-in-patients-with-mzl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-prima-pi-risk-assessment-tool-in-patients-with-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-or-outcomes-of-the-phase-ii-study-of-tazemetostat-in-patients-with-rr-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/axi-cel-receives-positive-opinion-by-the-european-chmp-for-rr-dlbcl-and-pmbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2018-lisocabtagene-maraleucel-jcar017-in-rr-aggressive-nhl-updated-results-from-the-transcend-nhl-001-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2018-or-phase-ibii-study-of-hu5f9-g4-in-rr-nhl monthly 0.9 2025-02-20T16:28:00.000Z https://lymphomahub.com/medical-information/asco-2018-or-final-analysis-of-the-ahl2011-lysa-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/astrid-pavlovsky-or-eha-2018-or-key-highlights-from-eha-on-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/anton-hagenbeek-or-eha-2018-or-relevant-findings-of-the-relevance-phase-iii-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/judith-trotman-or-eha-2018-or-key-findings-from-the-innovate-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/simon-rule-or-eha-2018-or-what-are-the-key-findings-of-the-acalabrutinib-study-in-patients-with-wm monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/john-kuruvilla-or-eha-2018-or-sadal-clinical-trial-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/paolo-ghia-or-eha-2018-or-early-results-of-the-captivate-phase-ii-study-in-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/martin-hutchings-or-eha-2018-or-key-outcomes-of-the-echelon-1-sub-analysis monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/martin-dreyling-or-eha-2018-or-overview-of-eha-presentations-in-indolent-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/jorge-castillo-or-eha-2018-or-overview-of-the-safety-and-efficacy-of-venetoclax-in-patients-with-wm monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/jean-marie-michot-eha-2018-or-what-are-the-key-safety-and-efficacy-outcomes-of-the-cc-122-and-obinutuzumab-study-in-rr-b-cell-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/toby-eyre-eha-2018-or-would-venetoclax-monotherapy-be-a-good-option-for-rr-mcl-post-btk-inhibitor-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/marek-trneny-or-eha-2018-or-was-the-prima-pi-prognostic-index-feasible-in-a-real-world-cohort-of-fl-patients monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/stefano-luminari-eha-2018-or-what-is-the-role-and-impact-of-radiotherapy-in-dlbcl-patients monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ulrich-jager-eha-2018-or-what-are-the-potential-causes-of-aggressive-b-cell-lymphomas-under-jak12-inhibition monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/pembrolizumab-fda-approval-for-the-treatment-of-rr-pmbcl monthly 0.9 2025-02-20T16:32:00.000Z https://lymphomahub.com/medical-information/asco-2018-or-ibrutinib-plus-venetoclax-shows-promising-efficacy-in-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2018-or-acalabrutinib-monotherapy-demonstrated-good-efficacy-in-wm monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2018-phase-iii-relevance-study-compares-r2-to-r-chemo monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2018-or-durable-responses-seen-in-large-b-cell-lymphoma-patients-treated-with-axi-cel monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/venclexta-plus-rituxan-approved-by-fda-for-previously-treated-cll monthly 0.9 2024-07-16T13:44:00.000Z https://lymphomahub.com/medical-information/william-wierda-or-asco-2018-or-ibrutinib-and-venetoclax-combination-for-first-line-cll-captivate-phase-ii-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/raul-cordoba-or-asco-2018-or-tailoring-therapy-for-aged-patients-with-aggressive-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/joseph-connors-or-asco-2018-or-risk-adapted-treatment-strategies-for-advanced-stage-hl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/nathan-fowler-or-asco-2018-or-key-findings-of-the-phase-iii-relevance-trial-in-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/susan-o-brien-or-asco-2018-or-what-is-the-role-of-chemo-immunotherapy-in-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/francine-foss-or-asco-2018-or-novel-therapies-for-ctcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/olivier-casasnovas-or-asco-2018-or-value-of-pet-driven-therapy-in-advanced-stage-hl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/stefano-luminari-or-asco-2018-or-overview-of-high-risk-follicular-lymphomas monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/frederick-locke-or-asco-2018-or-axi-cel-dor-in-rr-large-b-cell-lymphoma-patients-in-zuma-1 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/laurie-sehn-or-asco-2018-or-polatuzumab-vedotin-bendamustine-and-rituximab-combination-for-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/gilles-salles-or-welcome-to-asco-2018-message-from-our-chair monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/gilles-salles-or-asco-2018-or-advanced-stage-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/michael-hallek-or-asco-2018-or-the-potential-of-venetoclax-for-cll-patients-with-17p-deletion monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/sonali-smith-or-asco-2018-or-overview-of-the-current-advances-in-fl-from-asco monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/bruce-cheson-or-asco-2018-or-potential-for-chemotherapy-free-future-in-lymphoid-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/greg-nowakowski-or-asco-2018-or-gene-expression-profiling-in-abc-type-dlbcl-patients-robust-phase-iii-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/caron-jacobson-or-asco-2018-or-overview-of-car-t-and-other-vehicles-for-immunotherapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/anthony-mato-or-asco-2018-or-novel-molecules-for-cll-treatment monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/marek-trneny-asco-2018-or-retrospective-clsg-analysis-on-biopsy-proven-fl-transformation-in-the-rituximab-era monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/peter-hillmen-or-asco-2018-or-mrd-kinetics-for-rr-cll-from-the-phase-iii-murano-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/loretta-nastoupil-or-asco-2018-or-overview-of-checkpoint-inhibitors-in-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/catherine-diefenbach-or-asco-2018-or-novel-therapies-for-rr-hl-beyond-transplant monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/phase-ii-study-assesses-the-use-of-rituximab-and-bendamustine-in-frail-elderly-dlbcl-patients monthly 0.9 2023-05-16T15:54:00.000Z https://lymphomahub.com/medical-information/coltuximab-ravtansine-sar3419-phase-ii-trial-shows-moderate-clinical-activity-in-rr-dlbcl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/gemcitabine-based-chemotherapy-is-not-superior-to-chop-for-naive-ptcl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/a-new-prognostic-model-for-ptcl-nos-developed-on-prospectively-collected-data monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/three-year-follow-up-results-from-the-phase-iii-ray-trial-ibrutinib-vs-temsirolimus-for-mcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/superiority-of-ibrutinib-over-rituximab-for-rr-cllsll-in-the-asia-pacific-region-phase-iii-results monthly 0.9 2021-03-03T13:44:00.000Z https://lymphomahub.com/medical-information/auto-hct-versus-allo-hct-in-fl-patients-with-etf monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-second-approval-to-tisagenlecleucel-kymriah-for-the-treatment-of-rr-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-ii-trial-on-panobinostat-monotherapy-for-rr-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/voxtalisib-shows-promising-efficacy-in-rr-fl-but-not-for-other-inhl-and-cll monthly 0.9 2021-03-03T13:24:00.000Z https://lymphomahub.com/medical-information/significantly-higher-pfs-in-rr-cll-with-venetoclax-rituximab-combo-compared-to-bendamustine monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/nivolumab-use-for-rr-chl-after-asct-failure-extended-follow-up-of-the-checkmate-205-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/how-the-international-t-cell-project-can-improve-the-understanding-of-t-cell-lymphomas monthly 0.9 2021-05-13T15:36:00.000Z https://lymphomahub.com/medical-information/obinutuzumab-and-bendamustine-in-inhl-updated-analysis-of-the-gadolin-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/outcomes-of-ptcl-patients-failing-first-line-therapy-international-t-cell-project-analysis monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-i-study-evaluating-brentuximab-vedotin-and-chp-in-ptcl monthly 0.9 2021-05-13T15:16:00.000Z https://lymphomahub.com/medical-information/new-drug-application-for-duvelisib-accepted-and-granted-priority-review-by-fda monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/serious-infections-after-5-year-ibrutinib-therapy monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-managing-car-t-toxicities-with-a-multi-disciplinary-team monthly 0.9 2023-05-16T16:09:00.000Z https://lymphomahub.com/medical-information/fda-grants-priority-review-to-moxetumomab-pasudotox-for-the-treatment-of-hairy-cell-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/to-beeam-or-to-r-beam-prior-to-asct-in-b-cell-lymphomas monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-cord-blood-nk-car-therapy-may-be-an-alternative-to-car-t-in-the-treatment-of-lymphoma monthly 0.9 2021-05-13T15:57:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-cd30-specific-car-t-phase-i-dose-escalation-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-retrospective-analysis-of-the-role-of-allo-sct-in-ptcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-thiotepa-based-asct-is-safe-and-effective-in-cns-and-non-cns-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-lymphoma-working-party-consensus-on-defining-the-role-of-asct-and-allo-sct-in-wm monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dr-stephen-robinson-ebmt-2018-or-bridging-therapies-and-novel-salvage-strategies-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-efficacy-and-safety-of-lenalidomide-combined-with-r-eshap-regimen-in-dlbcl-patients-with-relapsed-or-refractory-disease monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dr-carlos-ramos-or-ebmt-2018-or-cd30-specific-car-redirected-lymphocytes monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-comparison-of-safety-outcomes-between-ptcy-based-haploidentical-and-hla-matched-related-or-unrelated-donor-transplantation-for-patients-with-rr-aggressive-nhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dr-leopold-sellner-or-ebmt-2018-or-idelalisib-before-allogeneic-stem-cell-transplantation monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-idelalisib-as-bridging-therapy-in-allo-sct-for-fl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/bechara-mfarrej-or-ebmt-2018-or-advice-for-the-management-of-toxicities-in-car-t monthly 0.9 2023-05-16T16:16:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-chromosomal-abnormalities-as-risk-factors-for-allo-hsct-atl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dr-miguel-angel-perales-or-ebmt-2018-or-immune-check-point-inhibitors-in-the-context-of-sct monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-pd-1-pd-l1-and-lag3-expression-may-predict-post-allo-sct-lymphoma-outcomes monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-marek-trneny-or-ebmt-2018-or-what-were-the-most-interesting-results-from-ebmt monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ebmt-2018-or-phase-ii-trial-on-chidamide-combination-with-hdc-and-asct-for-rr-and-high-risk-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-approves-adcetris-brentuximab-vedotin-with-combination-chemotherapy-for-advanced-stage-classical-hl monthly 0.9 2021-06-14T16:33:00.000Z https://lymphomahub.com/medical-information/dr-anna-sureda-or-ebmt-2018-or-summary-of-the-transplant-algorithm-in-hodgkin-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-or-ebmt-2018-or-emerging-car-t-cell-therapy-in-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/long-term-safety-and-efficacy-results-of-ibrutinib-use-in-cll-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-i-study-explores-clinical-activity-of-duvelisib-in-hematological-malignancies monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/predictive-gene-profiling-model-for-follicular-lymphomaa-fillip-for-fl-beyond-flipi monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-iia-trial-results-from-anti-cd19-therapy-for-rr-nhl monthly 0.9 2021-03-03T13:36:00.000Z https://lymphomahub.com/medical-information/a-great-loss-to-the-lymphoma-community-michael-pfreundschuh-dies-aged-68 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/retrospective-analysis-of-wm-patient-outcomes-receiving-combination-therapy-and-rituximab-maintenance monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-approves-sbla-for-new-four-week-dosing-schedule-of-opdivo-r-nivolumab monthly 0.9 2022-10-28T16:17:00.000Z https://lymphomahub.com/medical-information/phase-ii-results-for-the-use-of-rituximab-and-chemotherapy-combo-for-pcnsl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/large-retrospective-outcomes-analysis-of-allo-hct-in-relapsed-fl-by-the-ebmt-lymphoma-working-party-and-cibmtr-lymphoma-committee monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2018-abstract-submission-deadline monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rituximab-with-ifn-a-and-asct-demonstrated-good-survival-outcomes-in-rr-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/salvage-therapies-may-improve-survival-outcomes-of-lymphoma-patients-after-allo-hct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/autologous-transplant-in-follicular-lymphoma-after-treatment-failure monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/us-real-world-analysis-of-ibrutinib-in-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/predictive-value-of-pd-l1-and-mhc-ii-expression-for-chl-clinical-outcomes monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-ii-study-effects-of-brentuximab-vedotin-added-to-first-line-therapy-for-hodgkin-s-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/insights-into-the-argentine-experience-with-brentuximab-vedotin-and-its-combination-with-bendamustine-in-rr-chl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/transplant-outcomes-in-double-hit-and-double-expressor-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/autologous-transplant-in-gray-zone-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/duvelisib-new-drug-application-submitted-to-fda-for-rr-cll-and-relapsed-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/interventional-strategies-based-on-interim-18ffdg-pet-for-advanced-stage-hl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/haploidentical-versus-matched-related-donor-in-hodgkin-s-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/refining-rist-long-term-efficacy-and-safety-of-reduced-intensity-sct-in-relapsed-mcl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-in-relapsed-anaplastic-large-cell-lymphoma monthly 0.9 2021-05-13T15:15:00.000Z https://lymphomahub.com/medical-information/phase-ii-trial-assesses-safety-and-efficacy-of-r-cybord-for-nhl monthly 0.9 2021-03-03T13:18:00.000Z https://lymphomahub.com/medical-information/retrospective-analysis-of-bendamustine-plus-rituximab-versus-r-chop-in-grade-3a-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/should-age-affect-eligibility-for-autologous-stem-cell-transplant-in-elderly-lymphoma-patients monthly 0.9 2023-05-16T15:54:00.000Z https://lymphomahub.com/medical-information/venetoclax-potential-for-relapsed-cll-patients-who-progressed-after-bcri-therapies monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-plus-bendamustine-in-relapsed-hodgkin-s-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-iii-study-assesses-infections-in-patients-receiving-cd19-targeted-car-t-treatment monthly 0.9 2025-02-20T16:41:00.000Z https://lymphomahub.com/medical-information/adcetris-r-brentuximab-vedotin-has-been-approved-by-the-european-commission-for-cd30-positive-ctcl monthly 0.9 2021-05-13T15:11:00.000Z https://lymphomahub.com/medical-information/results-from-a-meta-analysis-in-cll-model-supports-mrd-as-primary-endpoint-in-cll-chemo-immunotherapy-trials monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/brentuximab-plus-nivolumab-combo-proves-active-and-well-tolerated-in-salvage-setting-for-rr-hl monthly 0.9 2021-03-03T13:53:00.000Z https://lymphomahub.com/medical-information/fda-priority-review-for-kymriahtm-tisagenlecleucel-in-the-treatment-of-adult-rr-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-from-a-phase-ii-study-brentuximab-plus-dtic-is-a-good-choice-in-elderly-front-line-hl-patients monthly 0.9 2023-05-16T15:54:00.000Z https://lymphomahub.com/medical-information/results-from-a-phase-ii-study-in-large-b-cell-lymphoma-axicabtagene-ciloleucel-is-latest-car-t-cell-therapy-to-demonstrate-durable-response monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2017-acalabrutinib-monotherapy-shows-durable-remission-results-with-rr-and-high-risk-disease-in-early-to-mid-stage-cll-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2017-or-physically-fit-cll-patients-show-high-response-rates-with-obinutuzumabibrutinib-combo-in-phase-ii-icll-07-filo-study monthly 0.9 2025-12-23T09:52:00.000Z https://lymphomahub.com/medical-information/ash-2017-or-early-acalabrutinibobinutuzumab-combo-data-in-cll-with-markedly-high-response-rates-in-both-rr-and-tn-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2017-combination-of-venetoclax-and-ibrutinib-promising-phase-ii-results-in-high-risk-and-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2017-identifying-mechanisms-of-venetoclax-resistance-in-cll monthly 0.9 2020-11-17T17:04:00.000Z https://lymphomahub.com/medical-information/ash-2017-nk-cell-counts-in-peripheral-blood-of-nhl-may-help-predict-outcomes-in-anti-cd20-treatment-strategies monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/assist-prof-emmanuel-bachy-or-ash-2017-or-new-follicular-lymphoma-prognostic-index monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/assist-prof-emmanuel-bachy-or-ash-2017-or-key-findings-in-lymphoma-biology-at-ash-2017 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-kanti-r-rai-or-ash-2017-or-take-home-messages-in-cll-from-ash-2017 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-won-kim-or-ash-2017-or-is-copanlisib-a-breakthrough-therapy-in-treatment-of-rr-indolent-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-francesc-bosch-or-ash-2017-or-do-you-believe-checkpoint-inhibitors-will-become-the-standard-of-care-in-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-andres-ferreri-or-ash-2017-or-key-messages-from-treatment-of-primary-cns-lymphoma-session monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-reid-merryman-or-ash-2017-or-what-is-the-role-of-different-immunotherapies-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/assist-prof-matthew-davids-or-ash-2017-or-ifcr-incorporated-into-armamentarium-for-treatment-of-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-adcetris-r-supplemental-bla-has-been-accepted-by-fda-for-advanced-hl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-judith-trotman-or-ash-2017-or-bright-study-results monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/assoc-prof-nicole-lamanna-or-ash-2017-or-duo-trial-based-on-phase-iii-duo-trial-which-cll-patients-would-most-benefit-from-duvelisib-therapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-andrew-davies-or-ash-2017-or-key-messages-from-session-on-tailoring-frontline-therapy-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-grzegorz-nowakowski-or-ash-2017-or-update-from-diagnosis-to-treatment monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-or-ash-2017-or-welcome-to-lymphoma-hub monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-nathan-fowler-or-ash-2017-or-highlights-of-ash-2017-in-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-a-mato-or-ash-2017-or-pet-ct-analysis-to-identify-richter-s-transformation-after-kinase-inhibitors monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-miles-prince-or-ash-2017-or-updated-analysis-of-the-alcanza-trial monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-ulrich-jager-or-ash-2017-or-personalisation-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-kieron-dunleavy-or-ash-2017-or-key-messages-from-the-educational-session-on-pmbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-marek-trneny-ash-2017-or-r-chop-plus-rituximab-maintenance-in-elderly-patients monthly 0.9 2024-06-20T09:44:00.000Z https://lymphomahub.com/medical-information/ash-2017-interim-analysis-of-phase-iii-murano-study-shows-improved-outcomes-with-venetoclax-plus-rituximab-in-patients-with-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2017-or-high-response-rates-seen-with-ctl019-in-rr-dlbcl-juliet-trial-primary-analysis monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2017-combination-of-ibrutinib-and-rituximab-in-cll-provides-quicker-more-durable-response-but-doesn-t-yield-better-pfs monthly 0.9 2025-12-23T09:51:00.000Z https://lymphomahub.com/medical-information/ash-2017-or-bcl-2-family-members-implicated-in-ibrutinib-and-venetoclax-resistance-in-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2017-10-year-updated-prima-study-results-for-fl-patients-receiving-rituximab-maintenance monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2017-duvelisib-emerges-as-a-formidable-treatment-option-in-cllsll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-john-gribben-or-ash-2017-or-major-advances-in-immunotherapies-during-ash-2017 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-or-ash-2017-or-rituximab-maintenance-in-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2017-or-novel-combinations-and-treatments-for-relapsed-nhl-three-clinical-studies monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-plus-avd-therapy-shows-improved-modified-pfs-compared-with-abvd-in-untreated-stage-iii-or-iv-hl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2017-phase-ii-results-of-ace-ly-004-for-acalabrutinib-in-rr-mcl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2017-or-long-term-follow-up-results-of-rituximab-maintenance-in-elderly-mcl-patients-after-first-line-immunochemotherapy monthly 0.9 2025-12-23T09:52:00.000Z https://lymphomahub.com/medical-information/ash-2017-or-bgb-3111-btk-inhibitor-use-in-patients-with-indolent-and-aggressive-nhl monthly 0.9 2025-12-23T09:50:00.000Z https://lymphomahub.com/medical-information/correlation-of-patient-type-and-inflammation-biomarkers-with-clinical-outcomes-in-jcar017-treatment-ash-2017-oral-abstract-193 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dr-astrid-pavlovsky-or-ash-2017-or-brentuximab-vedotin-in-chl-patients-in-argentina monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-grzegorz-nowakowski-or-ash-2017-or-time-from-diagnosis-to-treatment-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-anas-younes-or-ash-2017-or-addition-of-bv-echelon-1-study-in-the-practice-of-treating-advanced-hl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-saatva-neelapu-or-ash-2017-or-key-findings-in-1-year-follow-up-of-car-t-data-zuma-1 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2017-induction-chemo-immunotherapy-with-the-matrix-regimen-in-patients-with-newly-diagnosed-pcnsl-a-multicenter-retrospective-analysis-on-feasibility-and-effectiveness-in-routine-clinical-practice monthly 0.9 2025-12-23T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2017-or-pooled-analysis-results-of-ibrutinib-therapy-in-rr-mcl-patients-for-a-median-of-3-5-years monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-sonali-smith-or-ash-2017-or-highlights-of-ash-2017-in-aggressive-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-stefano-luminari-or-ash-2017-or-ielsg-38-rituximab-with-chlorambucil-for-malt-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/asst-prof-constantine-tam-or-ash-2017-or-bgb-3111-in-aggressive-and-indolent-nhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-stephen-ansell-or-ash-2017-or-key-messages-from-the-session-how-i-treat-patients-with-hl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-raul-cordoba-or-ash-2017-or-best-collaborative-care-for-elderly-lymphoma-patients monthly 0.9 2023-05-16T15:46:00.000Z https://lymphomahub.com/medical-information/asst-prof-loretta-nastoupil-or-ash-2017-or-added-value-of-checkpoint-inhibitors-in-relapsed-follicular-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/assoc-prof-biasoli-or-ash-2017-or-specific-challenges-in-brazil-for-treating-lymphoma-patients monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/results-from-a-long-term-observational-case-series-in-fl-r-chop-shown-to-be-effective-frontline-treatment-in-nhl-patients-with-flg3 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/otlertuzumab-to-be-evaluated-for-ptcl-in-phase-ii-trials monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-from-a-ebmt-registry-study-in-hodgkin-lymphoma-haplo-comparability-to-sib-and-mud-confirms-its-suitability-for-advanced-hl-when-lacking-a-conventional-donor monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-from-20-year-retrospective-study-in-mcl-r-chophd-asct-strong-choice-as-first-line-therapy-in-physically-fit-adult-mcl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-from-the-phase-iiib-mabease-study-strong-case-made-for-rituximab-sc-in-first-line-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-from-the-phase-iii-foll05-clinical-trial-in-advanced-stage-symptomatic-follicular-lymphoma-long-term-data-confirm-r-chop-is-best-choice-to-achieve-most-durable-disease-control monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ema-marketing-application-authorization-submitted-for-kymriah-r-tisagenlecleucel monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-from-the-phase-iib-arctic-clinical-trial-in-previously-untreated-cll-mitoxantronelow-dose-rituximab-combo-comes-up-short-in-non-inferiority-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-approves-gazyva-r-obinutuzumab-for-patients-with-previously-untreated-advanced-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/letter-to-editor-suggests-fcr-therapy-may-only-benefit-younger-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ema-s-chmp-adopts-a-positive-opinion-for-adcetris-r-brentuximab-vedotin-for-cd30-cutaneous-t-cell-lymphoma-ctcl monthly 0.9 2021-05-13T15:10:00.000Z https://lymphomahub.com/medical-information/fda-approves-adcetris-r-brentuximab-vedotin-for-treatment-of-primary-cutaneous-anaplastic-large-cell-lymphoma monthly 0.9 2021-05-13T15:15:00.000Z https://lymphomahub.com/medical-information/addition-of-bortezomib-to-r-chop-does-not-significantly-improve-outcomes-in-patients-with-non-gcb-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/observational-study-shows-good-clinical-activity-for-lenalidomide-in-rr-mcl-patients-after-ibrutinib-therapy-failure-mcl-004 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-ii-consortium-trial-shows-positive-results-for-ibrutinib-use-in-rr-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/myd88-mutation-shown-not-to-impact-overall-survival-in-wm monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/retrospective-analysis-of-surrogate-endpoints-for-outcomes-in-patients-with-fl-post-asct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-calquence-r-acalabrutinib-accelerated-approval-for-the-treatment-of-rr-mcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/identification-of-dlbcl-subtypes-by-rt-mlpa-classifier-and-its-potential-as-a-rapid-cost-effective-routine-diagnostic monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/brentuximab-vedotin-bv-with-dacarbazine-better-tolerated-in-the-treatment-of-elderly-treatment-naive-hodgkin-lymphoma-patients-compared-with-bv-bendamustine-combination-treatment monthly 0.9 2023-05-16T15:53:00.000Z https://lymphomahub.com/medical-information/phase-ii-study-of-rituximab-and-bendamustine-shows-positive-long-term-results-for-malt-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/published-case-study-primary-nkt-cell-lymphoma-with-metastasis-to-the-penis-carries-rapid-progression-and-poor-outcomes monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/calym-imagine-workshop-2018-registration-now-open monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/published-case-study-a-report-of-three-cases-of-nkt-cell-lymphoma-enrolled-in-the-prospective-kamuzu-central-hospital-lymphoma-study-in-malawi monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-approves-yescarta-axicabtagene-ciloleucil-for-treatment-of-rr-adult-b-cell-lymphomas-including-dlbcl-pmbcl-and-tfl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rituximab-maintenance-improves-outcomes-in-young-mcl-patients-after-asct-a-phase-iii-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/published-case-study-first-case-of-dlbcl-presenting-as-bilateral-internal-auditory-canal-lesions-and-mimicking-bilateral-schwannomas monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/benefit-seen-in-brentuximab-vedotin-therapy-in-relapsed-refractory-chl-prior-to-stem-cell-transplantation monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-iii-study-for-high-risk-cll-lenalidomide-maintenance-compared-with-placebo-after-first-line-therapy monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-grants-adcetris-r-breakthrough-therapy-designation-for-frontline-advanced-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/published-case-study-patient-with-an-intravascular-large-b-cell-lymphoma-diagnosed-late-and-with-thyroid-and-cerebellum-involvement monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dose-reduction-of-bendamustine-to-45mgm2-when-combined-with-rituximab-is-required-in-patients-with-previously-untreated-or-rr-cll-with-severe-comorbidities monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-dual-hdac-pi3k-inhibitor-cudc-907-as-monotherapy-and-in-combination-with-rituximab-achieves-responses-and-is-tolerable-in-heavily-pre-treated-rr-dlbcl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/gazyvaro-r-obinutuzumab-in-combination-with-chemotherapy-approved-by-the-ema-for-the-treatment-of-newly-diagnosed-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/r-thp-cop-demonstrates-similar-clinical-activity-to-r-chop-but-appears-to-have-a-more-favorable-toxicity-profile-in-elderly-newly-diagnosed-dlbcl-patients monthly 0.9 2023-05-16T15:53:00.000Z https://lymphomahub.com/medical-information/asco-sitc-clinical-immuno-oncology-symposium-abstract-submission-deadline-3rd-october monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/chemotherapy-followed-by-consolidative-proton-therapy-achieves-encouraging-relapse-free-survival-rates-in-patients-with-newly-diagnosed-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/soho-2017-or-a-standardized-comparison-of-scholar-1-versus-zuma-1-and-interim-results-from-a-phase-ii-study-of-tazemetostat monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/soho-2017-or-circulating-free-dna-can-be-used-for-genotyping-in-chl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/soho-2017-or-outcomes-and-mrd-analysis-in-the-pivotal-m13-982-trial-of-venetoclax-for-rr-del-17p-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/pooled-analysis-results-from-open-label-studies-for-patients-with-rr-mcl-treated-with-ibrutinib monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-aliqopa-r-copanlisib-accelerated-approval-for-the-treatment-of-relapsed-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/vitamin-d-insufficiency-is-predictive-of-early-clinical-failure-as-well-as-inferior-longer-term-prognosis-in-patients-with-grade13a-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/biologics-license-application-for-rixathon-rituximab-biosimilar-accepted-for-review-by-fda monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/published-case-study-fibrin-associated-ebv-positive-diffuse-large-b-cell-lymphoma-within-a-frontotemporal-arachnoid-cyst-with-hemorrhage monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/high-cxcl13-level-at-baseline-strongly-predicts-the-achievement-of-pr-or-better-following-one-year-of-ibrutinib-therapy-for-waldenstrom-macroglobulinemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/published-case-study-the-first-triple-negative-case-of-cutaneous-nkt-cell-intravascular-lymphoma-with-cytotoxic-immunophenotype-and-ebv-positivity monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-of-the-phase-iii-cll1-trial-risk-adapted-therapy-of-fludarabine-or-watch-and-wait-in-patients-with-early-stage-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/published-case-study-primary-cutaneous-dlbcl-too-medically-fragile-for-conventional-chemotherapy-and-so-administered-gentian-violet monthly 0.9 2021-05-13T14:34:00.000Z https://lymphomahub.com/medical-information/high-os-and-low-nrm-achieved-with-high-dose-chemotherapy-and-asct-in-patients-with-pcnsl-treated-in-first-complete-remission monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/published-case-study-pembrolizumab-to-treat-a-patient-with-both-chronic-lymphocytic-leukemia-and-metastatic-melanoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/transformed-follicular-lymphoma-survival-and-risk-retrospective-analysis-by-the-geltamo-group monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/published-case-study-primary-acral-cd8-positive-cutaneous-t-cell-lymphoma-with-a-history-spanning-over-30-years-of-relapsing-asymptomatic-nodules-of-the-left-ear monthly 0.9 2021-05-13T15:18:00.000Z https://lymphomahub.com/medical-information/first-line-response-adapted-therapy-with-rituximab-and-bendamustine-is-efficient-and-well-tolerated-in-patients-with-malt-lymphoma-long-term-results-of-the-phase-ii-geltamo-malt-2008-01-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/published-case-study-primary-refractory-dlbcl-with-brain-parenchyma-achieving-complete-remission-with-car-t-cell-therapy monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dexamethasone-rituximab-and-cyclophosphamide-regimen-demonstrates-efficacy-and-tolerability-in-newly-diagnosed-as-well-as-relapsedrefractory-patients-with-wm monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/breast-implant-associated-anaplastic-large-cell-lymphoma-overview-and-management-recommendations-based-on-a-series-of-18-uk-cases monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/supplemental-bla-for-gazyva-r-obinutuzumab-for-frontline-follicular-lymphoma-granted-priority-review-by-the-fda monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/concentration-and-integrity-of-ccfdna-presents-as-a-potentially-useful-non-invasive-technique-for-diagnosis-and-prognosis-of-patients-with-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/maintenance-rituximab-after-asct-confers-significant-survival-benefit-in-patients-with-mcl-a-single-center-experience-by-the-city-of-hope-national-medical-center monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-mogamulizumab-breakthrough-therapy-designation-for-relapsedrefractory-cutaneous-t-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/tp53-mutated-mcl-represents-a-phenotypically-distinct-and-highly-aggressive-disease-entity-that-responds-poorly-to-high-dose-strategies-including-rituximab-cytarabine-and-asct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-of-the-phase-iii-goya-trial-chop-combined-with-rituximab-or-obinutuzumab-demonstrates-similar-pfs-in-patients-with-treatment-naive-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/randomized-phase-ii-results-lenalidomide-is-not-a-viable-option-post-allogeneic-stem-cell-transplant-for-persistent-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/malt-ipi-a-simple-and-effective-tool-generated-from-phase-iii-ielsg-19-trial-data monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-iii-n1087-alliance-trial-akt-inhibitor-mk-2206-plus-bendamustine-and-rituximab-is-active-and-tolerable-for-rr-cll-and-sll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/first-meta-analysis-of-chemorefractory-dlbcl-outcomes-scholar-1 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/lenalidomide-monotherapy-for-rr-mcl-demonstrates-efficacy-and-predictable-safety-profile-in-long-term-analysis-of-three-phase-ii-trials monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/final-results-of-the-phase-ii-o-ma-1-trial-ofatumumab-demonstrates-efficacy-and-a-favorable-toxicity-profile-in-malt-lymphoma monthly 0.9 2023-05-16T16:12:00.000Z https://lymphomahub.com/medical-information/supplemental-bla-for-adcetris-r-brentuximab-vedotin-in-ctcl-granted-priority-review-by-the-fda monthly 0.9 2021-05-13T15:06:00.000Z https://lymphomahub.com/medical-information/rituximab-confers-a-significant-survival-benefit-when-used-as-part-of-first-line-treatment-for-wmlpl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rituximab-biosimilars-gp2013-and-ct-p10-shown-to-be-comparable-to-reference-rituximab monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/five-year-follow-up-of-abvd-brentuximab-vedotin-or-avd-brentuximab-vedotin-in-the-treatment-of-advanced-chl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-acalabrutinib-priority-review-for-the-possible-treatment-of-relapsedrefractory-mantle-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rapid-infusion-of-ofatumumab-appears-safe-and-reduces-infusion-related-reactions-in-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-acalabrutinib-breakthrough-therapy-designation-for-relapsedrefractory-mantle-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/induction-with-r-acvbp-is-not-superior-compared-to-r-chop14-and-pet-driven-consolidation-appears-feasible-in-patients-with-newly-diagnosed-cd20-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/marketing-authorization-application-has-been-submitted-to-the-ema-for-kite-s-kte-c19 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/cll-post-ibrutinib-car-t-cell-therapy-shown-to-result-in-durable-molecular-remissions monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/59th-ash-r-annual-meeting-and-exposition-abstract-submission-deadline-2nd-august monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/two-year-follow-up-of-the-phase-iii-resonate-trial-of-ibrutinib-versus-ofatumumab-in-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/inotuzumab-ozogamicin-plus-rituximab-therapy-is-not-superior-to-other-comparators-for-relapsed-refractory-b-cell-non-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/adcetris-r-brentuximab-vedotin-approved-by-health-canada-as-post-asct-consolidation-treatment-of-hodgkin-lymphoma-hl monthly 0.9 2021-05-13T14:03:00.000Z https://lymphomahub.com/medical-information/updated-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up-of-newly-diagnosed-and-rr-mantle-cell-lymphoma monthly 0.9 2024-07-16T14:15:00.000Z https://lymphomahub.com/medical-information/supplemental-blas-accepted-by-fda-for-new-four-week-dosing-schedule-of-opdivo-r-nivolumab monthly 0.9 2021-05-13T14:02:00.000Z https://lymphomahub.com/medical-information/gazyvaro-r-obinutuzumab-plus-chemotherapy-given-positive-opinion-by-ema-chmp-for-newly-diagnosed-advanced-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/pembrolizumab-is-beneficial-for-cll-patients-with-richter-transformation monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/everolimus-plus-r-chop-leads-to-a-high-rate-of-efs-at-24-months-in-dlbcl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2017-or-relapsedrefractory-aggressive-nhl-treatment monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-of-the-phase-iii-alcanza-trial-brentuximab-vedotin-found-to-be-superior-compared-to-methotrexate-or-bexarotene-in-patients-with-rr-cd30-cutaneous-t-cell-lymphoma monthly 0.9 2021-05-13T15:05:00.000Z https://lymphomahub.com/medical-information/phase-iii-h9-u-trial-in-newly-diagnosed-early-stage-classical-hodgkin-lymphoma-with-risk-factors-4-cycles-of-abvd-ifrt-or-beacoppbaseline-ifrt-found-to-be-non-inferior-to-6-cycles-of-abvd-ifrt monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/mycbcl2-dual-expresser-but-not-cell-of-origin-classification-is-highly-prognostic-of-poor-survival-in-diffuse-large-b-cell-lymphoma-patients-from-the-ricover-60-and-r-megachoep-trials monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/assist-prof-kami-maddocks-or-eha-2017-or-l-mind-study-in-rr-dlbcl-tolerability monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2017-treatment-of-relapsedrefractory-aggressive-nhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/assoc-prof-judith-trotman-or-eha-2017-or-comparison-of-ct-vs-pet-in-the-gallium-study-in-fl-patients monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-or-eha-2017-or-interim-analysis-of-the-juliet-study-of-ctl019-in-rr-diffuse-large-b-cell-lymphoma-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2017-treatment-of-hl-a-new-staging-system-for-wm-and-rituximab-monotherapy-for-smzl-clinical-oral-presentation-session monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2017-immunotherapy-for-dlbcl-and-hl-the-rationale-current-agents-and-is-hct-still-needed monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dr-marie-maerevoet-or-eha-2017-or-phase-iib-sadal-study-in-rr-diffuse-large-b-cell-lymphoma-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2017-molecular-biology-and-treatment-of-waldenstrom-macroglobulinemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-2017-first-line-treatment-for-aggressive-nhl-mantle-cell-and-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dr-valentin-goede-or-eha-2017-or-mantle-cell-lymphoma-mcl-in-elderly-patients monthly 0.9 2023-05-16T15:45:00.000Z https://lymphomahub.com/medical-information/prof-mark-trneny-or-eha-2017-or-dlbcl-patients-superior-80y-treated-with-anthracycline-based-chemotherapy monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-2017-or-new-approaches-in-indolent-non-hodgkin-lymphoma monthly 0.9 2021-05-13T14:25:00.000Z https://lymphomahub.com/medical-information/rituxan-hycelatm-approved-by-the-fda-for-adult-patients-with-fl-dlbcl-and-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-john-gribben-or-icml-2017-or-highlights-of-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2017-prognostic-tools-chronos-1-and-pembrolizumab-plus-rituximab-for-relapsed-patients-follicular-lymphoma-session-at-14-icml monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-sonali-smith-or-icml-2017-or-highlights-of-the-educational-session-on-aggressive-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-marek-trneny-icml-2017-or-highlights-of-mantle-cell-lymphoma monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-nathan-fowler-or-icml-2017-or-long-term-follow-up-of-lenalidomide-rituximab-in-inhl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-michael-dickinson-icml-2017-or-tazemetostat-in-fl-and-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-marek-trneny-icml-2017-or-update-on-the-phase-iii-goya-study-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-emmanuel-bachy-or-icml-2017-or-the-bcr-myd88-superpathway-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-andres-ferreri-icml-2017-or-extranodal-marginal-zone-lymphoma-and-the-use-of-clarithromycin monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-herve-tilly-icml-2017-or-pola-r-chp-in-treatment-naive-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/assoc-prof-constantine-tam-icml-2017-or-ibrutinib-venetoclax-in-rr-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2017-bgb-3111-cerdulatinib-and-other-inhibitors-for-aggressive-and-indolent-nhl-targeting-the-bcr-pathway-session monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/icml-2017-molecular-classification-outcomes-and-treatment-primary-mediastinal-b-cell-lymphoma-session monthly 0.9 2025-02-20T16:33:00.000Z https://lymphomahub.com/medical-information/icml-2017-genotyping-of-classical-hodgkin-lymphoma-using-liquid-biopsy-hodgkin-lymphoma-session monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/icml-2017-ongoing-trials-in-b-cell-nhl-including-robust-mcl-r2-elderly-and-sympatico-focus-on-session monthly 0.9 2022-10-03T14:09:00.000Z https://lymphomahub.com/medical-information/icml-2017-chemotherapy-free-combinations-for-patients-with-b-cell-nhl-focus-on-session monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-stephen-j-schuster-icml-2017-or-interim-results-of-the-juliet-trial-of-ctl019-in-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-miles-prince-or-icml-2017-or-phase-iii-alcanza-trial-final-results monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-icml-2017-or-l-mind-study-mor208-lenalidomide-in-rr-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-ulrich-jager-icml-2017-or-durvalumab-with-r-chop-or-lenalidomide-in-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-anas-younes-icml-2017-or-genome-sequencing-data-in-clinical-practice monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/icml-2017-interim-results-of-the-phase-ii-juliet-and-primary-results-of-the-pivotal-zuma-1-trials-car-t-cell-therapy-for-rr-dlbcl-joint-session monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/icml-2017-aggressive-b-cell-lymphomas-molecular-genetics-classification-and-treatment-educational-session monthly 0.9 2021-05-13T14:38:00.000Z https://lymphomahub.com/medical-information/icml-2017-response-adapted-therapies-for-hodgkin-lymphoma-meet-the-professor-session monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/icml-2017-chemotherapy-free-approaches-to-treat-follicular-lymphoma-meet-the-professor-session monthly 0.9 2026-09-11T16:25:00.000Z https://lymphomahub.com/medical-information/rituximab-maintenance-lacks-a-clear-overall-survival-benefit-for-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dr-sarit-assouline-or-2017-asco-annual-meeting-or-phase-ii-results-of-entospletinib-in-wm monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-jeff-sharman-2017-asco-annual-meeting-or-use-of-bendamustine-and-obinutuzumab-in-the-front-line-setting-of-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-ian-flinn-2017-asco-annual-meeting-or-the-results-of-the-bright-study-in-mcl-5-year-follow-up monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-paul-m-barr-2017-asco-annual-meeting-or-applying-the-new-who-classifications-in-lymphoid-malignancies monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/asco-2017-inhl-and-mcl-5-year-updated-results-of-the-bright-study-and-9-year-updated-results-of-the-stil-nhl1-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2017-understanding-the-revised-4th-edition-who-classification-of-lymphoid-malignancies-educational-session monthly 0.9 2021-05-13T14:16:00.000Z https://lymphomahub.com/medical-information/assist-prof-saar-gill-2017-asco-annual-meeting-or-results-of-using-the-combination-of-cd19-car-t-cells-and-ibrutinib-in-cll-patients monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/asco-2017-fl-results-of-the-phase-iiib-magnify-study-and-cibmtr-database-analysis-comparing-auto-hct-and-msd-and-mud-allo-hct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-or-2017-asco-annual-meeting-or-highlights-of-dlbcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/asco-2017-dlbcl-interim-results-of-the-phase-iii-optimalgreater60-trial-and-identification-of-clinically-relevant-copy-number-alterations-in-patient-plasma-samples monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2017-cll-results-of-the-phase-ii-calgb-10404-and-phase-iii-genuine-trials-and-a-retrospective-analysis-of-richter-s-transformation-with-novel-agents monthly 0.9 2021-05-06T10:08:00.000Z https://lymphomahub.com/medical-information/asco-2017-diagnosis-and-treatment-options-for-mantle-cell-lymphoma-educational-session monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-2017-asco-annual-meeting-or-highlights monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-loretta-nastoupil-or-2017-asco-annual-meeting-or-presents-on-pembrolizumab-and-rituximab-in-rr-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-jeff-sharman-or-2017-asco-annual-meeting-or-results-of-the-phase-iii-genuine-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-susan-o-brien-2017-asco-annual-meeting-or-highlight-on-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/asco-2017-diagnosis-and-treatment-options-for-double-hit-lymphoma-educational-session monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-pierre-soubeyran-or-2017-asco-annual-meeting-or-new-approaches-for-older-adults-individualized-management-of-aggressive-lymphoma monthly 0.9 2023-05-16T15:48:00.000Z https://lymphomahub.com/medical-information/prof-nathan-fowler-or-2017-asco-annual-meeting-or-phase-iii-trial-with-lenalidomide-obinutuzumab-in-relapsed-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-2017-asco-annual-meeting-or-introduction monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/intensification-with-2-cycles-of-beacoppesc-inrt-is-effective-in-stage-i-and-ii-hodgkin-lymphoma-patients-who-are-early-pet-positive-after-2-cycles-of-abvd-results-of-the-phase-iii-h10-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/capping-doxorubicin-dose-does-not-appear-to-result-in-inferior-efficacy-in-patients-with-dlbcl-and-elevated-body-surface-area monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-kte-c19-priority-review-for-the-treatment-of-transplant-ineligible-relapsedrefractory-non-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-ema-grants-mrg-106-orphan-drug-designation-for-cutaneous-t-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/nivolumab-is-effective-in-relapsedrefractory-hodgkin-lymphoma-patients-following-allogeneic-hct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-michael-hallek-or-iwcll-2017-or-the-new-iwcll-guidelines monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/subcutaneous-compared-to-intravenous-delivery-results-in-non-inferior-responses-and-safety-profile-of-rituximab-in-newly-diagnosed-patients-with-follicular-lymphoma-results-of-the-phase-iii-sabrina-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-silvia-deaglio-or-iwcll-2017-or-the-role-of-microenvironment-in-cll-development monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/hd7-to-hd12-trials-favorable-prognosis-found-for-classical-hodgkin-lymphoma-patients-with-late-compared-to-early-relapse monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-phase-iii-complement-2-trial-ofatumumab-plus-fc-improves-pfs-with-manageable-safety-versus-fc-alone-in-patients-with-relapsed-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-life-after-ibrutinib-pre-clinical-and-clinical-studies monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-on-the-origin-of-cll-evolution monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-allogeneic-transplantation-using-hla-compatible-donors-is-effective-in-younger-high-risk-cll-patients-an-ebmt-registry-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-final-results-of-the-phase-ii-icll03-ricac-pmm-trial-of-ric-allo-sct-for-high-risk-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-pi3k-isoform-inhibitors-in-cll-idelalisib-duvelisib-and-tgr-1202 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-jennifer-r-brown-iwcll-2017-or-the-role-of-pi3k-isoform-inhibitors monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/iwcll-2017or-anti-cd19-car-t-cell-therapy-with-defined-t-cell-subsets-for-ibrutinib-refractory-cll monthly 0.9 2025-02-20T16:41:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-venetoclax-plus-rituximab-is-highly-active-in-patients-with-relapsedrefractory-cllsll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-baseline-left-atrial-abnormality-independently-predicts-atrial-fibrillation-in-cll-patients-treated-with-ibrutinib monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dr-davide-rossi-or-iwcll-2017-or-timing-of-genotyping-in-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-matthew-s-davids-or-iwcll-2017-or-tgr-1202-ibrutinib-in-patients-with-relapsed-or-refractory-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-davide-rossi-or-iwcll-2017-or-the-role-of-karyotyping-in-cll monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-matthew-s-davids-or-iwcll-2017-or-ibrutinib-fcr-or-duvelisib-fcr-in-the-front-line-setting-for-high-risk-cll-patients monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-davide-rossi-or-iwcll-2017-or-comparison-of-ngs-and-sanger-sequencing-in-cll-in-routine-practice monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-ibrutinib-plus-fcg-induces-a-higher-rate-of-mrd-negative-remission-in-the-bone-marrow-than-fcg-alone-in-patients-with-newly-diagnosed-cllsll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-copanlisib-priority-review-for-the-possible-treatment-of-relapsedrefractory-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-complement-2-trial-mutated-notch1-presents-as-a-potential-predictive-marker-of-response-to-fc-plus-ofatumumab-for-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-resonate-resonate-2-and-helios-risk-factors-linked-to-poor-outcomes-with-other-therapies-may-be-irrelevant-when-predicting-outcomes-with-ibrutinib monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-revised-iwcll-guidelines-for-the-approach-to-a-cll-patient monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-clinical-approach-to-the-diagnosis-and-initial-evaluation-of-a-cll-patient monthly 0.9 2021-05-13T10:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-expression-of-ror1-in-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/highlights-of-iwcll-2017-from-a-biological-perspective-by-professor-john-g-gribben monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-autonomous-b-cell-receptor-bcr-signaling-in-chronic-lymphocytic-leukemia-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-additional-signaling-pathways-in-cll-and-their-interactions-with-the-bcr monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-ibrutinib-treatment-results-in-a-downregulatory-membrane-environment-and-an-overall-resting-phenotype-of-cll-b-cells monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-ongoing-ighv-d-j-mutations-result-in-substantial-clonal-complexity-and-presents-as-a-measure-of-genomic-instability-in-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-monocytes-and-nurse-like-cells-have-immunosuppressive-features-and-support-cll-cell-survival monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-ibrutinib-inhibits-il-4-production-by-t-cells-and-expression-of-smil-4r-on-cll-b-cells monthly 0.9 2021-05-13T10:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-ibrutinib-inhibits-cxcr4-expressionfunction-and-causes-cll-cell-death-by-neglect monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-progression-on-ibrutinib-in-patients-with-somatic-mutations-in-the-bcr-and-nf-kb-pathways monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-clonal-chronic-lymphocytic-leukemia-mutations-can-occur-extremely-early-in-the-hematopoietic-lineage monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-macrophage-response-to-mycobacterium-tuberculosis-may-be-compromised-in-patients-with-cll-treated-with-ibrutinib monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-epigenetics-of-cll-understanding-ontogeny-and-clinical-behavior monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-or-recurrent-somatic-mutations-and-their-functions-in-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-clinical-and-biological-insights-into-monoclonal-b-lymphocytosis monthly 0.9 2021-05-13T10:14:00.000Z https://lymphomahub.com/medical-information/prof-kanti-rai-iwcll-2017-or-introduction monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-what-is-the-cell-of-origin-of-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/iwcll-2017-insights-into-inherited-susceptibility-of-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/autologous-stem-cell-transplant-during-first-complete-remission-does-not-significantly-prolong-survival-in-patients-with-double-hit-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/keynote-087-phase-ii-results-pembrolizumab-shown-to-be-effective-when-given-once-every-three-weeks-in-relapsedrefractory-classical-hodgkin-lymphoma-chl monthly 0.9 2025-02-20T16:33:00.000Z https://lymphomahub.com/medical-information/mocetinostat-has-limited-single-agent-activity-and-acceptable-toxicity-profile-in-patients-with-relapsedrefractory-diffuse-large-b-cell-and-follicular-lymphoma monthly 0.9 2023-05-16T16:12:00.000Z https://lymphomahub.com/medical-information/keytruda-r-pembrolizumab-approved-by-the-ema-for-adult-patients-with-relapsedrefractory-classical-hodgkin-lymphoma monthly 0.9 2025-02-20T16:33:00.000Z https://lymphomahub.com/medical-information/early-stage-hodgkin-lymphoma-updated-analyses-based-on-long-term-follow-up-of-four-german-hodgkin-study-group-trials-hd7-hd8-hd10-and-hd11 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-patients-with-high-risk-genetics-respond-well-with-minimal-toxicity-to-onogs-4059-therapy-3-year-follow-up-results-of-a-phase-i-extension-study monthly 0.9 2023-05-16T16:12:00.000Z https://lymphomahub.com/medical-information/nice-recommend-long-term-funding-for-brentuximab-vedotin-for-adult-patients-with-cd30-relapsedrefractory-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-relapsedrefractory-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/r-chop-14-or-r-chop-21-which-is-more-effective-in-treating-elderly-dlbcl-patients monthly 0.9 2023-05-16T15:52:00.000Z https://lymphomahub.com/medical-information/the-ema-grants-pqr309-orphan-drug-designation-for-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/idelalisib-combined-with-ofatumumab-is-safe-and-effective-in-relapsed-chronic-lymphocytic-leukemia-patients-updated-results-of-a-phase-iii-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rituximab-biosimilar-rixathon-given-positive-opinion-by-the-ema-chmp-for-use-in-follicular-and-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/managed-access-program-to-launch-for-belinostat-for-patients-with-peripheral-t-cell-lymphoma-ptcl-in-europe monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rituximab-biosimilar-riximyo-given-positive-opinion-by-the-ema-chmp-for-use-in-follicular-and-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/novel-chemotherapy-free-dr2ive-regimen-achieves-favorable-results-in-heavily-pre-treated-mantle-cell-lymphoma-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/8-5-year-follow-up-of-mcl2-and-mcl3-trials-post-asct-pre-emptive-rituximab-for-mrd-relapse-resulted-in-temporary-molecular-remissions-in-patients-with-mantle-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/subgroup-analysis-of-the-phase-ii-delta-study-idelalisib-monotherapy-is-effective-and-has-acceptable-safety-profile-in-heavily-pretreated-patients-with-relapsedrefractory-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/analysis-of-patient-samples-from-the-phase-iii-lnh03-6b-trial-expression-of-bcl2-but-not-co-expression-of-bcl2-and-myc-predicts-survival-in-elderly-diffuse-large-b-cell-lymphoma-patients monthly 0.9 2023-05-16T15:52:00.000Z https://lymphomahub.com/medical-information/triple-combination-idelalisib-lenalidomide-and-rituximab-deemed-excessively-toxic-in-mantle-cell-and-follicular-lymphoma-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-ctl019-breakthrough-therapy-designation-for-adult-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-505025-pharmacodynamic-and-pharmacokinetic-relationship-of-single-agent-e7449-in-patients-with-relapsedrefractory-non-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-clears-investigational-new-drug-application-for-phase-i-trial-of-arq-531-in-patients-with-refractory-b-cell-malignancies monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-or-novel-therapeutic-opportunities-for-germinal-center-b-cell-lymphomas monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-517922-tk-216-the-first-in-class-fli1-inhibitor-demonstrates-in-vivo-and-in-vitro-anti-tumor-activity-in-lymphoma monthly 0.9 2021-05-13T14:59:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-46723-novel-epigenetic-approach-to-relapsed-mantle-cell-lymphoma-based-on-dual-inhibition-of-ezh1ezh2 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-405121-combination-efficacy-of-vorinostat-hdac-inhibitor-and-palbociclib-cdk-46-dual-inhibitor-against-therapy-resistant-mantle-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-ct13213-a-phase-iib-randomized-study-sadal-of-selinexor-achieves-durable-responses-in-gcb-and-non-gcb-subtypes-of-relapsedrefractory-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-or-overexpression-of-pd-l1-contributes-to-immune-evasion-of-adult-t-cell-leukemialymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-41825-the-two-novel-btk-inhibitors-m2951-and-m7583-show-in-vivo-anti-tumor-activity-in-pre-clinical-models-of-abc-type-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-45894-preclinical-investigation-of-the-novel-sgn-cd70a-antibody-drug-conjugate-in-t-cell-lymphomas monthly 0.9 2021-05-13T15:04:00.000Z https://lymphomahub.com/medical-information/china-food-and-drug-administration-accept-clinical-trial-application-for-jhl1101-in-phase-i-and-iii-trials-in-non-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/imbruvica-r-ibrutinib-for-chronic-lymphocytic-leukemia-added-to-watch-list-by-fda-adverse-event-reporting-system monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-or-zuma-1-trial-immune-signatures-of-crs-and-neurologic-events-in-subjects-with-refractory-diffuse-large-b-cell-lymphoma-treated-with-kte-c19 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-42954-az-5576-demonstrates-in-vitro-and-in-vivo-activity-in-preclinical-models-of-abc-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-or-targeting-bcl2-and-mcl1-in-blood-cancers monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/fda-biologics-license-application-submitted-for-kte-c19-for-transplant-ineligible-relapsedrefractory-patients-with-non-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-mrg-106-orphan-drug-designation-for-mycosis-fungoides-type-cutaneous-t-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-407919-first-in-class-sh7139-pre-clinical-toxicology-and-safety-in-non-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-419215-targeting-shp-1p-lyn-signaling-shows-therapeutic-potential-in-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-315010-plcg2-c2-domain-mutations-co-occur-with-btk-and-plcg2-resistance-mutations-in-chronic-lymphocytic-leukemia-undergoing-ibrutinib-therapy monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-313221-inhibition-of-the-integrin-avb3-improves-the-effect-of-bexarotene-in-the-treatment-of-cutaneous-t-cell-lymphoma monthly 0.9 2021-05-13T15:04:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-36314-delivery-of-a-cd20-transferrin-receptor-vnar-bispecific-antibody-to-the-brain-for-central-nervous-system-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-365124-preclinical-examination-of-the-effects-of-a-cd20-specific-engineered-toxin-body-mt-3724-in-mantle-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-37249-pd-l1-protein-expression-and-tumor-mutation-burden-correlates-with-hodgkin-and-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-39396-two-evolutionary-models-proposed-for-development-of-drug-resistance-between-primary-and-relapsed-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-216112-pharmacological-downregulation-of-bfl-1-by-cpi203-overcomes-abt-199-resistance-in-double-hit-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-or-primary-results-from-the-pivotal-zuma-1-trial-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity monthly 0.9 2023-05-16T16:13:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-or-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-years-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry monthly 0.9 2023-05-16T15:52:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma monthly 0.9 2023-05-16T16:13:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-or-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/mundesine-r-forodesine-hydrochloride-approved-by-japan-s-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-an-association-with-chromosomes-6-and-14 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-or-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3kdg-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-or-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fda-s-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/aacr-2017-or-immune-evasion-in-classical-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-malt-lymphomas monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-hairy-cell-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/keytruda-r-pembrolizumab-given-positive-opinion-by-ema-chmp-in-the-treatment-of-rr-chl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-treatment-of-wm monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-biology-of-wm monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-bispecific-antibodies-bites monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/pi3kd-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivo-r-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia monthly 0.9 2023-05-16T15:52:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-immune-checkpoint-inhibitors monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-double-hit-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-burkitt-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-biology-of-myc-driven-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/anti-cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-current-and-future-treatment-of-mcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-keytruda-r-pembrolizumab-accelerated-approval-for-the-treatment-of-rr-chl monthly 0.9 2025-02-20T16:34:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-advances-in-biology-of-mcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-t-cell-lymphoma-novel-treatment-options monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/eha-swg-2017-or-rare-lymphomas-biology-of-t-cell-lymphomas monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity monthly 0.9 2023-05-16T16:14:00.000Z https://lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ledaga-r-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rituximab-biosimilar-truxima-r-approved-by-the-ema-for-use-in-cll-and-nhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld monthly 0.9 2021-05-13T13:56:00.000Z https://lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment monthly 0.9 2024-07-16T14:16:00.000Z https://lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd monthly 0.9 2024-07-16T14:16:00.000Z https://lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy monthly 0.9 2024-07-16T14:16:00.000Z https://lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis monthly 0.9 2021-05-13T14:17:00.000Z https://lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/long-term-follow-up-of-phase-ii-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial monthly 0.9 2023-05-16T15:52:00.000Z https://lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/nice-approves-funding-for-imbruvica-r-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del-17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients monthly 0.9 2023-05-16T15:51:00.000Z https://lymphomahub.com/medical-information/imbruvica-r-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-and-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ledaga-r-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl monthly 0.9 2024-07-16T14:17:00.000Z https://lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-v-d-j-as-potential-prognostic-markers-in-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients monthly 0.9 2023-05-16T16:01:00.000Z https://lymphomahub.com/medical-information/prof-bruce-cheson-or-ash-2016-or-obinutuzumab-in-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-simon-rule-or-ash-2016-or-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-fda-grants-keytruda-r-pembrolizumab-priority-review-for-the-possible-treatment-of-chl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-marek-trneny-ash-2016-or-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-marek-trneny-ash-2016-or-is-mrd-testing-performed-by-community-hematologists monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-or-ash-2016-or-fl-new-insights-on-imaging monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-marek-trneny-ash-2016-or-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-or-ash-2016-or-highlights-on-new-agents-in-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-marek-trneny-ash-2016-or-rituximab-maintenance-after-asct-analysis-of-the-phase-iii-trial-of-the-lysagoelams-group-abstract-145 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-peter-johnson-or-ash-2016-or-highlights-in-hl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-marek-trneny-ash-2016-or-highlights-on-rituximab-in-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/arzerra-r-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/dr-gregorz-nowakowski-or-ash-2016-or-dlbcl-r-chop-remains-the-soc monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-anton-hagenbeek-or-ash-2016-or-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-simon-rule-or-ash-2016-or-highlights-on-mcl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-massimo-frederico-or-ash-2016-or-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-anton-hagenbeek-or-ash-2016-or-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-gregorz-nowakowski-or-ash-2016-or-dlbcl-which-drugs-can-be-combined-with-r-chop monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-massimo-federico-or-ash-2016-or-role-of-pembrolizumab-in-rr-ctcl-abstract-181 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-anton-hagenbeek-or-ash-2016-or-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-iii-gallium-study-plenary-session monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-stephen-ansell-or-ash-2016-or-hl-checkpoint-inhibitors-are-changing-current-practice monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-stephen-ansell-or-ash-2016-or-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-or-ash-2016-or-know-your-subtype monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-or-ash-2016-or-fl-highlights-on-patients-over-70-the-flash-group-results monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-gilles-salles-or-ash-2016-or-fl-highlights-on-r2-rituximab-lenalidomide monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-stefano-luminari-or-ash-2016-or-highlights-in-mzl monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/prof-martin-dreyling-or-ash-2016-or-mcl-moving-towards-a-chemotherapy-free-regimen monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients monthly 0.9 2023-05-16T15:51:00.000Z https://lymphomahub.com/medical-information/ash-2016-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl monthly 0.9 2023-05-16T15:51:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-lenalidomide-maintenance-in-rr-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-results-from-phase-ii-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl monthly 0.9 2023-05-16T15:50:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-final-results-of-the-phase-iii-study-of-obinutuzumab-or-r-chop-in-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-primary-results-of-the-gallium-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/venclyxto-r-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prof-andres-ferreri-or-ash-2016-or-pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-andres-j-m-ferreri-or-ash-2016-or-rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-andres-j-m-ferreri-or-ash-2016-or-rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474 monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-sonali-smith-or-ash-2016-or-why-didn-t-the-pfs-improvement-translate-into-an-os-improvement monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/dr-sonali-smith-or-ash-2016-or-will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients monthly 0.9 2022-05-03T09:49:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-8-5-years monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-iii-lyma-trial-of-the-lysagoelams-group monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-phase-iii-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-children-s-oncology-group-study-ahod0031 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm monthly 0.9 2021-05-13T15:00:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physician-s-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study monthly 0.9 2021-05-13T15:03:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study monthly 0.9 2025-02-20T16:34:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstrom-s-macroglobulinemia-a-randomized-phase-ii-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-phase-ii-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustine-rituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-long-term-follow-up-of-swog-s0016-phase-iii-randomized-study-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ash-2016-or-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/upfront-escalated-beacopp-or-abvd monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/metabolic-tumor-volume-hype-or-hope monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/does-interim-fluorodeoxyglucose-pet-have-predictive-value monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/cll-ipi-applied-and-validated-in-an-unselected-prospective-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-from-a-european-multicenter-phase-ii-mogamulizumab-trial monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/over-40-years-of-rai-cll-staging-system-celebrated monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/clinical-features-prognosis-and-therapy-in-fl3a monthly 0.9 2021-05-13T14:18:00.000Z https://lymphomahub.com/medical-information/del-and-dhl-as-indicators-of-poor-prognosis-after-asct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-recommendations-for-prognostic-tools monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-recommendations-for-prognostic-tools-1 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-recommendations-for-prognostic-tools-2 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-recommendations-for-prognostic-tools-3 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-recommendations-for-prognostic-tools-4 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/opdivo-r-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/venclyxto-r-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas monthly 0.9 2021-05-13T15:46:00.000Z https://lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics monthly 0.9 2021-05-13T14:25:00.000Z https://lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-2016-or-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-2016-or-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-2016-or-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment monthly 0.9 2025-01-10T10:42:00.000Z https://lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/r-hds-followed-by-asct-is-as-effective-as-r-chop14 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin monthly 0.9 2025-01-10T10:43:00.000Z https://lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting monthly 0.9 2023-05-16T16:00:00.000Z https://lymphomahub.com/medical-information/promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2016-or-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2016-or-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2016-or-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma monthly 0.9 2025-02-20T16:35:00.000Z https://lymphomahub.com/medical-information/asco-2016-or-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study monthly 0.9 2023-05-16T16:14:00.000Z https://lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2016-or-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2016-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2016-or-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2016-or-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll monthly 0.9 2023-05-16T16:00:00.000Z https://lymphomahub.com/medical-information/asco-2016-or-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2016-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2016-or-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2016-higher-rate-of-orr-achieved-with-mogamulizumab-vs-investigator-s-choice-for-treatment-of-rr-atl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/asco-2016-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl monthly 0.9 2023-05-16T15:50:00.000Z https://lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies monthly 0.9 2025-02-20T16:35:00.000Z https://lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/prospective-mrd-assessment-improves-prediction-of-patient-outcomes monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/which-is-a-better-treatment-option-abvd-or-beacopp monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/patients-benefit-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/update-on-drugs-for-follicular-lymphoma monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/follicular-lymphoma-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities monthly 0.9 2023-05-16T15:49:00.000Z https://lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin monthly 0.9 2021-05-13T15:02:00.000Z https://lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin monthly 0.9 2025-01-10T10:43:00.000Z https://lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop monthly 0.9 2023-05-16T16:00:00.000Z https://lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2 monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol monthly 0.9 2024-07-16T13:57:00.000Z https://lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options monthly 0.9 2023-05-16T15:49:00.000Z https://lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach monthly 0.9 2022-08-10T09:23:00.000Z https://lymphomahub.com/medical-information/international-prognostic-index monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/international-prognostic-index-1 monthly 0.9 2021-07-09T19:17:00.000Z https://lymphomahub.com/medical-information/treatment-strategies-and-prognostic-tools monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/medical-information/diagnosis-and-staging monthly 0.9 2021-05-13T14:26:00.000Z https://lymphomahub.com/medical-information/diagnosis-and-staging-1 monthly 0.9 2021-05-13T10:14:00.000Z https://lymphomahub.com/medical-information/role-of-the-microenvironment-in-pathogenesis monthly 0.9 2020-11-06T13:15:00.000Z https://lymphomahub.com/about-us/louise-niven monthly 0.6 2026-03-10T10:19:00.000Z https://lymphomahub.com/about-us/helen-croxall monthly 0.6 2026-03-10T10:19:00.000Z https://lymphomahub.com/about-us/jen-wilkinson monthly 0.6 2026-03-10T10:19:00.000Z https://lymphomahub.com/about-us/amelia-campbell-warner monthly 0.6 2026-06-08T16:12:00.000Z https://lymphomahub.com/about-us/devon-moss monthly 0.6 2026-09-23T15:19:00.000Z https://lymphomahub.com/about-us/jennifer-higgins monthly 0.6 2026-06-08T16:12:00.000Z https://lymphomahub.com/about-us/helen-clough monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/haimanti-mandal monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/beth-campbell monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/dylan-barrett monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/sari-cumming monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/amy-hopkins monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/megan-moore monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/becky-gribbell monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/addy-dullaghan monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/natasha-fort monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/alison-roddam monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/abbie-mckillop monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/monty-morris monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/nathalie-tipler monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/nathan-fisher monthly 0.6 2026-10-22T13:37:00.000Z https://lymphomahub.com/about-us/suzanna-de-barra monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/about-us/chris-barnes monthly 0.6 2026-09-17T18:27:00.000Z https://lymphomahub.com/contributors/prof-gilles-salles monthly 0.6 2026-04-02T13:04:00.000Z https://lymphomahub.com/contributors/prof-miles-prince monthly 0.6 2026-04-02T13:04:00.000Z https://lymphomahub.com/contributors/dr-michael-dickinson monthly 0.6 2026-04-02T13:04:00.000Z https://lymphomahub.com/contributors/prof-martin-dreyling monthly 0.6 2026-04-02T13:04:00.000Z https://lymphomahub.com/contributors/prof-stefano-luminari monthly 0.6 2026-04-02T13:04:00.000Z https://lymphomahub.com/contributors/prof-marek-trneny monthly 0.6 2026-04-02T13:04:00.000Z https://lymphomahub.com/contributors/dr-astrid-pavlovsky monthly 0.6 2026-04-02T13:04:00.000Z https://lymphomahub.com/contributors/prof-judith-trotman monthly 0.6 2026-04-02T13:04:00.000Z https://lymphomahub.com/contributors/julie-vose monthly 0.6 2026-04-02T13:04:00.000Z https://lymphomahub.com/contributors/pallawi-torka monthly 0.6 2026-04-02T13:04:00.000Z https://lymphomahub.com/contributors/jennifer-crombie monthly 0.6 2026-04-02T13:04:00.000Z https://lymphomahub.com/contributors/jacob-soumerai monthly 0.6 2026-04-07T11:38:00.000Z https://lymphomahub.com/contributors/professor-catherine-thieblemont monthly 0.6 2025-11-27T11:14:00.000Z https://lymphomahub.com/contributors/prof-irene-biasoli monthly 0.6 2025-04-29T14:15:00.000Z https://lymphomahub.com/contributors/dr-francesc-bosch monthly 0.6 2025-04-29T14:15:00.000Z https://lymphomahub.com/contributors/prof-ulrich-jager monthly 0.6 2025-04-29T14:15:00.000Z https://lymphomahub.com/contributors/prof-won-kim monthly 0.6 2025-04-29T14:15:00.000Z https://lymphomahub.com/contributors/prof-susan-o-brien monthly 0.6 2025-04-29T14:15:00.000Z https://lymphomahub.com/contributors/prof-kieron-dunleavy monthly 0.6 2025-04-29T14:15:00.000Z https://lymphomahub.com/contributors/prof-sonali-smith monthly 0.6 2025-04-29T14:15:00.000Z https://lymphomahub.com/contributors/dr-alison-moskowitz monthly 0.6 2025-04-29T14:15:00.000Z https://lymphomahub.com/contributors/dr-andrew-davies monthly 0.6 2025-04-29T14:15:00.000Z https://lymphomahub.com/steering-committees monthly 0.7 2026-10-28T17:50:43.911Z https://lymphomahub.com/about-us monthly 0.7 2026-10-28T17:50:43.911Z https://lymphomahub.com/newsletter monthly 0.7 2026-10-28T17:50:43.911Z https://lymphomahub.com/our-hubs monthly 0.7 2026-10-28T17:50:43.911Z https://lymphomahub.com/contact monthly 0.7 2026-10-28T17:50:43.911Z